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 1 
Summary 
 Notch is a highly conserved cell-to-cell communication pathway that plays an 
essential role in many biological processes. Notch exerts multiple effects in the 
hematopoietic system, especially during T cell development. Recent data suggest that 
Notch also regulates mature T cell differentiation and function. Here, we studied Notch 
signaling specifically in mature T cells using genetic loss-of-function approaches in two 
medically relevant T cell-mediated immune disorders: graft-versus-host disease (GVHD) 
and experimental autoimmune encephalomyelitis (EAE). We found that inhibition of 
Notch signaling provided long-term protection from lethal GVHD and EAE in mice. 
 In GVHD, Notch-deprived alloreactive T cells had markedly decreased 
production of multiple pro-inflammatory cytokines, including IL-17A, and IFNγ, despite 
preserved expression of the master transcription factors T-bet and Eomesodermin. Notch-
inhibited T cells acquired a hyporesponsive phenotype, but maintained in vivo expansion 
and cytotoxic potential. Notch1/2 and Dll1/4 mediated all the effects of Notch signaling 
in T cells during GVHD. Therapeutic targeting of the Notch ligands Dll1 and Dll4 
prevented GVHD even with a short-course of treatment. 
 In EAE, Notch-deprived T cells had preserved effector differentiation in 
secondary lymphoid organs but failed to accumulate in the central nervous system (CNS). 
Parking wild-type T cells with Notch-inhibited T cells allowed Notch-deprived T cells to 
accumulate in the CNS, although they failed to suppress disease induced by wild-type T 
cells. Once in the CNS, Notch-deprived T cells produced markedly decreased IL-17A and 
IFNγ, despite preserved T-bet expression.  
 Collectively, these data suggest that Notch signaling augments T cell responses in 
a context-dependent fashion. Inhibition of cytokine production with preserved expression 
of master transcription factors is reminiscent of costimulation blockade in T cells in 
mouse models of GVHD and EAE. Notch may regulate T cell responses in a context-
dependent manner by acting similarly to a costimulatory receptor. Thus, blockade of 
Notch signaling could be an attractive therapeutic target in T cell-mediated immune 
disorders. 
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Chapter 1  
Introduction 
1.1 Overview of Notch signaling 
 Notch signaling was first identified in Drosophila melanogaster on the basis of a 
heritable serrated or “notched” wing phenotype.1 Subsequently this pathway was named 
Notch, based on the described wing phenotype. The Notch gene was cloned in 1983.2 
Later genetic studies in fruit flies identified multiple other functions for Notch signaling 
as a result of Notch loss-of-function phenotypes, including neurogenesis, oogenesis, and 
developmental patterning defects.3-5 These studies resulted in the identification of two 
Notch interacting ligands in the fly, Delta and Serrate.6,7 Duplication events gave rise to 
four mammalian Notch receptor genes (Notch1-4) and five genes encoding mammalian 
Notch ligands (Dll1, 3, 4 and Jag1, 2).8-11 
 In mammals, Notch signaling exerts recurring functions in the development of 
multiple organ systems, adult tissue homeostasis, and cancer. Physiologically, Notch is 
required for the development of multiple organs, including kidney, heart, and vasculature, 
as well as homeostasis of the skin, gut, and other tissues in postnatal life.12-17 The first 
involvement for Notch signaling in cancer was the discovery that a t(7, 9) translocation 
resulted in generation of a constitutively active form of NOTCH1 in rare cases of T cell 
acute lymphoblastic leukemia (T-ALL).18,19 The importance of Notch gain-of-function 
mutations in T-ALL was found to be more extensive with the discovery of point 
mutations in the heterodimerization and PEST domains that destabilized the Notch 
receptor and increased the half-life of active Notch.20 Since then, Notch pathway 
mutations have been identified in a wide variety of cancers. For instance, gain-of-
function mutations were described in mantle cell lymphoma and B cell chronic 
lymphocytic leukemia, and loss-of-function mutations in cutaneous and lung squamous 
cell carcinoma and chronic myelomonocytic leukemia.21-24 Collectively, Notch signaling 
dynamically regulates multiple cell types in a variety of tissues. 
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1.2 Notch signaling pathway activation 
 Notch receptors are present on the cell surface as heterodimeric transmembrane 
proteins after proteolytic cleavage by a furin-like convertase at the “S1” site during 
transport through the Golgi apparatus (Figure 1.1A).25,26 Once present on the cell 
surface, Notch receptors (Notch 1-4) interact with Notch ligands of the Delta-like (Dll1, 
3, 4) or Jagged (Jag1-2) families to initiate Notch signaling (Figure 1.1A). 
 The expression of Notch receptors and ligands is highly regulated in the 
hematopoietic system, with interactions between specific Notch ligands and receptors 
being favored. For example, Notch1 in developing thymocytes interacts with Dll4 
expressed by the thymic epithelium, while Notch2 directs marginal zone B cell 
development through its interaction with Dll1.27-30 All the mechanisms accounting for 
preferential Notch ligand-receptor interactions are not fully understood. However, 
specific Notch receptors acquire enhanced avidity for specific Notch ligands, at least 
partially, through post-translational modifications mediated by Fringe family 
glycosyltransferases.31,32 Modification of Notch receptors by Fringe proteins results in 
differential ligand binding affinity and receptor activation.32 This modification of 
ligand/receptor specificity by Fringe proteins has been elegantly described in the case of 
T cell development as well as in the regulation of endothelial proliferation, during which 
Dll4 preferentially interacts with Fringe-modified Notch1.33-35  
 Upon receptor-ligand binding, the negative regulatory region of Notch receptors 
is displaced allowing matrix metalloproteases of the ADAM family to gain access to the 
“S2” cleavage site (Figure 1.1A).36 In developing thymocytes and marginal zone B cells, 
two well-described Notch-dependent populations, the “S2” cleavage is mediated by 
ADAM10.37 The “S2” cleavage renders the remaining Notch receptor unstable, leading to 
its intramembrane proteolysis by the γ-secretase complex, a rate-limiting step in Notch 
signaling activation.38 Although the γ-secretase complex can be pharmacologically 
inhibited to study Notch signaling, the γ-secretase complex is not specific to Notch 
signaling.39 Cleavage at the “S3” site by the γ-secretase complex results in the release of 
the intracellular domain of Notch (ICN) (Figure 1.1A).38 ICN acts as the effector of 
Notch signaling and translocates into the nucleus to interact with a core transcriptional 




Figure 1.1 Canonical Notch Signaling1.  
(A) Notch signaling occurs upon interaction between one of five ligands from either the Jagged 
(1, 2) or Delta-like (1, 3, 4) families and one of four Notch receptors (Notch1-4). Notch receptors 
are cleaved in the Golgi complex by a furin-like convertase (S1), leading to expression of a 
heterodimeric Notch receptor. Upon ligand binding, the S2 cleavage site is made accessible to an 
ADAM-type metalloprotease. The last cleavage (S3) is mediated by the γ-secretase complex and 
releases the Notch intracellular domain (ICN); (B) ICN translocates into the nucleus to interact 
with the DNA-binding protein, CSL/RBP-Jk (encoded by the Rbpj gene), a member of the 
Mastermind-like (Maml) family and other transcriptional coactivators. 
 
 The transcriptional activation complex consists of ICN, the DNA-binding factor 
CSL/RBP-Jκ, a coactivator of the Mastermind-like family (Maml1-3), and other 
transcriptional activators, like p300 (Figure 1.1B).40-43 Assembly of the core 
transcriptional activation complex leads to target gene activation. Collectively, this 
process is referred to as “canonical Notch signaling”. Most incidences of Notch signaling 
in mammals have been attributed to “canonical” Notch signaling, although “non-
canonical” Notch signaling has been described in Drosophila.44-48 Others have suggested 
                                                
1 Figure taken from: 
 
Sandy AR, Jones M, and Maillard I. 2010.  Notch signaling and development of the hematopoietic system.  
Reichrath J and Reichrath S (Eds.).  Notch signaling in embryology and cancer. Austin:  Landes Bioscience 
and Springer Science+Business Media. 
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that “non-canonical” Notch signaling occurs in mammals, but the mechanisms defining 
this activity of the Notch pathway in mammals are poorly characterized.49,50 
 In the absence of Notch signaling, CSL/RBP-Jκ is part of a repressor complex.51-
54 The functional importance of the repressor complex remains unclear, although some of 
its components have been elucidated. CSL/RBP-Jκ interacts with 
SMRT/mSin3A/HDAC-1 (SMRT, Silencing Mediator for Retinoic acid and Thyroid 
hormone receptor; HDAC-1, histone deacetylase-1), NCor/mSin3A/HDAC-1, 
CIR/SAP30/HDAC-2, and SHARP/CtBP/CtIP (SHARP, SMRT and HDAC associated 
repressor protein; CtBP, C-terminal binding protein; CtIP, CtBP Interacting Protein).51-54  
 Given the potent capacity of the Notch pathway to drive transcriptional output and 
major phenotypic consequences, the generation and half-life of ICN needs to be tightly 
controlled. The C-terminal PEST domain of ICN is targeted by E3 ubiquitin ligases, 
resulting in proteasome-mediated ICN degradation. For example, Sel10/Fbw7, Numb, 
and Itch have been shown to regulate degradation of ICN through ubiquitin modification 
of the PEST domain.55-58 The importance of the PEST domain and the E3 ubiquitin 
ligase, Fbw7, in turning off Notch signaling is exemplified by the recurrent mutations 
that occur in the PEST domain and Fbw7 in T-ALL.20,59  
 Altogether, Notch signaling is a highly controlled signal transduction pathway 
with complex regulation at the level of receptor ligand/expression, ligand/receptor 
affinity, receptor proteolysis, and transcriptional complex formation.  
 
1.3 Notch signaling in the hematopoietic system 
 In the hematopoietic system, Notch signaling is used recurrently in multiple 
contexts to drive different biological outcomes.60,61 For instance, Notch signaling is 
essential for the emergence of hematopoietic stem cells during definitive but not 
primitive hematopoiesis.62-64 At subsequent stages of hematopoiesis, Notch signaling is 
required to drive development of different lineages of the immune system (Table 1.1). 
For instance, Notch signaling drives T cell generation at the expense of B cell 
development from multipotent bone marrow progenitors that migrate into the 
thymus.29,65,66 Notch2 and Dll1 are required for the generation of marginal zone B cells in 
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a dose-dependent manner, as heterozygous loss of Notch2 or Dll1 results in a 50% 
reduction in marginal zone B cells.28,30 Moreover, Notch signaling is important for the 
generation of specific dendritic cell subsets. Notch-CSL/RBP-Jκ signaling is required for 
the development of CD8- dendritic cells in the spleen, and Notch2 is required for splenic 
CD11b+EsamHigh and intestinal lamina propria CD11b+CD103+ dendritic cells.67,68 Recent 
evidence also indicated that Notch signaling regulates the generation of 
megakaryocytes.69 Additionally, Notch was shown to restrict myeloid lineage 
differentiation, as inactivation of Nicastrin, encoding a component of the γ-secretase 
complex resulted in accumulation of granulocyte/monocyte precursors and a 
myeloproliferative disorder.24   
 More recently, emerging data suggested that Notch signaling also promotes the 
differentiation of subsets of innate lymphoid cells (ILCs). The recently described ILC 
classification mirrors that of T helper subsets.70-72 For example, ILC1, natural killer cells 
being the prototypical members, produce abundant IFN-γ. ILC2 express IL-5, IL-13, IL-
9, and some IL-4, while ILC3 produce IL-17A and/or IL-22. Similar to T helper subset 
responses, ILC1 are important for clearance of intracellular pathogens, ILC2 are required 
for allergic/asthma responses, and ILC3 mediate anti-microbial immunity. All three ILC 
lineages have been suggested to be Notch-dependent in some capacity (Table 1.2). For 
instance, transient Notch signaling was suggested to be important for murine and human 
(umbilical cord blood) natural killer cell/ILC1 development, at least in vitro.73,74 In 
conflicting reports, Notch signaling was suggested to be dispensable for natural killer cell 
development using in vitro assays.75,76 Also, Notch signaling was suggested to be 
important for the generation of Rorα+ ILC2 through in vitro gain-of-function assays, and 
aryl hydrocarbon receptor-dependent Rorγt+ ILC3 through in vitro gain-of-function 







Table 1.1 Notch regulation of adaptive immune system components. 
Cellular 








Mx1-cre x Notch1-/-, 
DNMAML expression,  
Lck-cre x DNMAML1f/f,  
Lck-cre x Notch1f/f 
Foxn1-cre x Dll4-/- 
Lck-cre x Rbpj-/- 
 
Notch1/Dll4 






zone B cells 
Mx1-cre x Notch2 f/f 
Cd19-cre x Notch2f/f 
Mx1-cre x Dll1f/f 
Maml1-/- 
 DNMAML1 expression 
Cd19-cre x Rbpjf/f 
Notch2/Dll1/ 
Maml1 drive 





Mx1-cre x Rbpj-/- 







Itgax-cre x DNMAML1f/f 
Itgax-cre x Notch2f/f 
Itgax-cre x Rbpjf/f 









Vav-cre x Nicastrinf/f 
Mx1-cre x Nicastrinf/f 













Table 1.2 Notch regulation of innate lymphoid cell subsets. 
ILC subset Notch manipulation Notch effect? References 
NK 
cells/ILC1 













in vitro development of 
human CD7+CD56+ 




In vitro generation of 





Notch inhibited in vitro 
NK cell development 






Promotion of rat NK cell 
development in Notch 
absence 
76 
ILC2 OP9-Dll1 in vitro nuocyte expansion 
79 
ILC3 















 The Notch-dependence of many hematopoietic cell populations highlights the 
requirement for studying Notch signaling in strict, cell-type specific genetic loss-of-
function contexts. The duration and intensity of Notch signaling is tightly regulated. 
Thus, gain-of-function approaches can result in unintended effects and unphysiological 
functions of Notch signaling. For example, gain-of-function approaches suggested a role 
for Notch signaling in adult hematopoietic stem cell (HSC) maintenance, which was 
correlated with expression of Notch ligands in the bone marrow and assumed to be 
relevant in vivo.90,91 However, strict loss-of-function approaches revealed that Notch is 
dispensable for adult HSC maintenance.92-94 Despite the presence of multiple Notch 
ligands in the bone marrow, Notch signaling is actively maintained in an off state through 
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the actions of LRF in repressing Dll4 expression in erythroblasts.65,95 Furthermore, the 
effects of Notch deprivation can be compensated by other signaling pathways in vivo. 
Thus, it is necessary to use in vivo loss-of-function approaches to identify the true 
functions of Notch signaling. The data presented in this thesis will demonstrate a clear 
role for Notch signaling in mature T cell function by using T cell-specific genetic Notch 
loss-of-function approaches. 
 
1.4 Regulation of T cell development by Notch signaling 
 Several genetic loss-of-function approaches were used to determine the effects of 
Notch signaling during T cell development in the thymus. Notch signaling was first 
described to regulate thymic αβT cell development. Early studies used complementary 
gain- and loss-of-function approaches to reveal the role of Notch signaling in developing 
T cells. Where loss of Notch1 or CSL/RBP-Jκ resulted in significant inhibition of T cell 
development and ectopic B cell development in the thymus, constitutively active forms of 
Notch signaling induced extrathymic T cell generation at the expense of B cell 
development.29,66,96 Later reports demonstrated a cell-autonomous requirement for 
Notch1 in developing T cells and Dll4 in thymic stroma for maintenance of T cell 
development.27,29 Recent work has started identifying specific targets downstream of 
Notch signaling, such as Tcf1 and Hes1, that elicit some of the effects of Notch signaling 
on T cell development.20,97 However, how Notch signaling interacts or crosstalks with 
other factors has not been fully elucidated.  
 Notch signaling is required to progressively restrict thymus-seeding progenitors to 
the T cell lineage at the expense of other hematopoietic lineages.29,80,85,98 Notch signaling 
is highest at the earliest state of T cell development, the early T progenitor (ETP), and is 
actively maintained through the double negative 2 (DN2) and DN3a stages (Figure 1.2). 
During the DN3a stage, Notch signaling promotes survival, proliferation, and 
differentiation of DN3 cells at least in part through the PI3K/Akt pathway.99 One way 
Notch signaling is turned off at the DN3a stage is through signaling downstream of the 
pre-T cell receptor that actively turns off Notch1 expression through a negative feedback 
loop involving antagonism of E2A-mediated Notch1 transcription by Id3.81,100,101 Failure 
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of Notch signaling to be turned off during later stages of T cell development can 
contribute to T-ALL in mouse models and humans.102 Notch signaling intensity remains 
very low during the subsequent DN4 and double positive (DP) CD4+CD8+ stages of T 
cell development, during which time positive and negative selection occur.83 Presumably, 
Notch signaling intensity is kept low at these stages to prevent interference of Notch 
signaling with positive and negative selection.83,103   
 
 
Figure 1.2 Regulation of Notch signaling intensity during T cell development and 
differentiation2. 
Notch signaling intensity varies throughout T cell development. The Notch target genes Dtx1 and 
Hes1 are expressed at low levels in bone marrow hematopoietic stem cells (HSCs). Upon arrival 
in the thymic environment, early T progenitors (ETPs) strongly upregulate Notch target gene 
expression. Expression levels of Notch target genes gradually increase from the ETP stage to the 
double negative 3a (DN3a) stage. After the β-selection checkpoint, during which Notch signaling 
is significantly downregulated, Notch signaling intensity steadily decreases from the DN3b stage 
to the CD4+CD8+ double positive (DP) stage. Thymic single positive (SP) CD4+ and CD8+ T cells 
as well as naïve peripheral T cells express low amounts of Notch target genes. Upon T cell 
activation in the periphery, Notch signaling intensity increases sharply in a context-dependent 
manner. 
  
                                                
2 Figure taken from: 
 
Sandy AR and Maillard I. 2009.  Notch signaling in the hematopoietic system.  Expert Opin Biol Ther, 
Nov 9(11): 1383-1389. 
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 Although it has been clearly demonstrated that Notch signaling plays a role in 
successive stages of T cell development, emerging data suggest that Notch signaling also 
regulates mature T cell differentiation during antigen-driven immune responses.   
 
1.5 Role of Notch signaling in mature T cell differentiation and function 
 Notch signaling is emerging as a key player in the differentiation and function of 
mature CD4+ and CD8+ T cells. Upon encountering activated, mature antigen presenting 
cells (APCs), CD4+ T cells can differentiate down a number of pathways, including T 
helper 1 (Th1), Th2, Th17, and T regulatory cells (Tregs).104 Th1 cells are important for 
cell-mediated immunity, express the master transcription factor T-bet, and produce IFNγ. 
In contrast, Th2 cells are required for allergic responses and helminthic immunity. Th2 
cells produce IL-4, IL-5, and IL-13 and their differentiation is driven by the transcription 
factor Gata-3. Anti-microbial immunity and inflammation is promoted by IL-17-
producing Th17 cells, driven by the master transcription factor Rorγt. Lastly, Tregs are 
essential for dampening and controlling immune responses. Mice and humans with 
mutations in the master transcription factor required for Treg generation, Foxp3, suffer 
from a multi-organ autoimmune disease, illustrating its importance for Treg suppressive 
function.105,106 These CD4+ T cell differentiation pathways are the most clearly defined. 
However, new T helper subsets are being discovered, and the plasticity of these lineages 
is only now beginning to be fully appreciated.104,107  
 Upon activation, CD8+ T cells differentiate under the influence of the master 
transcription factor Eomesodermin, which drives their cytolytic activity towards target 
cells. Eomesodermin is important for eliciting IFNγ production and cytotoxic molecule 
expression (Perforin and Granzyme B) in CD8+ T cells.108,109 Additionally, CD8+ T cells 
require CD4+ T cell help during the priming phase to respond optimally to pathogens.110 
Despite the significant amount of foundational research on CD4+ and CD8+ effector T 
cells, pathways that govern their differentiation are still being elucidated.  
 One such pathway that has the potential to regulate mature T cell differentiation is 
the Notch pathway. Notch signaling was first suggested to regulate T cell differentiation 
in a binary fashion, similar to its role in T cell development at the expense of B cells (see 
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section 1.4).111 For instance, the Flavell group suggested that Notch regulated a 
dichotomous switch between Th1 and Th2 differentiation.111 Using in vitro gain- and 
loss-of-function approaches, it was shown that Dll4 induced Th1 differentiation while 
Jag1 promoted Th2 differentiation.111,112 However, it is becoming clear that Notch 
signaling can regulate mature T cell responses in a context-dependent manner. Through 
multiple, complementary gain- and loss-of-function approaches in vivo, Notch signaling 
was shown to directly regulate transcription of Il4 and Gata3 during Th2 
differentiation.113-116 In contrast, Notch appeared dispensable for clearance of pathogens, 
like Leishmania major, that require Th1 cells for disease control.115 However, subsequent 
reports suggested that Notch might also regulate Th1 differentiation. Using γ-secretase 
inhibitors (GSIs), which target Notch as well as other transmembrane proteins, Notch1 
gain-of-function, and a Notch1 antisense strategy, it was purported that Notch1 directly 
regulates transcription of Ifng and Tbx21 (encoding T-bet).117 Others reported that 
inhibition of Notch signaling using systemic Dll4 blockade decreased or did not change 
IFNγ production by peripheral CD4+ T cells.118,119  
 Similar studies submitted that Notch signaling may promote Th17 and Treg 
differentiation.118,120-123 Using anti-Dll4 blocking antibodies administered systemically, 
Notch was suggested to either affect or not change IL-17A production.118,119 Also, Rorγt, 
the master transcription factor for Th17 cells, and the cytokine Il17a were proposed to be 
direct targets of Notch signaling.121 Using in vitro Notch ligand gain-of-function assays 
and some in vivo loss-of-function, Notch was suggested to regulate IL-17 production by 
direction regulation of IL-9 expression.124 
 Lastly, Treg differentiation and suppressive activity were also suggested to be 
regulated by Notch signaling.118,120,122,123 Using in vitro and in vivo GSI treatment, a 
Notch1 antisense strategy, or Notch1 gain-of-function, Notch was suggested to directly 
regulate Foxp3 expression through cooperation with Smad proteins.120,123 In contrast, 
other work using Notch ligand blocking antibodies reported that Notch inhibition 
promoted Treg development.118 Overall, Notch signaling seems to regulate mature T cell 
function based on the immune context, although no unifying mechanism has been found 
to account for the effects of Notch in CD4+ T cells. 
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 The role of Notch signaling in CD8+ T cells has been less studied in comparison 
to Notch in CD4+ T cells. Work by Yasutomo’s group showed that Notch2 could directly 
regulates Eomes (encoding Eomesodermin), and Gzmb (encoding Granzyme B) in 
cooperation with CREB1 in a CD8+ T cell line.125 Similarly, it was proposed that Notch1 
regulates expression of Eomes, Gzmb, and Prf1 (encoding Perforin).126 Furthermore, 
cooperation of T cell receptor and Notch signaling were purported to regulate IFNγ 
expression in CD8+ T cells through in vitro GSI treatment and a Notch1 antisense 
strategy.127 
 Collectively, the wide variety of conclusions available in the literature may reflect 
the different experimental systems used, many of which were gain-of-function strategies 
or systemic modulation (i.e. GSIs and blocking antibodies) of Notch signaling. As seen in 
section 1.3, Notch signaling has the ability to regulate a significant number of cellular 
subsets in the hematopoietic system.60,61 Thus, approaches that modulate Notch signaling 
systemically could be altering Notch signaling in multiple cell types, making 
interpretation of the findings difficult. 
 In contrast, data generated using strict T cell-specific loss-of-function approaches, 
such as those described in this dissertation, suggest that Notch regulates T cell responses 
in a context-dependent manner. For instance, Notch signaling may modulate the 
threshold of T cell activation resulting in T cell differentiation changes downstream. This 
concept is reminiscent of T cell differentiation changes as a consequence of costimulation 
blockade during T cell-mediated immune disorders. Thus, Notch signaling may be 
modulating T cell responses in a context-dependent manner by acting as a molecule 
providing costimulation-like signals to T cells. This hypothesis was formulated based on 
work in this thesis to investigate the role of Notch signaling in two T cell-mediated 
immune disorders: graft-versus-host disease (GVHD) and experimental autoimmune 
encephalomyelitis (EAE; discussed in Chapter 5). 
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1.6 Graft-versus-host disease 
1.6.1 GVHD – a historical perspective 
 In 1944, Medawar performed some of the earliest transplantation experiments 
using a skin allograft transplantation model.128 Medawar referred to the rejection of the 
allogeneic skin tissue as the host-versus-graft (HVG) response.128 Following Medawar’s 
early experiments, several cellular and genetic contributors to transplantation tolerance 
and rejection were identified.129,130 In 1951, injection of bone marrow cells into guinea 
pigs and mice was shown to rescue them from lethal irradiation injury.131 
 In the late 1940s and 1950s, there was a burst of activity in the field of 
transplantation. Several groups demonstrated that hematopoietic cells were significant 
mediators of transplantation tolerance or rejection, depending on the source of 
hematopoietic cells.132-138 However, studies in the 1950s and 1960s that sought to 
translate transplantation into patients were met with significant hurdles. While many 
patients failed to even engraft the donor cells, a significant number succumbed to severe 
GVHD, a syndrome initially ascribed to donor immunocompetent cells attacking the host 
tissues of compromised allogeneic recipients.139 Despite these failures, there was a 
renewed sense of hope for transplantation clinical translation with the identification of 
effective conditioning regimens, in part using dogs as a model transplantation system. 
Because of their high degree of genetic diversity similar to humans, dogs made an ideal 
system for transplantation studies.140 Following results of transplantation in large 
animals, the late 1960s brought about a flurry of studies translating transplantation into 
the clinic.  
 Despite early and more recent efforts, GVHD still remains the most significant 
complication following allogeneic bone marrow transplantation (allo-BMT).141,142 In 
many patients undergoing transplantation for malignant disorders, the goal of 
transplantation is to achieve efficient anti-tumor activity while minimizing the 
detrimental GVHD side effects. Patients preparing for transplantation are conditioned 
with chemotherapeutics and/or irradiation.143 These conditioning regimens promote the 
release of pattern associated molecular patterns and chemokines, as well as the release of 
gut microbiota constituents.144,145 These “danger signals” activate APCs. GVHD is 
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initiated when infused donor T cells recognize allo-antigens presented by donor or host 
hematopoietically or host non-hematopoietically derived APCs.146-150 These activated T 
cells produce abundant cytokines, coined the cytokine storm, and elicit GVHD as well as 
the beneficial graft-versus-tumor (GVT) effects.151,152 GVHD is divided into two forms: 
acute and chronic. Acute GVHD is characterized by strong inflammation while chronic 
GVHD has more autoimmune-like features, as well as chronic tissue inflammation and 
remodeling involving multiple cell types.141 For the purpose of this dissertation, I will 
focus on T cell intrinsic aspects of acute GVHD biology.  
 
1.6.2 Alloreactive T cell differentiation in GVHD 
 Initially, Th1 cells were thought to be the main aggressor inducing acute GVHD. 
However, it was later found that all T helper lineages could contribute to GVHD 
pathogenesis, each with their own tissue tropism and pathogenic effects.153,154 For 
instance, IL-17-/- donor T cells had increased differentiation to the Th1 lineage but 
delayed GVHD onset, although overall GVHD survival was not significantly 
changed.154,155 However, deletion of the master transcription factor of Th17 cells, Rorγt, 
had no measureable effect on survival of allogeneic transplant recipients as compared to 
WT T cell recipients.156 In contrast, genetic removal of both T-bet and Rorγt in donor T 
cells protected from GVHD, partly attributable to increased Treg frequency.157 These 
data suggest that both Th1 and Th17 cells differentially contribute to GVHD 
pathogenesis.  
 Investigation of Th2 cells in acute GVHD found that knocking out STAT6, an 
important signal transducer downstream of IL-4 signaling, in T cells resulted in slightly 
prolonged survival as compared to WT T cell recipients.153,158 Similarly, IL-4 knockout T 
cell recipients had improved survival after allo-BMT compared to WT T cell 
recipients.159 In contrast to these findings, in vitro polarization of T cells to the Th2 
lineage before transplantation decreased GVHD severity and serum IFNγ and TNFα 
levels.160 Collectively, these data suggest that Th1 cells may dominate the GVHD 
reaction when Th2 and Th17 responses are intact. Upon manipulation of specific T helper 
lineages, the balance can tip in favor of the other lineages for inducing GVHD pathology. 
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 Contrasting with the inflammatory environment created by T helper cells during 
GVHD, Tregs contribute to protection from GVHD. Before the discovery of the master 
transcription factor of Tregs, Foxp3 (Forkhead box P3), Tregs were identified by high 
expression of the cell surface marker CD25, the high affinity alpha chain of the IL-2 
receptor.161-166 Despite Foxp3 being a more specific marker for Treg identification, its 
intracellular location makes it difficult for use in human applications requiring cell 
separation. Thus, CD25 positivity still remains a reliable marker for Treg-enrichment. 
Early studies that co-transplanted naïve T cells with CD25+CD4+ Tregs demonstrated that 
Tregs could suppress GVHD at multiple time points post-transplantation.167-169 Despite 
the profound suppression of GVHD, co-infusion of Tregs with effector T cells at the time 
of transplant did not prevent the GVT reaction.167,169 Altogether, these data highlight the 
importance of Tregs in suppressing GVHD.  
 More recent studies have focused on translating Treg-related therapies to the 
clinic. Correlative studies have shown that there is a direct association between Treg 
frequency and GVHD severity in patients.170-172 In fact, clinical trials seeking to 
therapeutically expand Treg populations in GVHD patients using low-dose IL-2 therapy 
have shown promise in decreasing GVHD severity.173-176 In summary, a fine balance of 
proinflammatory conditions produced by effector T cells and suppressive activities 
mediated by Tregs regulates GVHD.  
 
1.6.3 T cell costimulatory and coinhibitory pathways in GVHD 
 Costimulatory and coinhibitory molecules also play a prominent role in GVHD 
severity and lethality. The immunoglobulin and tumor necrosis factor (TNF) 
superfamilies are the two main families of cosignaling molecules in T cells. The members 
of these families can demonstrate a promiscuous interaction pattern whereby one receptor 
can interact with a wide variety of ligands and one ligand can interact with many 
receptors. Additionally, interaction between members from different families has been 
shown, as is the case for the immunoglobulin family member BTLA interacting with the 
TNF family member HVEM.177 
 A non-exhaustive list of immunoglobulin superfamily members includes CD28, 
CD80/B7-1, CD86/B7-2, B7-H1/PD-L1, B7-DC/PD-L2, CTLA-4 (Cytotoxic T 
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lymphocyte antigen-4), PD-1 (Programmed death-1), BTLA (B- and T- lymphocyte 
attenuator), ICOS (Inducible T cell costimulatory), and ICOS ligand/B7-H2.178 The TNF 
superfamily consists of approximately 50 members including HVEM (herpes virus entry 
mediatory), TNFSF14 (LIGHT), OX40, OX40 ligand, 4-1BB, 4-1BB ligand, CD30, 
CD30 ligand, CD40, and CD40 ligand.179  
 All the molecules listed above have been studied in the context of GVHD. For 
instance, inhibiting the costimulatory molecules CD80, CD86, or CD28 with blocking 
antibodies resulted in reduced T cell expansion, increased survival after transplantation, 
and largely preserved GVT responses.180-182 Similar results were shown when T cells 
were CD28-deficient.183 Use of a superagonistic anti-CD28 antibody also yielded 
protection from GVHD and preserved GVT, but the effect was attributed to enhance 
expansion of Tregs, highlighting the differential sensitivity of effector T cells and Tregs 
to CD28 signaling.184,185 Moreover, blocking the costimulatory molecule CD40L or 
activating the coinhibitory molecule CTLA-4 (CTLA-4 Ig) alone or in combination with 
anti-CD40L resulted in decreased GVHD, at least partially attributable to tolerance 
induction in T cells.181,186-191 
 OX40 has also been studied in the context of GVHD elicited by CD4+ and CD8+ 
T cells. While OX40 deficiency in CD8+ T cells increased GVHD severity, OX40-/- or 
OX40L-/- CD4+ T cells induced less GVHD.192 Inhibition of other molecules, like 4-1BB, 
HVEM, CD30, and ICOS in T cells, has also resulted in reduced GVHD severity after 
transplantation usually owing to reduced effector T cell function or survival.193-201 On the 
other hand, consistent with a role for PD-1 in dampening T cell effector function, 
inhibition of PD-1 using either anti-PD-1 antibodies or PD-1 knockout T cells evoked 
increased GVHD severity, at least in part due to heightened IFNγ responses.202  
 These previous approaches seeking to block one or a few effector or 
costimulatory pathways did not yield a significant survival advantage.154,155,159,192,195,203-
207 Typically, inhibiting one pathway resulted in upregulation of other proinflammatory 
pathways, which is exemplified in the case of inhibiting certain T cell cytokines.154 In 
contrast, work presented in Chapters 2, 3, and 4 will demonstrate that inhibition of Notch 
signaling in alloreactive T cells significantly inhibits GVHD with broad effects in T cells 
that are not limited to inhibition of a single T helper lineage. Thus, inhibition of Notch 
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signaling provides beneficial immunomodulation without global immunosuppression, in 





















Chapter 2  
Notch signaling is a critical regulator of allogeneic CD4+ 
T cell responses mediating graft-versus-host disease3 
2.1 Abstract 
 Graft-versus-host disease (GVHD) remains the major barrier to the success of 
allogeneic hematopoietic stem cell transplantation (HSCT). GVHD is caused by donor T 
cells that mediate host tissue injury through multiple inflammatory mechanisms. 
Blockade of individual effector molecules has limited efficacy in controlling GVHD. 
Here, we report that Notch signaling is a potent regulator of T cell activation, 
differentiation, and function during acute GVHD. Inhibition of canonical Notch signaling 
in donor T cells markedly reduced GVHD severity and mortality in mouse models of 
allogeneic HSCT. Although Notch-deprived T cells proliferated and expanded in 
response to alloantigens in vivo, their ability to produce interleukin-2 and inflammatory 
cytokines was defective. Notch inhibition decreased the accumulation of alloreactive T 
cells in the intestine, a key GVHD target organ. However, Notch-deprived alloreactive 
CD4+ T cells retained significant cytotoxic potential, leading to improved overall survival 
of the recipients. These results identify Notch as a novel essential regulator of pathogenic 
CD4+ T cell responses during acute GVHD and suggest that Notch signaling in T cells 
should be investigated as a therapeutic target after allogeneic HSCT. 
2.2 Introduction 
 Graft-versus-host disease (GVHD) is a life-threatening complication that limits 
the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT).141,142,208,209 
Despite prophylaxis, GVHD still occurs in many allogeneic HSCT patients. Furthermore, 
standard immunosuppressive therapy for acute GVHD gives rise to disappointing 
                                                
3 Excerpts taken from: 
 
Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT, Friedman A, Kato K, He S, Cui S, Hexner E, 
Frank DM, Emerson SG, Pear WS, Maillard I. 2011. Notch signaling is a critical regulator of allogeneic 
CD4+ T cell responses mediating graft-versus-host disease. Blood 117: 299-308.  
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sustained response rates (< 50%) and impairs graft-versus-tumor (GVT) activity, 
increasing the risk of tumor relapse.209,210 GVHD is caused by donor T cells attacking 
normal host tissues, involving complex interactions of immune cells and inflammatory 
mechanisms mediating target organ injury.141,142,208,209 In particular, multiple T cell 
effector differentiation pathways can induce GVHD.154,155,159,203-206 Novel strategies that 
inhibit GVHD while preserving GVT could markedly improve allogeneic HSCT. 
Whether Notch signaling is critical to allogeneic T cell responses and GVHD remains 
unknown. 
 Here, we report that Notch inactivation in donor CD4+ T cells inhibits their 
capacity to mediate acute GVHD but preserved their cytotoxic potential. Notch-deprived 
CD4+ T cells expanded in response to alloantigens in vivo, but displayed a reduced 
accumulation in the gut and failed to produce a broad range of effector cytokines. These 
findings differ from past observations of Notch signaling in mature CD4+ T 
cells.60,117,125,126,211-213 Our results indicate that Notch inhibition in alloreactive T cells 
may be a promising strategy to control GVHD while preserving significant GVT effects 
after allogeneic HSCT. 
2.3 Results 
2.3.1 Inactivation of Notch signaling by DNMAML in donor T cells inhibits acute 
GVHD 
 To inactivate Notch in mature T cells, we conditionally expressed the pan-Notch 
inhibitor DNMAML. DNMAML contains the MAML1 Notch-binding domain fused to 
green fluorescent protein (GFP) and blocks transcriptional activation downstream of all 
Notch receptors.82,115 We crossed Cd4-Cre transgenic mice with C57BL/6 (B6) 
ROSA26DNMAMLf/+ mice.81,115 This resulted in Cre-mediated DNMAML activation in 
CD4+CD8+ thymocytes, followed by stable expression in CD4+ and CD8+ lymphocytes. 
This strategy does not interfere with the requirement for Notch signaling during early T-
cell development and produces normal numbers of T cells without baseline 
abnormalities.115 All mature CD4+ and CD8+ T cells in these mice cannot respond to 
Notch signaling, an excellent model to study the role of the Notch pathway during 
immune responses in vivo. 
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 We first tested the impact of Notch deprivation in alloreactive CD4+ T cells using 
the major histocompatibility complex (MHC)–mismatched B6 anti-BALB/c model (Fig. 
2.1). WT or DNMAML CD4+ B6 T cells (CD45.2, H-2b) were transplanted with T cell-
depleted bone marrow (TCD BM) from B6-SJL mice (CD45.1) into lethally irradiated 
BALB/c mice (H-2d). Control mice receiving TCD BM remained free of GVHD. All WT 
CD4+ T cell recipients developed severe acute GVHD with > 50% dying around day 10 
and all by day 40 (Fig. 2.1A). In contrast, BALB/c mice receiving DNMAML CD4+ T 
cells did not develop significant clinical signs of acute GVHD, with 75% surviving > 80 
days after transplantation. The survival rate of DNMAML T cell recipients was similar to 
that of TCD BM recipients. Assessment of the clinical GVHD score indicated markedly 
decreased acute GVHD severity in DNMAML compared with WT T cell recipients (Fig. 
2.1A). This suggested that DNMAML CD4+ T cells induced only mild disease. 
Histological examination of GVHD target organs showed markedly reduced 
inflammation in the skin, liver, and intestine of DNMAML compared with WT CD4+ T 
cell recipients (Fig. 2.1B). To further quantify the protection provided by Notch 
inhibition, we titrated up the number of donor DNMAML CD4+ T cells and down the 
number of WT CD4+ T cells (Fig. 2.1C). Mice receiving a very high dose of DNMAML 
CD4+ T cells (5.0 × 106) remained significantly better protected against GVHD lethality 
and morbidity than mice receiving only 0.5 × 106 WT CD4+ T cells. Thus, DNMAML 
expression had more protective effects than a 10-fold reduction in donor CD4+ T cells. 
DNMAML CD4+ T cells also had significantly preserved anti-leukemic activity in vivo 
(data not shown). Together, these results demonstrate that inactivation of Notch signaling 
in donor CD4+ T cells prevents acute lethal GVHD in mice. 
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Figure 2.1 Inactivation of Notch signaling in donor CD4+ T cells inhibits acute 
GVHD in irradiated MHC-mismatched hosts. 
(A) Lethally irradiated BALB/c mice (1000 rads) were transplanted with 5x106 TCD BM from 
B6-SJL mice (n=10), with or without 2x106 WT B6 CD4+ T cells (WT CD4, n=15) or B6 
DNMAML CD4+ T cells (DNMAML CD4, n=19). Survival was assessed over time (P< 0.001, 
WT versus DNMAML CD4+ T cells). Data shown are pooled from 3 independent experiments 
(left panel). Right panel, clinical GVHD score (*P< 0.05, WT versus DNMAML CD4+ T cells). 
Representative data from 1 of 2 independent experiments are presented. (B) Histological GVHD 
score. Tissues were collected at day 10 (n= 4 for each group) or >20 days (range 20-40; WT, n= 
8; DNMAML, n= 9) after transplantation (850 rads; left). Int, intestine; Liv, liver; Sk, skin. Right 
panel, histological analysis of intestine, liver, and skin after transplantation of WT (n= 8) or 
DNMAML (n= 9) CD4+ B6 T cells (x100), which is representative of 2 independent experiments. 
(C) Dose-response experiment. Lethally irradiated BALB/c mice were transplanted with 5x106 
TCD BM from B6-SJL mice (n= 13), or TCD BM with 0.5x106 or 2x106 WT B6 CD4+ T cells 
(WT CD4, n= 10/group) versus 2x106 or 5x106 DNMAML CD4+ T cells (DNMAML CD4, n= 
10/group). Survival (left panel) and clinical GVHD score (right panel) were assessed over time. 
Survival (P= 0.012) and GVHD severity (P < 0.01) were worse after administration of 0.5x106 
WT CD4+ than 5x106 DNMAML CD4+ T cells (0.5x106 WT versus 5x106 DNMAML CD4+ T 
cells). 
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2.3.2 Extensive proliferation and expansion of donor DNMAML CD4+ T cells in 
irradiated MHC-mismatched hosts 
 To determine the mechanisms by which Notch inhibition in CD4+ T cells prevents 
GVHD, we first assessed engraftment and expansion of Notch-deprived donor T cells. 
We tracked DNMAML CD4+ T cells in irradiated BALB/c recipients at day 5 after 
transplantation (Fig. 2.2A-E). We found modestly but significantly increased donor-
derived CD4+ T cell numbers in spleens from BALB/c recipients of DNMAML 
compared with WT T cells (Fig. 2.2A, B). When CFSE was used to track cell division, 
both groups had a similar percentage of donor CFSElow T cells (approximately 99%), 
consistent with extensive proliferation, although the full division history could not be 
compared due to fluorescence of the DNMAML-GFP fusion protein (Fig. 2.2C). To 
assess proliferation of DNMAML-expressing CD4+ T cells without GFP interference, we 
labeled donor T cells with the tracking dye eFluor670 (Fig. 2.2D). This revealed a similar 
eFluor670 dilution profile in day 5 WT and DNMAML B6 CD4+ T cells. Furthermore, 
we pulsed BALB/c recipient mice with BrdU and assessed BrdU incorporation by donor-
derived CD4+ T cells (Fig. 2.2E). A high percentage (approximately 60%) of both WT 
B6 and B6 CD4+ DNMAML T cells were found to be BrdU+, consistent with a similar 
rate of cell cycle entry. To evaluate if Notch inhibition affected the expansion of 
alloreactive T cells at later stages, we tracked donor-derived CD45.2+ B6 and B6-
DNMAML CD4+ T cells in the spleen, BM, liver, and thymus of recipient BALB/c mice 
at days 14 and 21 (Fig. 2.2F). Higher numbers of donor-derived CD4+ T cells were 
recovered from these organs in B6-DNMAML compared with WT B6 recipients, most 
prominently at day 21 after transplantation. Given their similar proliferation rate, this 
increased expansion could be related to decreased activation-induced cell death of the 
DNMAML CD4+ T cells. 
 Because immune-mediated intestinal damage is a prominent cause of mortality in 
the B6 anti-BALB/c GVHD model, we assessed accumulation of WT or DNMAML 
donor-derived CD4+ T cells in the small intestine at days 11 and 14 after transplantation 
(Fig. 2.2G). Few IELs were recovered at these time points in both groups (data not 
shown). In contrast, a significant number of donor WT CD4+ T cells were recovered from 
the lamina propria. We observed a significant decrease (4- to 10-fold) in the number of 
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infiltrating DNMAML CD4+ T cells at both time points (Fig. 2.2G). To assess if this was 
related to a cell-autonomous effect of Notch inhibition, we coinjected equal numbers of 
WT and DNMAML CD4+ T cells.  
 
Figure 2.2 Preserved proliferation and in vivo expansion of DNMAML alloreactive 
CD4+ T cells. 
(A) Identification of donor-derived CD4+ T cells in the spleen on day 5 after transplantation. 
DNMAML T cells expressed the DNMAML-GFP fusion protein. Data are representative of 5 
experiments. (B) Absolute number of donor-derived CD4+ T cells in the spleen at day 5 (mean + 
SD, n= 4). (C) Tracking of CFSE-labeled donor CD4+ T cells at day 5. Both WT and DNMAML 
CD4+ T cells had undergone extensive proliferation, as shown by the high percentage of CFSElow 
cells. Fluorescence levels appear higher in the DNMAML-expressing cells due to fluorescence of 
the covalently fused GFP protein. This effect is absent in Rbpj knockout mice. (D) Tracking of 
eFluor670-labeled donor WT and DNMAML CD4+ T cells at day 5, showing extensive 
proliferation in both (% eFluor670low cells). (E) BrdU uptake by donor WT and DNMAML CD4+ 
T cells at day 5. Mice were pulsed with BrdU 6 hours before harvest (n= 5 per group). (F) 
Absolute number of CD45.2+ donor-derived WT and DNMAML CD4+ T cells in spleen, liver, 
BM, and thymus on day 14 (WT, n= 12; DNMAML, n= 11) and 21 (WT, n= 7; DNMAML, n= 5) 
post-transplantation (pool of 2 independent experiments). (G) Decreased number of donor- 
derived DNMAML compared with WT CD4+ T cells in the lamina propria of the small intestine 
on days 11 (WT, n= 5; DNMAML, n= 5) and 14 after transplantation (WT, n= 6; DNMAML, n= 
4). *P< 0.05, **P< 0.01 (2-tailed unpaired Student t test). 
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In this context, DNMAML CD4+ T cells were not excluded from the intestine (data not 
shown), indicating that Notch does not directly control their homing to or retention in the 
gut. Instead, the decreased accumulation of donor CD4+ T cells in the gut of DNMAML 
compared with WT recipients may result from a reduced inflammatory response initiated 
by the alloreactive T cells. 
 Altogether, Notch-deficient donor CD4+ T cells were able to proliferate and 
accumulate in lymphoid and hematopoietic tissues of allogeneic HSCT recipients, but 
showed decreased accumulation in the gut, a key GVHD target organ. This might account 
at least in part for the decreased GVHD severity and mortality in DNMAML T cell 
recipients. 
2.3.3 Impaired activation and effector functions of alloreactive DNMAML CD4+ T 
cells 
 We next assessed the in vivo effect of Notch inhibition on the activation and 
effector functions of alloantigen-stimulated CD4+ T cells. Donor T cells were recovered 5 
days after transplantation. CD25 expression was reduced in donor DNMAML CD4+ T 
cells, suggesting decreased activation (Fig. 2.3A). Intracellular staining showed that 
production of the inflammatory cytokines IFNγ and TNFα, as well as IL-2, was markedly 
decreased in DNMAML CD4+ T cells (Fig. 2.3B). Further analysis revealed that 
DNMAML CD4+ cells displayed impaired production of cytokines associated with Th1 
(IFNγ, TNFα), Th2 (IL-4), and Th17 differentiation (IL-17), in addition to IL-2 (Fig. 
2.3C). These data suggest that DNMAML-expressing alloreactive CD4+ T cells had a 
markedly decreased ability to produce a broad range of cytokines. This included 
cytokines from multiple T helper cell subsets as well as IL-2, an effect of Notch 
inhibition in mature T cells that has not been previously reported. 
 Next, we assessed whether DNMAML impaired in vivo expansion of Foxp3-
expressing CD4+ T cells (Fig. 2.3D). In contrast to decreased cytokine production and 
CD25 expression, we found a slightly but significantly increased percentage of Foxp3+ 
cells among day 5 donor-derived B6 DNMAML compared with WT B6 CD4+ T cells. To 
evaluate if increased T cell–mediated suppression could account for all the effects of 
DNMAML in preventing acute GVHD, we cotransferred equal numbers of WT and 
DNMAML B6 CD4+ T cells into irradiated BALB/c mice (Fig. 2.4A). Comparable 
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expansion of both populations was observed in vivo (Fig. 2.4B). Recipients of mixed WT 
and DNMAML CD4+ T cells still developed severe lethal GVHD, similar to mice 
receiving only WT cells (Fig. 2.4C). Thus, it is unlikely that an increased suppressive 




Figure 2.3 Impaired activation and cytokine response in alloreactive DNMAML 
CD4+ T cells. 
WT or DNMAML B6 CD4+ T cells were tracked after transplantation into lethally irradiated 
MHC-mismatched BALB/c mice (900 rads). (A) Decreased expression of CD25 (IL-2Rα) in 
DNMAML CFSElow donor CD4+ T cells. Bar graphs show the percentage of cells expressing 
CD25 and the CD25 mean fluorescence intensity (MFI; mean + SD, n= 3). (B) Intracellular 
staining for IFNγ, TNFα, and IL-2 after ex vivo restimulation with plate-bound anti-CD3 and 
anti-CD28 antibodies. Data are representative of 5 experiments. Bar graphs show mean + SD (n= 
3). (C) Cytokine production by 3x104 donor-derived CD4+ T cells sort-purified 5 days after 
transplantation and cultured for 6 hours in the presence of anti-CD3/anti-CD28 antibodies (mean 
+ SD). (D) Intracellular staining for FoxP3 in donor WT and DNMAML CD4+ T cells on day 5. 
*P< 0.05, **P< 0.01 (2-tailed unpaired Student t test). 
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Figure 2.4 Enhanced suppression does not mediate the decreased pathogenicity of 
DNMAML CD4+ T cells. 
(A) Experimental design. T cell depleted bone marrow (TCD BM) was transplanted into lethally 
irradiated BALB/c recipients, with or without 2x106 MACS-purified CD4+ T cells from control 
wild type B6 mice (WT), DNMAML B6 mice, or a 1:1 mixture of WT and DNMAML CD4+ T 
cells. (B) Tracking of donor-derived T cells at day 5 in the group receiving the 1:1 mixture of WT 
and DNMAML cells. Close to 50% of donor-derived CD4+ T cells expressed DNMAMLGFP, 
consistent with similar in vivo expansion. (C) Overall survival after transplantation. Similarly to 
recipients of WT CD4+ T cells (n=5), high-grade lethality was observed in the group receiving 
both WT and DNMAML CD4+ T cells (n=6), indicating that enhanced immune suppression by 
DNMAML CD4+ T cells did not account by itself for the reduced pathogenicity of these cells. 
  
2.3.4 Loss of CSL/RBP-Jκ  impairs the effector functions of alloreactive CD4+ T cells 
 Notch-mediated transcriptional activation requires CSL/RBP-Jκ, encoded by Rbpj 
.31,214 To rule out off-target effects of DNMAML, we studied T cells with conditional 
Rbpj inactivation (Fig. 2.5).214 This also allowed tracking of CFSE-labeled T cells 
without interference from DNMAML-GFP fluorescence. Five days after transfer into 
BALB/c recipients, Rbpjf/f Cd4-Cre+ T cells had proliferated extensively, with most cells 
having divided > 8 times, similar to control cells (Fig. S2.5A). The expansion of 
CSL/RBP-Jκ-deficient CD4+ T cells was preserved. As with DNMAML, CD25 
expression (Fig. 2.5B) and production of IFNγ, TNFα, and IL-2 were reduced in 
CSL/RBP-Jκ–deficient CD4+ T cells (Fig. 2.5C, D). When assessed around the onset of 
proliferation, CSL/RBP-Jκ-deficient CD4+ T cells displayed normal up-regulation of the 
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activation markers CD69, CD44, and CD25 (Fig. 2.5E). The equivalent effects of 
CSL/RBP-Jκ loss and DNMAML expression independently validate the critical role of 
Notch in alloreactive T cells. 
 
 
Figure 2.5 Preserved proliferation and expansion but defective function of 
alloreactive CSL/RBP-Jk-deficient CD4+ T cells. 
CFSE-labeled CD4+ T cells were tracked after transplantation of 2x106 cells from WT B6 or Cd4-
Cre Rbpjf/f donors (KO, lacking CSL/RBP-Jκ) into lethally irradiated MHC-mismatched BALB/c 
mice (900 rads). (A) Tracking and CFSE dilution profile of donor-derived CD4+ T cells in the 
spleen at day 5 after transplantation. Absolute numbers of donor-derived CD4+ T cells recovered 
from the spleen at day 5 (mean ± SD, n=3). (B) Decreased expression of CD25 in donor-derived 
Cd4-Cre Rbpjf/f T cells at day 5. Bar graphs show the percentage of cells expressing CD25 and the 
CD25 mean fluorescence intensity (MFI) among CFSElow donor-derived CD4+ T cells (mean ± 
SD, n=3). (C) Intracellular staining for IFNγ and TNFα as well as IL-2 (D) after ex vivo 
restimulation with plate-bound anti-CD3 antibody. Data are representative of three experiments. 
(E) Normal early activation of CSL/RBP-Jκ-deficient CD4+ T cells as assessed through 
upregulation of CD69, CD44 and CD25 36 hours after transplantation. *p<0.05, **p<0.01 (two-
tailed unpaired Student t test). 
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2.3.5 Preserved in vitro and in vivo cytotoxicity of Notch-deficient alloreactive CD4+ 
T cells 
 To assess the global impact of DNMAML expression on CD4+ T cell–mediated 
cytotoxicity in vivo, we quantified the ability of BALB/c recipients of WT B6 or 
DNMAML CD4+ T cells to eliminate CFSE-labeled allogeneic I-Ad+ BALB/c targets 
(Fig. 2.6A). Compared with TCD BM recipients, only a small fraction of infused 
BALB/c allogeneic targets was recovered from both WT and DNMAML CD4+ T cell 
recipients, indicating similar and efficient in vivo cytotoxic activity. Furthermore, 
DNMAML alloreactive CD4+ T cells effectively killed A20 leukemic cells in an in vitro 
assay, at least at high effector:target ratios, despite their modestly reduced killing 
capability compared with WT alloreactive T cells (Fig. 2.6B). Altogether, Notch 
blockade profoundly impaired the ability of alloreactive T cells to produce effector 
cytokines, with less drastic effects on their cytotoxic potential. 
 
 
Figure 2.6 Preserved cytotoxic potential of Notch-deprived CD4+ T cells. 
A) In vivo cytotoxic activity of WT or DNMAML CD4+ T cells against infused CFSEhigh host-
type BALB/c (H-2d) B cell targets, compared with control CFSElow B6-SJL cells (H-2b). 
Analysis was performed on day 14, 18 hours after infusion of CFSE-labeled targets at a 1:1 ratio 
(107 each). Data are shown as percent residual CFSEhighH-2Kd+ cells among all infused CFSE-
labeled B cells. The dotted line represents expected recovery in the absence of cytotoxicity. (B) In 
vitro cytotoxic activity of WT or DNMAML CD4+ T cells against A20 leukemia cells. *P< 0.05 
(2-tailed unpaired Student t test). 
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2.4 Discussion 
 Identifying the critical signals controlling the complex features of alloimmunity is 
essential for regulating the balance between harmful and beneficial effects of allogeneic 
HSCT.208,210 Our findings demonstrate a critical role for Notch signaling in alloreactive 
CD4+ T cell activation, differentiation, and function during acute GVHD. Notch 
inactivation in donor CD4+ T cells preserved their ability to engraft and proliferate, but 
inhibited their accumulation in the gut and acquisition of selected effector functions 
during the acute GVH reaction. Notch inhibition decreased the production of multiple 
cytokines by alloantigen-activated CD4+ T cells, including IL-2, and prevented severe 
GVHD through mechanisms that differed from past observations of Notch function in 
mature T cells. However, Notch inhibition preserved significant cytotoxic activity in 
alloreactive CD4+ T cells.  
 Multiple studies have shown that inhibition of single effector pathways provides 
limited therapeutic benefit in GVHD.154,155,159,203-206 For example, inhibition of single 
cytokines or inactivation of the master transcription factors controlling individual effector 
T cell lineages has not translated into a marked survival advantage. In many cases, organ 
injury mediated by a specific T cell lineage (e.g. Th1 cells) is replaced by another pattern 
of target organ injury mediated by other lineages (e.g. Th2 or Th17 cells). In contrast, 
Notch inhibition had functional consequences on multiple CD4+ T helper lineages. As a 
result, Notch inhibition had a dramatic impact on survival even in otherwise uniformly 
lethal models of GVHD. However, Notch inhibition did not merely cause 
immunosuppression, because in vivo expansion of alloreactive CD4+ T cells and 
significant cytotoxic activity were preserved. Thus, we suggest that Notch signaling in 
CD4+ T cells should be explored as a novel therapeutic target after allo-HSCT. 
 Past reports using overexpression of Jagged Notch ligands have shown that 
Jagged can modulate the reactivity of T cells to alloantigens, inducing expansion of Tregs 
and T cell hyporesponsiveness.215 This differs from our observations, because we 
observed a significant trend for enhanced in vivo Treg expansion and decreased 
production of effector CD4+ T cell cytokines. Thus, in vitro gain-of-function assays do 
not predict the in vivo function of Notch signaling in alloimmunity. In addition, it is 
possible that the effects of Jagged ligands in these studies could differ from and even 
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antagonize those of Delta like ligands, as reported in other experimental systems.216 In 
addition, our results also differ from past reports in which GSIs and anti-Notch1 
antibodies were shown to inhibit Treg function in vitro and in a mouse model of allergic 
airway inflammation.122,217 Although the reasons underlying these differences remain to 
be explored, this also highlights the value of assessing the role of Notch signaling in vivo 
in specific types of immune response using genetic strategies of pan-Notch inhibition. 
 Although Notch-deficient alloreactive T cells had multiple functional defects, 
their initial activation, proliferation, and expansion appeared generally normal. 
Subsequently, significant features of Notch deprivation included decreased expression of 
CD25 (IL-2Rα). Notch signaling was reported to regulate CD25 at least in developing T 
cells.81,218 It is possible that decreased CD25 expression could contribute to impaired 
activation of Notch-deprived T cells through decreased IL-2 sensitivity. However, we did 
not observe decreased CD25 expression at all time points and in all models of allogeneic 
HSCT. For example, decreased CD25 expression was not observed in unirradiated semi-
allogeneic recipients, despite multiple changes in DNMAML T cell differentiation (data 
not shown). Thus, reduced CD25 expression cannot account for all functional defects in 
Notch-deprived T cells. Furthermore, preserved proliferation despite impaired IL-2 
production is consistent with past studies of alloreactive T cells showing that other 
cytokines such as IL-15, but not IL-2, are most important to sustain their proliferation in 
vivo.219 
 Our work presents the first example of a disease model in which Notch inhibition 
prevents otherwise uniform lethality. Although systemic Notch inhibition can cause 
significant side effects, in particular gastrointestinal toxicity due to combined 
Notch1/Notch2 inhibition, multiple strategies are being developed to overcome this 
important limitation. This includes targeting of specific Notch receptors and ligands, 
intermittent administration of Notch inhibitors, or pharmacological strategies that 
counteract the effects of Notch inhibition in the gut.61,220-222 In allogeneic HSCT, creative 
approaches to bypass systemic side effects of Notch inhibition could include 
manipulation of the cellular product administered to patients so that Notch is inhibited 
only in infused donor T cells. 
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 In the future, it will be important to determine whether Notch is important only at 
the onset of allogeneic responses or remains active later. If its main effects are restricted 
to priming and early differentiation of T cells, it may be desirable to inhibit Notch 
transiently after allogeneic HSCT, which would avoid consequences of Notch inhibition 
on extrahematopoietic tissues or de novo T cell generation. Although our observations 
were made after allogeneic HSCT, they may extend to other types of immune responses 
with exposure to persistent antigens. For example, Notch may regulate organ rejection 
(data not shown) and autoimmune diseases (Chapter 5). From a therapeutic perspective, 
our work points to the Notch pathway as an attractive target to achieve beneficial context-

















Chapter 3  
T cell-specific Notch inhibition blocks graft-versus-host 
disease by inducing a hyporesponsive program in 
alloreactive CD4+ and CD8+ T cells 4 
 
3.1 Abstract 
 Graft-versus-host disease (GVHD) induced by donor-derived T cells remains the 
major limitation of allogeneic bone marrow transplantation (allo-BMT). We previously 
reported that the pan-Notch inhibitor DNMAML markedly decreased the severity and 
mortality of acute GVHD mediated by CD4+ T cells in mice (Chapter 2). To elucidate the 
mechanisms of Notch action in GVHD and its role in CD8+ T cells, we studied the effects 
of Notch inhibition in alloreactive CD4+ and CD8+ T cells using mouse models of allo-
BMT. DNMAML blocked GVHD induced by either CD4+ or CD8+ T cells. Both CD4+ 
and CD8+ Notch-deprived T cells had preserved expansion in lymphoid organs of 
recipients, but profoundly decreased IFNγ production despite normal T-bet and enhanced 
Eomesodermin expression. Alloreactive DNMAML T cells exhibited decreased 
Ras/MAPK and NF-κB activity upon ex vivo restimulation through the TCR. In addition, 
alloreactive T cells primed in the absence of Notch signaling had increased expression of 
several negative regulators of T cell activation, including Dgka, Cblb and Pdcd1. 
DNMAML expression had modest effects on in vivo proliferation but preserved overall 
alloreactive T cell expansion while enhancing accumulation of preexisting natural 
regulatory T cells. Overall, DNMAML T cells acquired a hyporesponsive phenotype that 
blocked cytokine production but maintained their expansion in irradiated allo-BMT 
recipients, as well as their in vivo and ex vivo cytotoxic potential. Our results reveal 
                                                
4 Taken from: 
 
Sandy AR, Chung J, Toubai T, Shan GT, Tran IT, Friedman A, Blackwell TS, Reddy P, King PD, and 
Maillard I. 2013. T cell-specific Notch inhibition block graft-versus-host disease by inducing a 
hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol, In press. 
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parallel roles for Notch signaling in alloreactive CD4+ and CD8+ T cells that differ from 
past reports of Notch action and highlight the therapeutic potential of Notch inhibition in 
GVHD. 
 
3.2 Introduction  
 Using genetic models of Notch inhibition, we discovered an essential role of 
Notch signaling in CD4+ T cells mediating graft-versus-host disease (GVHD) after 
allogeneic bone marrow transplantation (allo-BMT), which was the subject of Chapter 
2.223 In mouse allo-BMT models, pan-Notch blockade in donor T cells led to markedly 
reduced GVHD severity and improved survival.223 Notch-deprived alloreactive CD4+ T 
cells had decreased production of inflammatory cytokines, including IFNγ, TNFα, IL-
17A, IL-4 and IL-2. Concomitantly, Notch inhibition led to increased accumulation of 
regulatory T cells (Tregs). However, Notch-deprived CD4+ alloreactive T cells were 
capable of extensive proliferation, allowing for their enhanced accumulation in lymphoid 
tissues. Despite reduced cytokine production, Notch-deprived CD4+ T cells retained 
potent cytotoxic potential in vitro and in vivo.   
 However, both CD4+ and CD8+ T cells have pathogenic effects during GVHD. 
Although we reported an essential function of Notch in CD4+ alloreactive T cells, no 
information has been available about Notch in CD8+ T cell-driven GVHD. Furthermore, 
it is unclear if the profound effects of Notch signaling in acute GVHD can be explained 
by its previously reported effects in T cells, or if new mechanisms are involved. Past 
work highlighted independent effects of Notch signaling in CD4+ and CD8+ T cells. 
Notch was shown to regulate Il4 and Gata3 expression during Th2 differentiation.114,115 
In Th1 cells, pharmacological inhibitors and a Notch1 antisense strategy suggested that 
Notch controlled expression of Tbx21, encoding T-bet, a transcription factor regulating 
Ifng transcription.117 Notch signaling was also shown to influence Th17 and Treg 
differentiation, as well as CD4+ T cell longevity, at least in vitro.120,121,123,224 In CD8+ T 
cells, Notch was suggested to act directly at the Eomes and Gzmb loci, with an impact on 
differentiation and function.125,126 However, these findings originate from heterogeneous 
experimental systems, different immune contexts and variable strategies to manipulate 
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Notch signaling, including gain-of-function approaches and pharmacological inhibitors. 
These results can be confounded by off-target effects and may not reflect the 
physiological functions of Notch in T cells. 
 Thus, we investigated the cellular and molecular mechanisms underlying the 
effects of Notch signaling in alloreactive CD4+ and CD8+ T cells during GVHD. Our 
strategy relied on in vivo priming of donor T cells in the presence or absence of all 
canonical CSL/RBP-Jκ and MAML-dependent Notch signals specifically in T cells, 
ensuring that T cells were exposed to relevant Notch ligands in the post-transplantation 
environment. Notch-deprived alloreactive CD4+ and CD8+ T cells shared a profound 
defect in IFNγ production, suggesting parallel effects of Notch in both T cell subsets. 
Decreased IFNγ was observed despite preserved or enhanced expression of the 
transcription factors T-bet and Eomesodermin, consistent with the absence of a classical 
Th1 or effector CD8+ T cell differentiation defect. Notch-deprived alloreactive CD4+ and 
CD8+ T cells acquired a hyporesponsive phenotype with decreased Ras/MAPK and NF-
κB signaling. Notch inhibition led to increased expression of selected negative regulators 
of T cell activation. Some of these characteristics have been observed in anergic T cells, 
suggesting that Notch-inhibited CD4+ and CD8+ T cells acquire an anergy-like phenotype 
after allo-BMT, resulting in decreased production of inflammatory cytokines. Despite 
these changes, Notch inhibition preserved alloreactive T cell expansion in vivo and only 
had modest effects on their proliferative potential, while increasing expansion of 
preexisting natural Tregs and preserving high cytotoxic potential. Altogether, our data 
demonstrate a novel, shared mechanism of Notch action in alloreactive CD4+ and CD8+ T 
cells during allo-BMT which differs from all previous reports of Notch activity in T cells. 
Understanding these effects is essential to harness the therapeutic benefits of Notch 




3.3.1 Notch inhibition blocks acute graft-versus-host disease mediated by CD4+ or 
CD8+ T cells 
 We previously reported an essential role for Notch in CD4+ T cells during acute 
GVHD in a major histocompatibility complex-mismatched allo-BMT model (B6 anti-
BALB/c).223 To assess if alloreactive CD8+ T cells were also sensitive to Notch signaling, 
we used ROSA26DNMAMLf x Cd4-Cre (DNMAML) mice as source of Notch-deprived 
CD4+ and CD8+ T cells. These mice express the DNMAML pan-Notch inhibitor in all 
mature CD4+ and CD8+ T cells. Wild-type (WT) or DNMAML B6 splenocytes were 
transplanted into irradiated BALB/c mice. Recipients were monitored for survival and 
GVHD severity. Allo-BMT recipients of B6 T cells died rapidly with severe GVHD (Fig. 
3.1A). In contrast, recipients of DNMAML CD4+ and CD8+ T cells survived as well as 
mice infused only with T cell-depleted bone marrow (Fig. 3.1A). We then performed 
allo-BMT with purified CD4+ or CD8+ T cells. DNMAML expression blocked severe 
GVHD induced by CD4+ T cells (Fig. 3.1B). Purified CD8+ T cells also induced 
significant lethality post-transplantation with <40% long-term survival (Fig. 3.1C). In 
contrast, DNMAML CD8+ T cell recipients had >94% survival by day 100, similar to 
mice receiving no T cells (Fig. 3.1C). These data demonstrate that Notch is an essential 
regulator of GVHD induced by either or both CD4+ and CD8+ T cells after MHC-
mismatched allo-BMT. 
 To further investigate the role of Notch in CD4+ and CD8+ alloreactive T cells, we 
used the B6 anti-BALB/c model as well as a minor histocompatibility antigen (miHA)-
mismatched model (B6 anti-BALB/b) in which lethal GVHD is mediated by CD4-
dependent CD8+ T cells.225 Together, WT CD4+ and CD8+ T cells induced significant 
lethality with <20% long-term survival in both models (Fig. 3.2A, B). DNMAML CD4+ 
and CD8+ T cell recipients achieved ~80% survival (Fig. 3.2A, B). When either CD4+ or 
CD8+ T cells expressed DNMAML, recipients were protected from severe GVHD with 
80-90% of the mice surviving long-term (Fig. 3.2A, B). These data indicate that Notch is 
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required in both CD4+ and CD8+ T cells to fully induce GVHD in MHC- and miHA-
mismatched allo-BMT models. 
 
 
Figure 3.1 DNMAML inhibits graft-versus-host disease mediated by CD4+ and/or 
CD8+ T cells after MHC-mismatched bone marrow transplantation. 
Lethally irradiated BALB/c mice (H-2d) were transplanted with B6 T cell-depleted bone marrow 
(TCD BM, 5x106 cells) alone or with (A) B6 (H-2b) splenocytes containing CD4+ and CD8+ T 
cells from wild-type (WT) or DNMAML mice (10x106 cells; 16 mice/group) (p<0.001 for WT 
vs. TCD and WT vs. DNMAML survival); (B) purified B6 WT or DNMAML CD4+ T cells 
(2x106 cells; 8-17 mice/group) (p<0.001 for WT vs. TCD and WT vs. DNMAML survival); (C) 
purified B6 WT or DNMAML CD8+ T cells (5x106 cells; 13-17 mice/group) (p<0.01 for WT vs. 
TCD; p<0.001 for WT vs. DNMAML survival). Recipients were monitored over time for 




Figure 3.2 DNMAML-mediated Notch inhibition in CD4+ and CD8+ T cells protects 
against lethal GVHD in major and minor histocompatibility antigen-mismatched 
allo-BMT models. 
(A) Lethally irradiated (900 rads) BALB/c (H-2d) recipients received B6 T cell-depleted bone 
marrow (TCD BM, 5x106 cells) alone or with 0.4x106 CD4+ and 2x106 CD8+ T cells (p<0.001 for 
WT CD4+ and CD8+ vs. TCD; p<0.001 for WT CD4+ and CD8+ vs. DNMAML CD4+ and CD8+, 
WT CD4+ and DNMAML CD8+, DNMAML CD4+ and WT CD8+ survival); (B) Lethally 
irradiated BALB/b (H-2b) recipients were transplanted with B6 TCD BM (5x106 cells) alone or 
with 2x106 CD4+ and 2x106 CD8+ T cells (p<0.001 for WT CD4+/CD8+ vs. TCD; p<0.01 for WT 
CD4+/CD8+ vs. DNMAML CD4+/CD8+ or WT CD4+/DNMAML CD8+; p<0.05 for WT 
CD4+/CD8+ vs. DNMAML CD4+/WT CD8+ survival). Recipients were monitored for survival 
and clinical GVHD score after transplantation (n=5-10/group, representative of 2 experiments). 
 
3.3.2 Alloreactive DNMAML CD8+ T cells display intrinsic and CD4+ T cell-
dependent defects in IFNγ  production 
 Notch inhibition preserves CD4+ T cell expansion after allo-BMT, but profoundly 
decreases IFNγ production.223 Since CD8+ T cells are a major source of IFNγ during 
GVHD, we assessed DNMAML CD8+ T cell expansion and IFNγ production. After 
transplantation in the B6 anti-BALB/c model (Fig. 3.3A), we recovered similar numbers 
of donor-derived WT and DNMAML CD4+ and CD8+ T cells from lymphoid organs of 
allo-BMT recipients, indicating that Notch blockade did not prevent in vivo expansion of 
these cells (Fig. 3.3B-C). In contrast, DNMAML expression markedly decreased IFNγ 
production by both alloreactive CD4+ and CD8+ T cells (Fig. 3.3D), suggesting parallel 
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effects of Notch in these two subsets. These differences in IFNγ production could not be 
explained by increased apoptosis of Notch-deprived T cells during the restimulation 
period (data not shown). To determine if changes in IFNγ production by Notch-deprived 
alloreactive T cells were biologically relevant, serum IFNγ levels were measured on day 
5 after transplantation (Fig. 3.3E). Serum IFNγ levels were markedly reduced in 
recipients of DNMAML T cells. Since IFNγ production by CD8+ T cells is influenced by 
cell-intrinsic signals and CD4+ T cell help, we studied DNMAML CD8+ T cells in the 
presence of WT or DNMAML alloreactive CD4+ T cells (Fig. 3.3F). WT CD4+ and 
CD8+ T cells transplanted together produced abundant IFNγ. In the presence of WT CD4+ 
T cells, DNMAML expression in CD8+ T cells markedly decreased but did not abolish 
IFNγ production. When both DNMAML CD4+ and CD8+ T cells were infused, CD8+ T 
cells had little to no IFNγ production. Thus, Notch promotes maximal IFNγ production 
by alloreactive CD8+ T cells via cell-intrinsic changes in the CD8+ compartment and 
effects on CD4+ T cell help. 
 To verify that Notch signaling was potently inhibited in both alloreactive 
DNMAML CD4+ and CD8+ T cells, we assessed expression of the Notch target gene 
Dtx1 (Fig. 3.3G). Dtx1 transcripts were significantly reduced in both subsets of 
alloreactive DNMAML T cells. Collectively, inhibition of Notch signaling in alloreactive 
T cells preserved their expansion but profoundly reduced T cell-dependent 
IFNγ production and systemic IFNγ levels. 
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Figure 3.3 Alloreactive DNMAML CD4+ and CD8+ T cells have preserved in vivo 
expansion but markedly decreased IFNγ  production. 
(A) Experimental design: lethally irradiated BALB/c mice were transplanted with combinations 
of WT or DNMAML CD4+ and CD8+ B6 T cells; (B) Donor-derived T cells were tracked by flow 
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cytometry based on expression of donor/host MHC class I molecules and DNMAML-GFP; (C) 
Preserved expansion of donor-derived H-2Kb+H-2Kd– DNMAML CD4+ and CD8+ T cells as 
compared to WT T cells on day 5 post-transplantation (n=3-5 mice/group, 2 independent 
experiments); (D) Intracellular staining for IFNγ in donor-derived H-2Kb+H-2Kd– CD4+ and 
CD8+ spleen T cells after ex vivo anti-CD3/CD28 restimulation (n=3-5 mice/group, representative 
of >3 experiments). DNMAML inhibited IFNγ production by CD4+ and CD8+ T cells; (E) Serum 
was collected on day 5 after transplantation and IFNγ levels were measured by ELISA (n=5 
mice/group, >2 independent experiments); (F) Mixed populations of WT or DNMAML CD4+ 
and CD8+ T cells (2x106 each) were transplanted into lethally irradiated BALB/c recipients. IFNγ 
production was measured by intracellular flow cytometry on day 5 post-transplantation. 
DNMAML blocked IFNγ production in CD8+ T cells both through cell-intrinsic and CD4-
dependent effects (n=3/group, representative of two experiments); (G) Abundance of Dtx1 Notch 
target gene mRNA in sort-purified alloreactive CD4+ and CD8+ T cells on day 5 post-
transplantation (n=3 mice/group, representative of >3 experiments). **p<0.01; ***p<0.001. 
 
3.3.3 Notch inhibition blocks IFNγ  production in alloreactive CD4+ and CD8+ T cells 
despite preserved T-bet and Eomesodermin expression. 
 Notch was suggested to control the expression of Tbx21 (encoding T-bet) in CD4+ 
T cells and Eomes (encoding Eomesodermin) in CD8+ T cells.117,125,126 To assess if these 
mechanisms accounted for decreased IFNγ production by Notch-deprived CD4+ and 
CD8+ T cells after allo-BMT, we measured T-bet and Eomesodermin levels at the peak of 
the effector response. Alloreactive DNMAML CD4+ and CD8+ T cells had preserved 
Tbx21 and increased Eomes transcripts as compared to WT T cells (Fig. 3.4A). We used 
flow cytometry to assess intracellular T-bet and Eomesodermin and established antibody 
specificity by staining alloreactive T cells from WT mice compared to Tbx21–/– and 
Eomesf/f x Cd4-Cre mice (Fig. 3.4B).108,226 Consistent with mRNA findings, alloreactive 
DNMAML CD4+ and CD8+ T cells had preserved intracellular T-bet and increased 
Eomesodermin (Fig. 3.4C). As expected, we observed more Eomesodermin protein in 
CD8+ T cells than CD4+ T cells, consistent with accurate detection of Eomesodermin.108 
These data indicate that decreased IFNγ production by DNMAML CD4+ and CD8+ T 
cells was not caused by decreased Th1 and effector CD8+ T cell differentiation resulting 
from reduced expression of these master transcription factors. 
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Figure 3.4 Preserved T-bet and enhanced Eomesodermin expression in alloreactive 
Notch-deprived CD4+ and CD8+ T cells, allowing restoration of IFNγ  production 
after treatment with PMA and ionomycin. 
Lethally irradiated BALB/c mice (900 rads) were transplanted with B6-CD45.1 TCD BM (5x106 
cells) and splenocytes (10x106 cells) from WT or DNMAML B6 mice. (A) Preserved Tbx21 
mRNA (encoding T-bet) and enhanced Eomes transcripts in DNMAML CD4+ and CD8+ T cells. 
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Donor-derived H-2Kb+H-2Kd–CD45.2+ CD4+ and CD8+ T cells were sort-purified and subjected 
to qRT-PCR (day 14, n=4-5 mice, representative of 3 experiments); (B) Specific detection of T-
bet and Eomesodermin in alloreactive T cells with anti-T-bet (4B10) and anti-Eomesodermin 
(Dan11mag) antibodies. Splenocytes from WT, B6.129S6-Tbx21tm1Glm/J or Eomesf/fxCd4-Cre 
mice were transplanted into irradiated BALB/c recipients. Histograms show intracellular staining 
with isotype control or specific antibodies in donor-derived H-2Kb+H-2Kd–CD45.2+ CD4+ or 
CD8+ T cells (day 5) (n=2); (C) Representative intracellular flow cytometry plots and mean 
fluorescence intensity (MFI) for T-bet and Eomesodermin expression in alloreactive WT and 
DNMAML CD4+ and CD8+ T cells (day 14, n=4-5 mice, representative of 4 experiments); (D-G) 
At day 5 after transplantation, spleen and lymph node cells were incubated for 6 hours with either 
anti-CD3/anti-CD28 (2.5 µg/ml each), or PMA and ionomycin (50 ng/ml and 500 ng/ml, 
respectively). Percent IFNγ+ cells as measured by intracellular flow cytometry in WT and 
DNMAML donor-derived (D) CD4+ and (E) CD8+ T cells, or WT and CSL/RBP-Jk-deficient 
donor-derived (F) CD4+ and (G) CD8+ T cells (n=5 mice/group, representative of >2 
experiments). Representative flow cytometry plots are shown. Numbers indicate the percentage 
of cells in each quadrant. * p<0.05; *** p<0.001. 
 
 PMA (a diacylglycerol analog) and ionomycin (a calcium ionophore) are often 
used to elicit cytokine production to study T cell differentiation. This strategy can reveal 
defective IFNγ production by Tbx21–/– T cells.227 In contrast, restimulation of alloreactive 
DNMAML T cells with PMA/ionomycin restored IFNγ production by both CD4+ (Fig. 
3.4D) and CD8+ T cells (Fig. 3.4E) close to levels observed in WT T cells. Partial rescue 
of IL-2 production was also apparent (data not shown). We confirmed the effects of 
DNMAML-mediated Notch blockade on IFNγ production using Rbpj–/– T cells lacking 
CSL/RBP-Jκ, a central component of the Notch transcriptional activation complex (Fig. 
3.4F-G). Altogether, our observations were consistent with the presence of functional T-
bet and Eomesodermin capable of activating Ifng transcription in DNMAML or 
CSL/RBP-Jκ-deficient alloreactive T cells, suggesting that PMA/ionomycin restored 
activation of other pathways regulating cytokine production in these cells. 
3.3.4 Notch-deprived alloreactive CD4+ and CD8+ T cells develop blunted 
Ras/MAPK and NF-κB activation 
 One of the major pathways activated by PMA is Ras/MAPK signaling, a key 
contributor to T cell cytokine gene transcription.228 To assess if alloreactive DNMAML T 
cells had decreased Ras/MAPK activation, we measured phosphorylation of Erk1/2 and 
its upstream kinase Mek1. Notch-deprived CD4+ and CD8+ T cells were primed in vivo 
before sort-purification and ex vivo restimulation through the TCR and CD28 co-receptor.  
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Figure 3.5 Alloreactive Notch-deprived CD4+ and CD8+ T cells have an acquired 
defect in Ras/MAPK pathway activation that is rescued by PMA. 
(A) WT or DNMAML B6 splenocytes were transplanted into lethally irradiated BALB/c 
recipients. On day 5, H-2Kb+H-2Kd– alloreactive WT and DNMAML CD4+ and CD8+ T cells 
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were sort-purified and restimulated in vitro for 5-10 minutes at 37oC with anti-CD3/anti-CD28 
and IgG crosslinking. Baseline activation was assessed by incubating cells at 37oC with IgG 
crosslinker alone (0 minute time point). Phosphorylated Erk1/2 and Mek1 were detected by 
Western blotting as compared to total Erk1/2 and Mek1; (B) Naïve CD62LHighCD44Low CD4+ and 
CD8+ T cells were sort-purified from WT and DNMAML mice. Mek1 phosphorylation was 
assessed after anti-CD3/CD28 restimulation; (C) Sort-purified, day 5 alloreactive WT and 
DNMAML CD4+ or CD8+ T cells were restimulated ex vivo with PMA for 5 minutes (or DMSO 
as negative control). In all experiments, the abundance of phosphorylated proteins was measured 
by densitometry relative to total protein levels. WT T cells were set to 100% (n=2-4 individual 
experiments, 6 mice/group in each experiment); (D) cell surface CD3ε, (E) TCRβ, and (F) CD28 
levels were assessed in alloreactive WT and DNMAML CD4+ and CD8+ T cells on day 5 post-
transplantation. Representative flow cytometry plots and mean fluorescence intensity are shown. 
**p<0.01. 
 
Both alloreactive DNMAML CD4+ and CD8+ T cells had a significant reduction in Mek1 
and Erk1/2 phosphorylation (Fig. 3.5A). Interestingly, naïve CD62LHighCD44Low 
DNMAML CD4+ T cells only had slightly decreased Erk1/2 phosphorylation, while 
naïve DNMAML CD8+ T cells activated Erk1/2 normally, suggesting that the majority of 
the Ras/MAPK defect was acquired in vivo in the absence of Notch signaling (Fig. 3.5B). 
Next, we assessed if PMA rescued Ras/MAPK activation in DNMAML alloreactive T 
cells. PMA induced similar Erk2 phosphorylation in WT and DNMAML T cells, 
indicating restoration of Ras/MAPK signaling in DNMAML T cells (Fig. 3.5C). 
 NF-κB is another major pathway activated downstream of diacylglycerol that can 
regulate Ifng transcription in T cells.229 To capture the overall NF-κB activity in Notch-
deprived alloreactive T cells, we bred DNMAML mice to transgenic NF-κB-GFP-
Luciferase (NGL) reporter mice and used F1 progeny as donors for allo-BMT (Fig. 
3.6).230 On day 5 post-transplantation, alloreactive NGL and NGL/DNMAML CD4+ and 
CD8+ T cells were sort-purified and restimulated with anti-CD3/CD28 antibodies. 
DNMAML CD4+ and CD8+ T cells had significantly reduced NF-κB/luciferase activity. 
Blunted signal transduction downstream of the TCR occurred in the absence of any 
changes in TCRβ (Fig. 3.5D) or CD3ε (Fig. 3.5E) surface expression, although we 
observed a slight but significant decrease in CD28 expression (Fig. 3.5F). Altogether, 
both DNMAML CD4+ and CD8+ alloreactive T cells acquired a blunted capacity for 
Ras/MAPK and NF-κB activation downstream of TCR/CD28 signals after allo-BMT. 
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Figure 3.6 Reduced NF-kB activity in Notch-deprived alloreactive CD4+ and CD8+ T 
cells. 
(A) Experimental design. ROSA26DNMAMLf x Cd4-Cre mice were bred with NF-kB-GFP-
Luciferase (NGL) reporter mice. F1 progeny (NGL or NGL/DNMAML) were used as donors for 
allo-BMT into irradiated BALB/c mice; (B) Alloreactive NGL and NGL/DNMAML CD4+ and 
CD8+ T cells were sort-purified on day 5 after transplantation. Purified CD4+ and CD8+ T cells 
were restimulated in vitro with anti-CD3/anti-CD28 for 16 hours to achieve detectable luciferase 
activity. NGL/DNMAML CD4+ and CD8+ T cells had significantly reduced luciferase activity 
(relative light units) as a surrogate for NF-kB activity compared to WT T cells (set to 100%; n=2-
3 individual experiments, 6 mice/group in each experiment). **p<0.01. 
 
3.3.5 Alloreactive DNMAML CD4+ and CD8+ T cells have increased expression of 
multiple negative regulators of T cell activation 
 Decreased Ras/MAPK signaling leading to reduced cytokine production has been 
described in certain forms of T cell hyporesponsiveness or anergy.231,232 Mechanistically, 
increased expression of diacylglycerol kinases (Dgk) such as Dgkα and Dgkζ was linked 
to increased degradation of diacylglycerol into phosphatidic acid, resulting in blunted 
Erk1/Erk2 activation and cytokine production.233,234 Interestingly, restimulated 
alloreactive DNMAML CD4+ T cells had elevated levels of Dgka and Dgkz mRNA, 
while DNMAML CD8+ T cells had increased Dgka and a trend for more Dgkz transcripts 
(Fig. 3.7A). This constellation of effects was reminiscent of T cell anergy. Therefore, we 
studied a panel of anergy-associated genes, starting with the NFAT-dependent genes, 
Egr2/3.235,236 Egr3 but not Egr2 transcripts were increased in alloreactive DNMAML 
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CD4+ and CD8+ T cells (Fig. 3.7B). We also observed increased expression of Rnf128 
and Cblb, encoding Grail and Cbl-b, two E3 ubiquitin ligases that function as negative 
regulators of T cell activation.237,238 In contrast, Itch expression was not significantly 
changed (Fig. 3.7C). As co-inhibitory receptors can also regulate alloreactive T cell 
activation and function, we investigated expression of Btla, Ctla4 and Pdcd1 (encoding 
Pd-1) in DNMAML T cells. Although Ctla4 expression was slightly decreased, 
alloreactive DNMAML CD4+ T cells had increased Btla and DNMAML CD8+ T cells 
elevated Pdcd1 mRNA (Fig. 3.7D). These mRNA changes correlated well with protein 
expression with decreased Ctla-4 and increased Btla and Pd-1 in alloreactive DNMAML 
CD4+ and CD8+ T cells (Fig. 3.7E). Finally, DNMAML alloreactive T cells had 
increased intracellular cAMP, a second messenger that provides negative feedback 
regulation of T cell activation (Fig. 3.7F).239 
 Altogether, Notch-deprived alloreactive CD4+ and CD8+ T cells acquired features 
of hyporesponsive T cells, including increased expression of several negative regulators 
of T cell activation, some of which are NFAT-dependent. Importantly, naïve DNMAML 
CD4+ and CD8+ T cells expressed normal levels of these negative regulators (except for 
Cblb and Itch which were mildly elevated in naïve DNMAML CD4+ T cells) (Fig. 3.8). 
These findings suggest that Notch deprivation results in changes in naïve T cells that only 
become apparent after allo-BMT or that Notch inhibition has minimal influence on naïve 
T cells, but profound effects on T cells in vivo during allo-BMT. 
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Figure 3.7 Increased levels of Dgka mRNA and other negative regulators of T cell 
activation in alloreactive DNMAML CD4+ and CD8+ T cells. 
H-2Kb+H-2Kd–CD45.2+alloreactive WT or DNMAML T cells were sort-purified at day 5 after 
transplantation. (A) Abundance of Dgka/Dgkz and (B) Egr2/Egr3 transcripts in anti-CD3/anti-
CD28 restimulated alloreactive WT or DNMAML CD4+ and CD8+ T cells (n=4 mice, 
representative of >2 experiments); (C) Expression of anergy-associated E3 ubiquitin ligases Cblb, 
Rnf128, and Itch and (D) expression of T cell co-inhibitory receptors Btla, Ctla4, Pd-1 in sort-
purified WT or DNMAML CD4+ and CD8+ T cells. Each symbol represents triplicate qRT-PCR 
data for cells purified from one individual recipient (n=5 mice, representative of 2 experiments); 
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(E) Cell surface levels of T cell co-inhibitory receptors in WT and DNMAML CD4+ and CD8+ T 
cells (n=5 mice/group, representative of 2 experiments). Representative flow cytometry plots and 
mean fluorescence intensity are shown; (F) Increased intracellular cAMP in alloreactive 
DNMAML CD4+ and CD8+ T cells relative to WT T cells on day 5 after transplantation. cAMP 
levels were very low in naïve cells irrespectively of DNMAML expression (n=3 experiments, 6 
mice/group in each experiment). *p<0.05; **p<0.01; ***p<0.001. 
 
 
Figure 3.8 Expression of anergy-associated transcripts in naive DNMAML CD4+ 
and CD8+ T cells. 
(A) Abundance of Dgka/Dgkz and (B) Egr2/Egr3 transcripts in sort-purified, anti-CD3/anti-CD28 
restimulated naïve (CD62LHighCD44Low) DNMAML CD4+ and CD8 T cells relative to WT T cells 
(n=4 mice); (C) Expression of E3 ubiquitin ligases associated with T cell anergy, Cblb and Itch. 
Rnf128 was undetected (data not shown); (D) expression of the T cell co-inhibitory receptors 
Btla, Ctla4 and Pdcd1 in naïve DNMAML CD4+ and CD8+ T cells compared to WT T cells (n=5 
mice, representative of 2 experiments). **p<0.01; ***p<0.001. 
 
3.3.6 Notch inhibition modestly reduces in vivo proliferation of alloreactive CD4+ 
and CD8+ T cells while enhancing expansion of natural Tregs 
 DNMAML alloreactive T cells acquire increased levels of negative regulators that 
have previously been associated with decreased proliferation, at least using in vitro 
models of T cell anergy.240 However, in vitro and in vivo T cell proliferation are regulated 
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by different stimuli. To evaluate in detail the impact of Notch blockade on T cell 
proliferation in vivo after allo-BMT, we used Rbpjf/f x Cd4-Cre mice (Fig. 3.9). As 
DNMAML T cells, CSL/RBP-Jκ-deficient T cells fail to respond to Notch signals, but 
lack DNMAML-GFP fluorescence, allowing use of CFSE to track proliferation. At day 3 
after allo-BMT, Notch-deficient T cells had proliferated slightly less than WT T cells 
(Fig. 3.9A). However, by day 5, >99% of donor WT and CSL/RBP-Jκ-deficient T cells 
had proliferated for >6-8 divisions (Fig. 3.9B). Thus, despite modestly reduced initial 
proliferation in the absence of Notch signaling, Notch-deprived T cells accumulated to 
levels similar to WT T cells by day 5 after allo-BMT. After this initial burst, ex vivo 
restimulation of Notch-deprived alloreactive T cells revealed only modest cycling defects 
(Fig. 3.9C-D). Similar in vivo and in vitro results were observed when DNMAML T cells 
were labeled with eFluor670 (data not shown). To assess ongoing in vivo proliferation, 
we performed a BrdU pulse-chase experiment 5-8 days after allo-BMT (Fig. 3.9E-G). 
CSL/RBP-Jκ-deficient T cells demonstrated slightly reduced initial BrdU incorporation 
during the pulse phase (Fig. 3.9F). During chase, decreased loss of BrdU was apparent in 
Notch-deprived T cells (Fig. 3.9G). Thus, Notch inhibition modestly reduced in vivo 
proliferation of alloreactive CD4+ and CD8+ T cells, while preserving their massive initial 
expansion. 
 Traditional immunosuppressants often prevent Treg expansion, which can 
increase GVHD severity.241 If inhibition of Notch signaling is to be used to prevent or 
treat GVHD, we needed to assess the impact of Notch deprivation on Treg expansion. 
Using Foxp3-IRES-RFP+ DNMAML mice, we observed increased accumulation of 
DNMAML as compared to WT Foxp3+ donor T cells (Fig. 3.10A).242 Furthermore, 
depletion of Tregs from the donor DNMAML inoculum completely prevented Treg 
expansion (Fig. 3.10B-D). These data indicate that rather than increasing conversion to 





Figure 3.9 Notch-deprived alloreactive CD4+ and CD8+ T cells have a reduced initial 
proliferative burst and subsequent decreased proliferation in vitro and in vivo. 
CFSE-labeled T cells from WT or Rbpjf/f x Cd4-Cre mice (RB KO, lacking all CSL/RBP-Jk-
mediated Notch signals) were transplanted into lethally irradiated BALB/c recipients (900 rads). 
Flow cytometry plots show CFSE dilution at (A) day 3 and (B) day 5 in donor-derived H-2Kb+H-
2Kd– CD4+ and CD8+ T cells. WT or RBP-Jk KO T cells were transplanted into lethally 
irradiated BALB/c recipients. On day 5, purified WT and RBP-Jk KO (C) CD4+ or (D) CD8+ T 
cells were CFSE-labeled and restimulated in vitro for 3 days with anti-CD3/CD28 +/- IL-2. 
Division history of donor-derived H-2Kb+H-2Kd– B6 T cells was measured by flow cytometry 
(n=6-7 mice/group in each experiment, representative of >2 experiments); (E) Design of BrdU 
pulse-chase experiment. Lethally irradiated BALB/c recipients were transplanted with 
splenocytes from WT or RBP-Jk KO mice. Between days 4 and 5, transplant recipients received 3 
doses of BrdU 12 hours apart; (F) Four hours after the last BrdU injection, mice were euthanized 
for day 5 BrdU incorporation analysis (pulse); (G) At day 8 after transplantation, residual BrdU 
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content was assessed (chase). n=5 mice/group in each experiment, representative of 2 
experiments. *p<0.05 
 
Figure 3.10 Notch inhibition enhances the accumulation of natural Foxp3+ 
regulatory T cells after allo-BMT. 
(A) Detection of live regulatory T cell (Tregs) on day 5 post-transplantation using Foxp3-IRES-
RFP (FIR) mice crossed to ROSA26DNMAMLf x Cd4-Cre mice, showing expanded Tregs among 
Notch-deprived alloreactive T cells; (B) To determine the origin of the expanded Tregs, lethally 
irradiated BALB/c recipients were transplanted with WT or DNMAML CD4+ T cells with or 
without FIR+ Tregs and analyzed on day 14 post-transplantation; (C) Post-sort purity of WT and 
DNMAML CD4+ T cell fractions after depletion of FIR+ cells; (D) Frequency of donor-derived 
FoxP3-IRES-RFP+ T cells as assessed by flow cytometry after transplantation of WT or 
DNMAML CD4+ T cells, including Tregs (+Treg), or depleted of Tregs (-Treg). Day 14 
alloreactive DNMAML Tregs were derived from preexisting Tregs. *p<0.05; *** p<0.001. 
 
3.3.7 Preserved anti-host and anti-tumor cytotoxicity of alloreactive Notch-deprived 
CD8+ T cells 
 Our previous work showed that alloreactive Notch-deprived CD4+ T cells had 
preserved cytotoxicity against allogeneic host and tumor cells after transplantation.223 To 
test the overall in vivo cytotoxic potential of DNMAML B6 CD4+ and CD8+ T cells, 
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BALB/c transplant recipients were challenged with a 1:1 mix of CFSEHigh BALB/c and 
CFSELow B6-CD45.1 splenocytes. Cytotoxicity against BALB/c targets was measured by 
flow cytometry (Fig. 3.11A). While recipients receiving TCD BM could not elicit 
cytotoxicity against the BALB/c targets, mice receiving WT or DNMAML splenocytes 
showed high and similar cytotoxicity against CFSEHigh BALB/c targets (Fig. 3.11A).  
 To determine if alloreactive purified DNMAML CD8+ T cells could lyse 
allogeneic tumor cells, an in vitro cytotoxicity assay was used. T cells were primed in 
vivo in lethally irradiated BALB/c recipients before assessing cytotoxicity ex vivo. 
Incubation of alloreactive WT or DNMAML CD8+ T cells with 51Chromium-labeled 
allogeneic A20 and P815 (H2kd+) tumor cells showed efficient cytotoxicity, with 
preserved cytotoxicity against A20 cells and preserved or only slightly reduced 
cytotoxicity against P815 cells (Fig. 3.11B). As expected, syngeneic EL4 (H2kb+) tumor 
cells were not killed (Fig. 3.11B). Collectively, these data demonstrate that Notch 
inhibition in alloreactive CD8+ T cells preserved a high degree of cytotoxic potential after 
transplantation. 
 
Figure 3.11 Alloreactive Notch-deprived CD8+ T cells maintain high cytotoxic 
potential. 
(A) In vivo cytotoxicity assay. Transplanted BALB/c recipient mice were challenged on day 14 
with a 1:1 mixture of CFSE-labeled allogeneic targets and control cells (CFSEHigh H-2Kd+ 
BALB/c and CFSElow control H-2Kb+ B6-CD45.1 splenocytes, respectively). After 18 hours, 
elimination of the BALB/c targets was assessed in the spleen by flow cytometry; (B) BALB/c 
recipients were transplanted with TCD BM and WT or DNMAML splenocytes (5x106 each). On 
day 8, alloreactive WT and DNMAML and naïve CD8+ T cells were MACS-purified and 
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incubated with 51Chromium-labeled tumor cells at various E:T ratios for 5 hours (representative 
of n=3 independent experiments). A20 and P815 cells were allogeneic targets (H2kd). EL4 cells 
were syngeneic controls (H2kb). **p<0.01; ***p<0.001. 
 
3.4 Discussion 
 Our findings highlight a new, shared mechanism of Notch action in alloreactive 
CD4+ and CD8+ T cells that differs from all previously reported Notch functions in T 
cells (Table 3.1). We used pan-Notch inhibition specifically in T cells to study the effects 
of Notch signaling in CD4+ and CD8+ T cell differentiation and function in several 
models of acute GVHD. Notch was absolutely required in both CD4+ and CD8+ T cells to 
mediate lethal acute GVHD. Notch inhibition preserved in vivo T cell expansion, but led 
to profoundly decreased IFNγ production by both T cell subsets. Decreased IFNγ 
production was not explained by an overall defect in Th1 CD4+ or effector CD8+ T cell 
differentiation, as expression of the master transcription factors T-bet and Eomesodermin 
was preserved or even enhanced in the absence of Notch signaling. In contrast, analysis 
of signal transduction pathways downstream of the TCR revealed defects in Ras/MAPK 
and NF-κB activation in Notch-deprived T cells, in addition to increased expression of 
multiple negative regulators of T cell activation (Fig. 3.12). These features of 
hyporesponsiveness were observed in vivo upon T cell activation without Notch 
signaling. Importantly, Notch inhibition preserved the overall expansion of alloreactive T 
cells and efficient cytotoxic potential, while leading to increased accumulation of 
preexisting natural Foxp3+ Tregs. This constellation of effects led to beneficial 
immunomodulation, indicating that Notch is an attractive therapeutic target to control 








Table 3.1 Summary of biochemical features of alloreactive Notch-deprived T cells. 
 Wild-type CD4
+ and 
CD8+ T cells 
Notch-deprived CD4+ 
and CD8+ T cells 
IFNγ production + + + +/- 
T-bet expression + + + + + + 
Eomesodermin expression + + + + + + + 
Ras/MAPK activity + + + + 
NFκB activity + + + + 
Negative regulators of  
T cell activation + + + + 
NF-AT target genes + + + 
 
 
Figure 3.12 Summary of biochemical changes in Notch-deprived alloreactive T cells. 
Alloreactive Notch-deprived T cells had decreased Ras/MAPK and NF-κB pathway activity 
concomitant with increased Dgka and Dgkz mRNA. Other negative regulators of T cell receptor 
signaling were also elevated in Notch-deprived T cells, such as cAMP, Pdcd1 (encoding PD-1), 
Cblb, and Rnf128 (encoding Grail). Based on expression analysis of NF-AT target genes, NF-AT 
was seemingly preserved. TCRβ and CD3ε expression levels were also preserved. These data 
suggest that Notch-deprived alloreactive T cells acquire a predominant defect downstream of the 
TCR but upstream of DAG. , decreased activity/expression; , increased activity/expression; 
≈, preserved activity/expression 
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 Past work in other immune contexts suggested that Notch could directly regulate 
Tbx21 transcription in CD4+ T cells and Eomes expression in CD8+ T cells.117,125,126 In 
contrast, Notch appeared dispensable for transcriptional activation of these genes in 
alloreactive T cells during GVHD (Fig. 3.4A-C).223 It is possible that use of different 
experimental systems to manipulate Notch signaling could underlie these discrepant 
observations. Others reported that Notch receptors could have “non-canonical” effects 
independent of CSL/RBP-Jκ and MAML, although the nature of these effects is not well 
defined.49,50 However, in alloreactive T cells at least, the dominant effects of Notch are 
mediated by “canonical” signaling and do not involve decreased Tbx21 and Eomes 
expression. Alternatively, different signaling pathways may be required to activate Tbx21 
and Eomes transcription in distinct immune responses. After allo-BMT, T cell exposure 
to abundant alloantigens in a highly inflammatory environment may bypass the 
requirement for Notch signaling to activate these genes. Moreover, an interesting feature 
of Notch-deprived alloreactive T cells was increased Eomes expression, a finding that 
was particularly apparent in CD8+ T cells but also detected in the CD4+ compartment. 
Although the regulation of Eomes expression during T cell differentiation is incompletely 
understood, decreased IL-12 signaling and increased Foxo1 activity were reported to 
enhance Eomes at the expense of Tbx21 expression.243,244 The effects of Notch 
deprivation on Eomes could be mediated via interference with these pathways. 
Interestingly, increased Eomes expression was reported in memory CD8+ T cells that 
acquire an enhanced ability for long-term persistence, as opposed to terminal 
differentiation.245 This mechanism could contribute to the enhanced expansion and 
survival of Notch-deprived alloreactive T cells after allo-BMT. 
 In contrast to past findings suggesting that Notch regulates independent aspects of 
CD4+ and CD8+ T cell biology, our results revealed similar effects of Notch in the CD4+ 
and CD8+ T cell compartments during GVHD. Notch-deprived CD4+ and CD8+ T cells 
shared key functional properties and gene expression changes after allo-BMT. During in 
vivo activation, DNMAML alloreactive T cells acquired elevated levels of several 
negative regulators of T cell activation, including genes whose activation is NFAT-
dependent (Fig. 3.12). A prominent feature of Notch-deprived T cells was decreased 
activation of Ras/MAPK and NF-κB pathways. Ras/MAPK and NF-κB activation are 
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controlled by diacylglycerol, whose levels are negatively regulated by the lipid kinases 
Dgkα/ζ. Elevated Dgka and Dgkz expression in DNMAML T cells is reminiscent of past 
observations in models of T cell hyporesponsiveness with decreased Ras/MAPK 
activation.233,234,240 However, DNMAML T cells also acquired elevated expression of 
other negative regulators of T cell activation, including E3 ubiquitin ligases and co-
inhibitory receptors, in addition to increased intracellular cAMP. Thus, the functional 
properties of Notch-deprived alloreactive T cells may not be explained entirely by 
decreased Ras-MAPK and NF-κB activation. Altogether, our data suggest that the 
predominant defect of Notch-deprived alloreactive T cells lied downstream of the TCR 
complex but upstream of diacylglycerol (Fig. 3.12).  
 Despite the profound effects of Notch inhibition on cytokine production and a 
slight reduction in their initial proliferative burst, the overall accumulation of DNMAML 
T cells was preserved in vivo. These findings contrast with many other interventions that 
decrease expansion of alloreactive T cells in vivo. Interestingly, past work suggested that 
in vivo proliferation of alloreactive T cells was independent of IL-2 and may be 
controlled by IL-15, at least in MHC-mismatched allo-BMT models.219 Furthermore, 
classical models of T cell hyporesponsiveness and anergy have often been examined in 
vitro, a situation in which IL-2 production may play a critical role to support proliferation 
that does not reflect its effects in vivo.240 Other possible mechanisms accounting for the 
preserved or even enhanced in vivo expansion of DNMAML alloreactive T cells include 
decreased activation-induced cell death, for example as a result of reduced exposure to 
IFNγ.246 In parallel to these effects on conventional alloreactive T cells, Notch inhibition 
markedly enhanced in vivo expansion of Foxp3+ Tregs without inhibiting effector T cell 
expansion, which was explained by increased expansion of preexisting natural Tregs 
present in the transplant inoculum. These findings may contribute to the protective effects 
of Notch inhibition in GVHD and contrast with a shortcoming of many 
immunosuppressive strategies, including calcineurin inhibitors, which limit Treg 
proliferation.241 
 Alloreactive Notch-deprived CD8+ T cells had largely preserved cytotoxicity after 
allo-BMT similar to our previously reported effects of Notch deprivation in CD4+ T 
cells.223 An interesting feature of alloreactive Notch-deprived T cells is their decreased 
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cytokine production but preserved cytotoxic potential. Dissociation of cytokine 
production from cytotoxicity responses could reflect differential sensitivity of these 
pathways to Notch inhibition. Preserved or even enhanced T-bet and Eomesodermin 
expression in Notch-deprived T cells could be responsible for maintaining their cytotoxic 
potential after allo-BMT. Prior work has shown that T-bet and Eomesodermin are 
important for transcription of cytotoxic molecules.109 Collectively, Notch inhibition in 
alloreactive CD4+ and CD8+ T cells preserved efficient cytotoxicity while minimizing 
GVHD. 
 Altogether, our findings reveal a broad effect of Notch signaling in CD4+ and 
CD8+ alloreactive T cells during GVHD. Notch-deprived alloreactive T cells acquired 
features previously associated with hyporesponsiveness or anergy. However, this had 
differential effects on T cell effector functions in vivo in the post-transplantation 
environment, with profound inhibition of cytokine production but preserved T cell 
expansion, cytotoxic potential, and natural Treg accumulation. Notch-deprived T cells 
maintained potent cytotoxic activity in vivo, suggesting a “split anergy” phenotype.247 
These findings are summarized in Table 3.1. Overall, Notch inhibition in T cells induced 
a unique combination of effects that potently inhibited GVHD, highlighting the promise 
of this new therapeutic strategy after allo-BMT. Moreover, Notch signaling may play an 
important role in other T cell-mediated immune disorders with persistent antigen, such as 










Chapter 4  
Blockade of individual Notch ligands and receptors 




 Graft-versus-host disease (GVHD) is the main complication of allogeneic bone 
marrow transplantation. Current strategies to control GVHD rely on global 
immunosuppression. These strategies are incompletely effective and decrease the anti-
cancer activity of the allogeneic graft. We previously identified Notch signaling in T cells 
as a new therapeutic target to prevent GVHD (Chapter 2 and 3). Notch-deprived T cells 
showed markedly decreased production of inflammatory cytokines, but normal in vivo 
proliferation, increased accumulation of regulatory T cells and preserved anti-cancer 
effects. Here, we report that GSIs can block all Notch signals in alloreactive T cells, but 
lead to severe on-target intestinal toxicity. Using newly developed humanized antibodies 
and conditional genetic models, we demonstrate that Notch1/Notch2 receptors and the 
Notch ligands Delta-like1/4 mediate all the effects of Notch signaling in T cells during 
GVHD, with dominant roles for Notch1 and Delta-like4. Delta-like1/4 inhibition blocked 
GVHD without limiting adverse effects, while preserving substantial anti-cancer activity. 
Transient blockade in the peri-transplant period was sufficient to provide long-lasting 
protection. These findings open new perspectives for selective and safe targeting of 
individual Notch pathway components in GVHD and other T cell-mediated human 
disorders. 
                                                
5 Excerpts taken from: 
 
Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT, Radojcic V, Friedman A, Gridley T, Shelton 
A, Reddy P, Samuelson LC, Yan M, Siebel CW and Maillard I. 2013. Blockade of individual Notch ligands 




 Allogeneic bone marrow or hematopoietic cell transplantation (allo-BMT) is an 
essential therapeutic modality for patients with hematological malignancies and other 
blood disorders. Unfortunately, T cells also mediate damage to normal host tissues, 
leading to graft-versus-host disease (GVHD).141,208,248 Current strategies to control 
GVHD involve T cell depletion from the graft or global immunosuppression.141,249 
Despite these interventions, acute and chronic GVHD still arise in many allo-BMT 
patients.141,209 Thus, new approaches are needed to prevent GVHD without eliminating 
GVT activity in allo-BMT recipients. 
 We have discovered a critical role for Notch signaling in pathogenic host-reactive 
T cells after allo-BMT.223,250 To assess the overall effects of Notch signaling in T cells 
after allo-BMT, we conditionally expressed a dominant negative Mastermind-like 
(DNMAML) pan-Notch inhibitor in mature CD4+ and CD8+ T cells.115,223,250 DNMAML 
is a truncated fragment of the Mastermind-like1 coactivator fused to GFP that blocks 
transcriptional activation downstream of all Notch receptors.82,92,115,251 DNMAML 
expression in donor T cells led to markedly reduced GVHD severity, without causing 
global immunosuppression.223,250 DNMAML alloreactive T cells displayed decreased 
production of multiple inflammatory cytokines and increased expansion of natural 
regulatory T cells (Treg), leading to reduced target organ damage. However, DNMAML 
T cells proliferated and expanded in vivo as well, or even better, than wild-type 
alloreactive T cells. Importantly, DNMAML T cells retained potent cytotoxic potential 
and cytotoxic activity. Our findings identify Notch signaling in donor T cells as an 
attractive new target to achieve beneficial immunomodulation and inhibit GVHD after 
allo-BMT. 
 Although genetic strategies are invaluable to study the role of Notch signaling in 
disease models, pharmacological interventions are required to harness the therapeutic 
potential of Notch inhibition.221 Here, we report that GSIs blocked Notch signaling in 
alloreactive T cells during GVHD, but led to severe on-target side effects in the intestinal 
epithelium after allo-BMT. To bypass this limiting toxicity, we targeted individual Notch 
ligands and receptors in mice using newly developed potent and specific neutralizing 
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humanized monoclonal antibodies.221,252 These antibodies block both mouse and human 
proteins.221,252 We found that Notch1/2 and Dll1/4 accounted for all the effects of Notch 
signaling in alloreactive T cells, with dominant effects for Notch1 and Dll4. In particular, 
combined blockade of Dll1 and Dll4 was safely achieved after allo-BMT, with no 
evidence of intestinal side effects. Remarkably, transient Dll1 and Dll4 inhibition was 
sufficient to provide long-lasting protection against GVHD. Protection was associated 
with persistent Treg expansion. These findings identify novel strategies to safely and 
efficiently target individual elements of the Notch pathway after allo-BMT, which could 
lead to new strategies for GVHD control in human patients. Since aberrant Notch 
signaling has been linked to many human diseases, our work may have broad 




4.3.1 Pharmacological pan-Notch inhibitors block Notch signaling in alloreactive T 
cells but lead to severe gastrointestinal toxicity 
 The rate-limiting step in proteolytic activation of the Notch receptors can be 
targeted with GSIs, a class of compounds available for preclinical and early clinical 
interventions.253 To assess the potential of pan-Notch inhibition with GSIs to control 
GVHD, we used the B6 anti-BALB/c MHC-mismatched model of allo-BMT and treated 
recipient mice with the GSI dibenzazepine (DBZ). DBZ decreased the production of 
inflammatory cytokines such as IFNγ and IL-2 by alloreactive T cells to a similar extent 
as genetic blockade of Notch signaling by DNMAML (Fig. 4.1A-B).223 DBZ-treated WT 
and vehicle-treated DNMAML T cells had similarly decreased expression of Dtx1, a 
direct Notch target gene (Fig. 4.1B), indicating efficient inhibition of Notch signaling. To 
assess if DBZ-mediated pan-Notch inhibition resulted in improved outcome, we 
monitored survival of allo-BMT recipients (Fig. 4.1C). While DNMAML-mediated 
Notch blockade in alloreactive T cells drastically reduced GVHD severity and increased 
survival of allo-BMT recipients223, DBZ-treated mice died within 4-8 days after 
transplantation with signs of severe diarrhea, even when no T cells were present in the 
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donor inoculum (Fig. 4.1C). This rapid lethality and intestinal toxicity were much more 
severe than previously reported with GSIs in steady-state conditions, suggesting an 
essential role for Notch signaling to support recovery of intestinal integrity after total 
body irradiation. Thus, GSIs can target Notch in alloreactive T cells but lead to profound 
intestinal adverse effects after allo-BMT. 
 
Figure 4.1 Efficient Notch inhibition in alloreactive T cells but severe intestinal 
toxicity of GSIs after allo-BMT. 
Lethally irradiated (900 rads) BALB/c mice were transplanted with B6 TCD BM (5 × 106 cells) 
with or without WT or DNMAML (DN) B6 T cells (10 × 106 splenocytes). The GSI DBZ was 
administered daily as compared with vehicle (i.p., 10 µmol/kg). (A) Cytokine production by 
donor-derived H2Kb+H2Kd– CD4+ spleen T cells at day 5 after allo-BMT. Representative flow 
cytometry plots show intracellular IFNγ and IL-2 after anti-CD3/CD28 restimulation. (B) 
Relative abundance of transcripts for Ifng, Il2, and the Notch target gene Dtx1 in day 5 donor-
derived CD4+ T cells after anti-CD3/CD28 restimulation. (C) Short survival of DBZ-treated mice 
after allo-BMT, even upon transplantation of TCD BM only (P < 0.01, WT vehicle vs. WT DBZ; 
P < 0.0001, TCD vehicle vs. TCD DBZ). In contrast, DNMAML expression in donor T cells led 
to markedly prolonged survival (P < 0.0001, WT vs. DNMAML vehicle) (n = 14 for vehicle-
treated, n = 6 for DBZ-treated groups). 
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4.3.2 Notch1 and Notch2 account for all the effects of Notch signaling in alloreactive 
T cells, with a dominant role for Notch1 
 In steady-state conditions, Notch1 and Notch2 exert largely redundant functions in 
the gut epithelium.17,221,254 Thus, targeting only Notch1 or Notch2 could be safer than 
pan-Notch inhibition after allo-BMT. We studied Notch1-4 expression in naïve and 
alloreactive CD4+ and CD8+ T cells (Fig. 4.2). Both Notch1 and Notch2 transcripts were 
present (Fig. 4.2A). Notch1 mRNA was more abundant than Notch2 mRNA. Notch3 and 
Notch4 transcripts were not detectable, even in activated alloreactive T cells (Fig. 4.2B-
C). To assess the respective role of Notch1 and Notch2 functionally, we used humanized 
antibodies that target the extracellular negative regulatory region of each receptor to 
prevent Notch activation.221 As a control for the quality of these reagents, we found that 
in vivo administration of anti-Notch1 or anti-Notch2 antibodies led to profound depletion 
of Notch1-dependent thymocytes and Notch2-dependent marginal zone B (MZB) cells, 
respectively, with no crossreactivity (data not shown).29,30 These findings indicate high 
efficacy and specificity. 
 We tested the impact of Notch1 and/or Notch2 inhibition after allo-BMT, using 
cytokine production as a surrogate endpoint and DNMAML T cells as positive control for 
efficient pan-Notch inhibition (Fig. 4.3). Combined Notch1 and Notch2 blockade 
reduced IFNγ (Fig. 4.3A) and IL-2 (Fig. 4.3B) production by alloreactive T cells to a 
similar extent as DNMAML expression. Notch1 inhibition alone was sufficient to 
partially block IFNγ and prevent IL-2 production. Notch2 blockade had minor effects on 
the mean fluorescence intensity of IFNγ staining and on IL-2 production. This indicated a 
dominant role for Notch1 with additional contribution from Notch2. To verify that Notch 
receptors exert cell-autonomous effects in T cells, we studied alloreactive T cells with 
genetic inactivation of Notch1, Notch2 (Fig. 4.4), or both (Fig. 4.5). Production of IFNγ 
and IL-2 in CD4+ T cells and IFNγ in CD8+ T cells was profoundly decreased upon 
DNMAML expression or combined Notch1/2 inhibition (Notch1 inactivation with 
systemic Notch2 blockade, Notch2 inactivation with systemic Notch1 blockade, or 
Notch1/Notch2 inactivation). Thus, cell-autonomous effects of Notch1 and Notch2 
accounted for all the effects of Notch signaling in alloreactive CD4+ and CD8+ T cells, 
with a dominant role for Notch1. 
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Figure 4.2 Expression of Notch1 and Notch2 mRNA and absence of detectable 
Notch3/4 transcripts in naïve and alloreactive T cells. 
Naïve CD44lowCD62Lhigh CD4+ and CD8+ T cells were sort-purified from B6 mice. Alloreactive 
T cells were purified as donor-derived H2Kb+H2Kd– CD4+ and CD8+ T cells from the spleen of 
BALB/c allo-BMT recipient mice at day 5 after transplantation. Quantitative RT-PCR was 
performed. (A) Absolute quantification of Notch1 and Notch2 mRNA using a titration curve 
generated from known amounts of each PCR product. This allowed for direct comparison of 
Notch1 and Notch2 transcript abundance. Data are expressed as arbitrary units after normalization 
to Hprt1 mRNA. (B) Relative quantification of Notch3 transcripts using the ΔΔCt method. 
Lineage–CD44lowCD25high “double negative 3” (DN3) B6 thymocytes were used as a positive 
control for Notch3 expression. (C) Relative quantification of Notch4 transcripts using the ΔΔCt 
method. I-Ab+CD11c+ spleen dendritic cells (DC) were used as a positive control for Notch4 
expression. Each symbol represents data obtained from one individual mouse. Relative rather 
than absolute quantification was performed in (B) and (C), as Notch3 and Notch4 amplicons were 




Figure 4.3 Notch1 and Notch2 control the production of IFNγ  and IL-2 by 
alloreactive T cells, with dominant effects of Notch. 
WT or DNMAML B6 T cells were transplanted into irradiated BALB/c recipients (900 rads). 
Isotype control, anti-Notch1 (anti-N1), anti-Notch2 (anti-N2), or both anti-Notch1/Notch2 
antibodies were administered at day 0 and day 3. DNMAML T cells exposed to isotype control 
antibodies were a positive control for pan-Notch inhibition. (A) Intracellular staining for IFNγ in 
donor-derived H2Kb+H2Kd– CD4+ spleen T cells after anti-CD3/CD28 restimulation. MFI of the 
IFNγ+ cells is shown. (B) Intracellular staining for IL-2 under the same conditions. MFI of IL-2+ 
cells is shown. Representative flow cytometry plots are shown. Numbers indicate the percentage 
of cells in each quadrant. Bar graphs represent mean ± SD (n = 3) from 1 of 3 representative 




Figure 4.4 Notch1 and Notch2 exert cell-autonomous effects on cytokine production 
in alloreactive CD4+ and CD8+ T cells. 
Lethally irradiated BALB/c mice (900 rads) were infused with TCD BM and WT, DNMAML, 
Notch1f/f Cd4-Cre+ (N1 KO) or Notch2f/f Cd4-Cre+ (N2 KO) spleen T cells. Isotype control, anti- 
Notch1 or anti-Notch2 monoclonal antibodies were administered i.p. as indicated (5 mg/kg, day 0 
and day 3). At day 4.5, splenocytes were restimulated with plate-bound anti-CD3/CD28 
antibodies followed by intracellular staining. (A) Percentage of IFNγ+ cells among donor-derived 
H2Kb+H2Kd– CD4+ T cells; (B) Percentage of IL-2+ cells among donor-derived CD4+ T cells; 
(C) Percentage of IFNγ+ cells among donor-derived CD8+ T cells. Representative flow cytometry 
plots are shown. Numbers indicate the percentage of cells in each quadrant. Bar graphs represent 




Figure 4.5 Combined Notch1 and Notch2 inactivation inhibits cytokine production 
to a similar extent as DNMAML expression in alloreactive T cells. 
Lethally irradiated BALB/c mice (900 rads) were infused with TCD BM and WT, DNMAML or 
Notch1f/fNotch2f/f Cd4-Cre+ (N1/N2 DKO) spleen T cells. At day 5, splenocytes were restimulated 
with plate-bound anti-CD3/CD28 antibodies followed by intracellular staining. (A) % IFNγ+ cells 
in donor-derived H2Kb+H2Kd– CD4+ T cells; (B) % IL-2+ cells in donor-derived CD4+ T cells; 
(C) % IFNγ+ cells in donor-derived CD8+ T cells. Representative flow cytometry plots are shown. 
Numbers indicate the percentage of cells in each quadrant. Bar graphs represent mean +/– SD 
(n=4/group). **p<0.01. 
4.3.3 Dll1 and Dll4 Notch ligands mediate Notch signaling in alloreactive T cells, 
with a dominant role for Dll4 
 Past reports suggested a role for Delta-like and not Jagged ligands in promoting 
Th1-like inflammatory T cell responses, which dominate in GVHD.111 Thus, we studied 
the possibility of inhibiting Dll1 and Dll4, the two agonistic Delta-like ligands, using 
newly developed neutralizing antibodies that target the Dll1 or Dll4 extracellular 
domain.31,255 As a control, these antibodies led to profound depletion of Dll1-dependent 
marginal zone B cells and Dll4-dependent thymocytes, respectively, showing high 
efficiency and specificity (data not shown).28,256 After allo-BMT, combined inhibition of 
Dll1 and Dll4 blocked production of IFNγ and IL-2 to a similar extent as DNMAML 
expression in T cells (Fig. 4.6). Anti-Dll4 antibodies had the most profound effects, while 
Dll1 blockade only had a minimal impact by itself. Importantly, Dll1/Dll4 blockade 
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allowed for increased numbers of Tregs to accumulate (Fig. 4.7). Thus, transient 
Dll1/Dll4 inhibition blocked production of inflammatory cytokines (Fig. 4.6) and led to 
increased donor Tregs. Together, compared to the effects of DNMAML-mediated pan-
Notch inhibition, Dll1 and Dll4 appeared to account for all the effects of Notch signaling 
on cytokine secretion by alloreactive T cells, with a dominant role for Dll4. 
 
 
Figure 4.6 Dll1 and Dll4 Notch ligands control the production of IFNγ  and IL-2 by 
alloreactive T cells, with dominant effect of Dll4. 
WT or DNMAML B6 T cells were transplanted into irradiated BALB/c recipients (900 rads). 
Isotype control, anti-Dll1, anti-Dll4, or anti-Dll1/Dll4 antibodies were administered at day 0 and 
day 3. DNMAML T cells exposed to isotype control antibodies were a positive control for pan-
Notch inhibition. (A) Intracellular staining for IFNγ in donor-derived H2Kb+H2Kd– CD4+ spleen 
T cells after anti-CD3/CD28 restimulation. MFI of IFNγ+ cells is shown. (B) Intracellular staining 
for IL-2 under the same conditions. MFI of IL-2+ cells is shown. Representative flow cytometry 
plots are shown. Numbers indicate the percentage of cells in each quadrant. Bar graphs represent 




Figure 4.7 Increased accumulation of donor-derived Foxp3+ CD4+ T cells upon 
Dll1/Dll4 blockade after allo-BMT as revealed using a Foxp3-IRES-mRFP reporter 
allele. 
Lethally irradiated BALB/c recipients (900 rads) were transplanted with TCD BM (5x106) and 
5x106 splenocytes from B6 FoxP3-IRES-mRFP reporter mice (expressing mRFP under control of 
endogenous Foxp3 regulatory sequences). Isotype control or anti-Dll1/4 antibodies were 
administered twice weekly. On day 11, mRFP fluorescence was studied by flow cytometry 
among H2Kb+ donor-derived CD4+ T cells or in host CD4+ T cells as a negative control. 
 
4.3.4 Dll1 and Dll4 blockade abrogates acute GVHD and preserves cytotoxic 
potential, even when applied transiently after bone marrow transplantation.  
 We assessed if Dll1 and/or Dll4 blockade could protect mice from the morbidity 
and lethality of acute GVHD (Fig. 4.8). Individual Dll1 or Dll4 inhibition extended the 
median survival of allo-BMT recipients by about 25 and 50 days, respectively, although 
ultimately all animals succumbed to GVHD. However, when both Dll1 and Dll4 were 
inhibited, we observed increased long-term survival and decreased GVHD severity to an 
extent similar to that seen with DNMAML-mediated pan-Notch inhibition. Remarkably, 
short-term Dll1/Dll4 blockade after allo-BMT (day 0-10) conferred as much protection as 
continuous blockade for 60 days after transplantation. Therapeutic targeting of Notch1 
and 2 receptors could not be achieved due to significant toxicity, presumably from on-
target gastrointestinal side effects post-irradiation (data not shown). Thus, targeting 
Delta-like ligands rather than Notch receptors did not induce limiting toxicity and 
revealed the protective effects of Notch inhibition in GVHD. 
 DNMAML T cells have preserved cytotoxic activity after allo-BMT.223,250 Thus, 
we next assessed the effect of short-term anti-Dll1/Dll4 treatment (Fig. 4.9). Overall 
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cytotoxic potential was captured with an in vivo cytotoxicity assay (Fig. 4.9A-B). Allo-
BMT recipients were challenged on day 14 with CFSE-labeled allogeneic target cells. 
Efficient elimination of allogeneic targets was observed in recipients of wild-type T cells 
treated with isotype control or anti-Dll1/Dll4 antibodies. Cytotoxic activity was slightly 
reduced in anti-Dll1/Dll4-treated recipients. However, it was efficient when compared to 
recipients of T cell-depleted BM only (Fig. 10b). These data demonstrate that Dll1/4 
blockade inhibits GVHD while preserving substantial cytotoxic activity. 
 
 
Figure 4.8 Transient blockade of Dll1 and Dll4 protects mice from lethal GVHD. 
Survival after transplantation and clinical GVHD score demonstrate increasing protection with 
Dll1, Dll4, and combined Dll1/Dll4 blockade (P = 0.005, WT vs. anti-Dll1; P = 0.0001, WT vs. 
anti-Dll4; P < 0.0001, WT vs. anti-Dll1/Dll4). Anti-Dll1/Dll4 antibodies provided nearly as much 
protection as DNMAML T cells, even upon short-term administration (P = 0.21, DNMAML vs. 





Figure 4.9 Dll1/Dll4 blockade preserved substantial in vivo cytotoxicity. 
Allo-BMT and transient administration of anti-Dll1/Dll4 or control antibodies (days 0–10) were 
performed as described in Figure 4.8 legend. (A) In vivo cytotoxicity assay. Allo-BMT recipient 
mice were challenged on day 14 with a 1:1 infusion of CFSE-labeled allogeneic targets and 
control cells (CFSEhighH2Kd+ BALB/c and CFSElow control H2Kb+ B6-CD45.1 splenocytes, 
respectively). After 18 hours, elimination of the BALB/c targets was assessed in the spleen by 
flow cytometry. (B) Summary of in vivo cytotoxicity data in individual mice (n = 6–10/group). 
**P < 0.01. 
4.3.5 Dll1 and Dll4 inhibition does not impair hematopoietic recovery after allo-
BMT  
 To further assess the safety of short-term Dll1/Dll4 blockade, we studied 
hematopoietic and thymic reconstitution. Blood counts and in particular platelet recovery 
were not impaired by Dll1/Dll4 blockade (Fig. 4.10A). Bone marrow progenitor contents 
were not affected as compared to mice receiving WT or DNMAML T cells (Fig. 4.10B). 
When CD45.1 was used to track cells derived from the T cell-depleted bone marrow, 
similar engraftment efficiency was observed (Fig. 4.10C). Thus, no major defect in 
hematopoietic reconstitution was apparent in these conditions. 
 Thymic output after allo-BMT can be profoundly decreased by GVHD-induced 
damage to the thymic epithelium (tGVHD).257,258 However, Dll4 is the physiological 
ligand driving early T cell development in the thymus.256 We quantified CD4+CD8+ 
double positive (DP) thymocytes as a measure of thymic function after allo-BMT (Fig. 
4.11). Recipients of wild-type T cells had markedly reduced DP numbers as a result of 
severe tGVHD. Infusion of DNMAML T cells preserved thymic cellularity, consistent 
with markedly decreased tGVHD. Interestingly, Dll1/Dll4 blockade was associated with 
low DP contents at day 21, consistent with blockade of Dll4-dependent T cell 
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development. However, after time had elapsed allowing antibodies to be cleared, thymic 
cellularity increased up to levels seen in DNMAML recipients (day 35). Thus, transient 




Figure 4.10 Preserved hematopoietic recovery after allogeneic transplantation in 
mice treated with anti-Dll1/Dll4 antibodies. 
Allo-BMT and transient administration of anti-Dll1/Dll4 or control antibodies (days 0–10) were 
performed as described in Figure 4.8. (A) Weekly complete blood counts after allo- BMT 
showing unimpaired recovery in recipients treated with anti-Dll1/Dll4 antibodies. (B) CFU-GM 
activity in the BM on day 21 after transplantation. (C) Absolute numbers of CD45.1+ cells 
derived from B6-CD45.1 donor TCD BM at days 14, 21, and 35. This showed preserved 





Figure 4.11 Protection from thymic GVHD upon transient systemic Dll1/Dll4 
blockade. 
Lethally irradiated (850 rads) BALB/c mice were transplanted with TCD BM (5×106 cells) with 
or without WT or DNMAML T cells (10×106 splenocytes). Isotype control vs. anti-Dll1/Dll4 
antibodies were administered i.p. at days 0, 3, 7, and 10 (short course). (A) Thymus was assessed 
using flow cytometry to identify newly formed CD4+CD8+ DP thymocytes. At day 21, 
thymopoiesis was inhibited in the presence of anti-Dll4 antibodies (red arrow). At day 35, after 
antibody clearance, large numbers of DP thymocytes arose in anti-Dll1/Dll4–treated mice (blue 
arrow), indicating protection from GVHD-induced thymic damage. (B) Absolute number of 
CD4+CD8+ DP thymocytes at days 21 and 35 in individual allo-BMT recipients, quantifying 
preserved thymic recovery at day 35 in anti-Dll1/ Dll4–treated mice. *P < 0.05. 
4.4 Discussion 
 Our findings highlight the therapeutic potential of targeting individual Notch 
receptors or ligands as a new strategy to control GVHD after allo-BMT. We used genetic 
pan-Notch inhibition as an experimental benchmark to identify non-redundant effects of 
specific Notch receptors and ligands in alloreactive T cells. Notch1 had dominant effects 
with a minor contribution from Notch2, while Notch3-4 transcripts were not detectable in 
donor T cells. Delta-like ligands appeared to account for all the pathogenic effects of 
Notch in T cells, with dominant effects of Dll4. In terms of efficacy and safety, short-
term combined blockade of Dll1/4 Notch ligands with monoclonal antibodies emerged as 
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the most promising strategy to harness the beneficial effects of Notch inhibition after 
allo-BMT in the pre-clinical mouse models that we used. 
 Past work has described redundant roles for Notch1 and Notch2 in T cells in other 
immune contexts.113,259,260 Several reasons could explain the more dominant effects of 
Notch1 in GVHD. Although both receptors were expressed, Notch2 was less abundant 
than Notch1 mRNA in alloreactive T cells, especially during peak activation. In addition, 
Notch1 may preferentially interact with the Dll4 Notch ligand during GVHD. This is 
reminiscent of the specific requirement for Notch1 and Dll4 in early T cell development 
and neoangiogenesis.252,256,261 It remains to be determined which cells present Dll1/Dll4 
ligands to alloreactive T cells in the post-bone marrow transplant environment. 
Moreover, Fringe glycosyltransferases could be important by increasing the avidity of 
Notch receptors for Delta-like as opposed to Jagged ligands.33,262 This mechanism has not 
been explored in peripheral T cell immunity, but could account in part for the dominant 
effects of Delta-like ligands during GVHD. 
 Early work exploring a role for Notch in alloreactivity relied on Notch ligand 
overexpression in dendritic cells or in artificial APCs.215,263,264 This strategy induced 
hyporesponsiveness of alloreactive T cells, leading the authors to suggest that Notch 
might be important to induce tolerance after transplantation. In contrast, our work 
indicates that Notch signaling is required for pathogenic functions of alloreactive T cells 
in vivo after allo-BMT. This is consistent with a recent report describing delayed organ 
rejection upon Dll1 inhibition in a model of allogeneic heart transplantation, although our 
observations identified more profound overall effects of the pathway.265 Our data 
illustrate the value of studying the effects of Notch signaling in vivo in specific immune 
responses using loss-of-function approaches. In vitro studies and gain-of-function 
approaches may not reliably model the physiological and pathophysiological conditions 
in which T cells encounter Notch ligands.  
 Similar to genetic pan-Notch inhibition, Dll1/Dll4 blockade dramatically 
decreased production of inflammatory cytokines and GVHD without causing global 
immunosuppression (Chapter 2, 3, and 4 summarized in Figure 4.12). Indeed, Notch 
deprivation preserved in vivo proliferation and increased expansion of alloreactive T cells 
in lymphohematopoietic organs. Because proliferation was not changed, enhanced 
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accumulation was likely related to decreased activation-induced T cell death upon Notch 
inhibition. These findings differ from the effects of most interventions used to control 
GVHD, including calcineurin inhibitors and many methods that decrease proliferation 
and expansion of alloreactive T cells. We also observed long-lasting expansion of donor-
derived Tregs, even when Dll1/Dll4 ligands were blocked transiently after allo-BMT. It is 
possible that these Tregs helped maintain long-term GVHD control upon Notch 
inhibition. Mechanistically, our findings indicate that Notch blockade has profound 
effects on the production of inflammatory cytokines that trigger tissue damage and 
GVHD. More work will be needed in the future to dissect the differential effects of Notch 
signaling on distinct effector functions in T cells. 
 Our findings identify a promising new preclinical strategy of Notch blockade with 
an improved safety index when compared to systemic pan-Notch inhibition with GSIs. 
GSIs are currently being explored for their anti-cancer activity in early clinical trials. 
Gastrointestinal toxicity has emerged as a significant dose-limiting on-target adverse 
effect in mice and humans.222,254,266 Concomitant administration of corticosteroids has 
been reported to decrease gut toxicity in mice.220 However, corticosteroids induce global 
immunosuppression, which is an unattractive choice after allo-BMT. Intermittent 
administration schedules are also being tested to improve the safety of GSIs in cancer 
patients. However, our observations suggest that minimizing gut toxicity of GSIs may be 
particularly challenging in allo-BMT patients given the heightened requirement for Notch 
signaling during intestinal regeneration after irradiation, precisely at the time when Notch 
exerts its effects on alloreactive T cells. Thus, GSIs are not promising agents for 
therapeutic intervention after allo-BMT. 
 The humanized antibodies that we used in this study were designed to block both 
mouse and human proteins. Thus, our preclinical work could be efficiently translated into 
new strategies for GVHD control in clinical trials. Although our observations were made 
after allogeneic HSCT, they may extend to other types of immune responses with 
exposure to persistent antigens. For example, Notch may regulate organ rejection 
(unpublished data) and autoimmune diseases (Chapter 5). From a therapeutic perspective, 
our work points to the Notch pathway as an attractive target to achieve beneficial context-




Figure 4.12 Summary of observations after inhibition of Notch signaling in T cells 
during GVHD.  
(A) Notch-inhibited T cells induce significantly less GVHD concomitant with markedly reduce 
cytokine production and natural Treg expansion. Notch inhibition largely preserved proliferation 
and cytotoxic potential; (B) Infused T cells expressing Notch1 and 2 interact with antigen-
presenting cells expressing Dll4 and Dll1. Notch1 and Dll4 play a dominant role in mediating 





Chapter 5  
Notch regulates T cell accumulation and function in the 




 Systemic inhibition of Notch signaling was previously shown to attenuate 
experimental autoimmune encephalomyelitis (EAE). Different studies attributed these 
effects to decreased expression of T-bet, enhanced regulatory T cell function, or reduced 
T cell chemotaxis to the central nervous system (CNS). Interpretation of these 
heterogeneous findings is difficult, since many cell populations could be affected by 
systemic Notch blockade. To resolve the role of Notch signaling in T cells during EAE, 
we used the pan-Notch inhibitor DNMAML and several complementary loss-of-function 
approaches specifically in myelin-reactive T cells. Notch inhibition in T cells markedly 
decreased EAE incidence and severity. Notch-deprived myelin-reactive T cells had 
preserved activation and effector differentiation in secondary lymphoid tissues. However, 
Notch-deprived T cells failed to accumulate in the CNS post-immunization. Parking 
wild-type and DNMAML T cells together in bone marrow chimeras increased 
accumulation of DNMAML T cells in the CNS post-immunization but did not prevent 
EAE, indicating the absence of dominant suppression by DNMAML T cells. Analysis of 
CNS-infiltrating Notch-deprived T cells revealed profoundly defective production of IL-
17A and IFN-γ, despite preserved expression of T-bet. Thus, Notch controls 
accumulation and pathogenic functions of CD4+ T cells within their target organ but not 
in lymphoid tissues during EAE. 
                                                
6 Taken from: 
 
Sandy AR, Stoolman J, Malott K, Pongtornpipat P, Segal B, and Maillard I. Notch regulates T cell 
accumulation and function in the CNS during experimental autoimmune encephalomyelitis. In preparation. 
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5.2 Introduction  
  
5.2.1 Etiology and pathogenesis of Multiple Sclerosis 
 Multiple Sclerosis (MS) is an autoimmune demyelinating syndrome of the central 
nervous system (CNS). The earliest recorded case of MS was probably described by 
Auguste d’Este (1794–1848), grandson of George III of England, in his diary.267 MS may 
have existed even in the 14th century or before, but the case of August d’Este is the most 
obvious one based on his detailed account of his own illness.268 Early microscopic 
descriptions of MS pathology and plaques were detailed by Rindfleisch and Charcot.268-
270 Rindfleisch noted that  
 
“nerve fibers primarily lose their myelin and then can be traced a 
considerable distance into the connective tissue of the lesions as axons, 
devoid of sheaths.”268 
  
 Today, MS is known as a chronic disease of the brain and spinal cord. The 
inflammatory plaque in the white matter is the histopathological hallmark of MS.271 MS 
is classified as relapsing-remitting, primary progressive, or secondary progressive 
disease, with the majority of patients experiencing relapsing-remitting MS.272 The 
etiology of MS is unclear although there are several hypotheses in the field. Genetics is 
likely to be a contributing factor to MS. There is a 20-30% and 5% disease 
correspondence between monozygotic and same-sex dizygotic twins, respectively.273 The 
MHC class II gene HLA-DRB1 as well as several non-MHC genes identified through 
genome-wide association studies seem to confer susceptibility to MS.274,275 Along with 
genetics, Vitamin D deficiency, and Epstein-Barr Virus (EBV) infection have also been 
suggested to be MS risk factors. MS prevalence increases as distance from the equator 
increases, although decreased exposure to ultraviolet light and vitamin D deficiency 
effects are difficult to separate.276 Vitamin D deficiency inversely correlates with relapse 
rate and disability, and vitamin D administration to mice in a mouse model of MS, 
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experimental autoimmune encephalomyelitis (EAE), prevents EAE.277-279 Prior infection 
with EBV is associated with increased MS prevalence.280 Moreover, in many cases, EBV 
seroconversion occurred prior to MS diagnosis.281 Due to the uncertain etiology of MS, 
mouse models used to study MS have focused on pathogenic mechanisms rather than 
etiology. 
 
5.2.2 Th1, Th17, and Tregs in MS and EAE 
 MS is thought to be primarily mediated by autoreactive CD4+ Th1 and Th17 T 
cells, with contributions from CD8+ T cells and B cells now becoming apparent. In fact, 
patients with relapsing-remitting MS seem to have a higher frequency of myelin-reactive 
CD8+ T cells than chronic progressive patients or healthy controls.282,283 Studies 
investigating the role of B cells in MS pathogenesis revealed that B cells found in the 
cerebrospinal fluid of MS patients have undergone somatic hypermutation to presumably 
CNS-specific peptides, since these clones are absent from the periphery.284,285 Indeed 
treatment of some MS patients with a B cell targeting therapy, Rituximab has shown 
efficacy.286,287 Cells of the innate immune system including, dendritic cells, natural killer 
cells, mast cells, invariant natural killer T cells, and γδ T cells, have also been shown to 
contribute to MS pathology, at least in animal models.288 However, for the purpose of this 
dissertation, I will focus on the contributions of CD4+ T cells to MS pathology. 
 In EAE, myelin-reactive T cells become activated in the periphery and traffic to 
the CNS after breakdown of the blood-brain-barrier.289,290 Upon entry into the CNS, T 
cells are reactivated by resident and infiltrating activated APCs.291-293 Cognate 
interactions between T cells and APCs results in increased inflammation resulting in 
demyelination and axonal damage and loss.  
 The contributions of CD4+ Th1 and Th17 cells to EAE are being delineated but 
some results still do not fit into current paradigms. Before the discovery of Th17 cells in 
2006, Th1 cells were thought to be the primary T cell population responsible for 
promoting EAE. However, this idea was challenged when studies were carried out using 
a series of knockouts that should render Th1 cells non-functional. For instance, IFNγ-/- 
and Stat1-/- mice were just as susceptible to EAE as WT mice, but T-bet-/- mice (master 
transcription factor of Th1 cells) were resistant to EAE.294,295 These results were 
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unexpected since patients that received exogenous IFNγ had exacerbated disease.296 To 
further investigate the contribution of Th1 cells to EAE, the receptor components of the 
IL-12 receptor, p40 and p35, were deleted in mice. IL-12 signaling is important for Th1 
development.297,298 Adding to the confusion, while IL-12p40-/- mice were resistant to 
EAE induction, IL-12p35-/- mice were susceptible, suggesting, at the time, a redundancy 
in the system for Th1 development.299 Later it was discovered that another cytokine, IL-
23, shared a common receptor component with IL-12, IL-12p40. The IL-23 receptor is 
composed of the unique p19 subunit and the shared p40 subunit.300 Remarkably, IL-
23Rp19-/- mice (lacking only IL-23) were resistant to EAE induction.301 These results 
presented the likelihood that another population of autoreactive pathogenic T cells 
existed and contributed to EAE.  Later, this population, now known as Th17 cells, was 
characterized as producing IL-17A, IL-17F, IL-6, and TNFα. Adoptive transfer of this 
population into mice yielded EAE.302 These data were corroborated by findings that IL-
17-/- and Rorγt-/- mice had significantly attenuated EAE.303,304 These findings did not 
negate a contribution of Th1 cells to EAE pathogenesis since adoptive transfer studies 
comparing Th1 and Th17 cells demonstrated that both populations could induce EAE.305 
However, each population induced a unique inflammation pattern in the CNS with a 
requirement for different subsets of chemokines. Therapeutic targeting of IL-23p19 or IL-
12/23p40 has shown efficacy in EAE even during established disease (relapse 
phase).306,307 Unfortunately, in this case, animal models did not translate well to treatment 
of human MS, as clinical trials targeting IL-12/23p40 did not show efficacy.308 However, 
these studies do not explain the role of T-bet in encephalitogenic T cell responses during 
EAE. It has been suggested that T-bet controls the encephalitogenicity of T cell responses 
during EAE rather than specific cytokine responses or Th1 versus Th17 differentiation.309 
Nevertheless, how T-bet regulates T cell responses during EAE is still unclear and 
whether its functions translate to MS pathogenesis has yet to be determined. 
 Tregs have also been shown to play an important role in EAE pathogenesis. For 
example, myelin basic protein (MBP) TCR transgenic mice crossed to RAG-1-/- mice 
develop spontaneous EAE due to the absence of natural Tregs.289  Moreover, adoptive 
transfer of CD4+CD25+ T cells three days before immunization or transferred at the same 
time as autoreactive T cells significantly reduced EAE severity.310 However, other work 
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has shown that even when Tregs accumulate in the CNS, they fail to control EAE, 
suggesting a requirement for Tregs in dampening the immune response in the periphery 
before entry into the CNS.311 Related to these findings in EAE, MS patients have 
decreased FOXP3 mRNA and FOXP3 protein in purified CD4+CD25+ T cells.312 
Moreover, expansion of Tregs has been one proposed mechanism of action of the MS-
approved drug, glatiramer acetate.313  
   
5.2.3 T cell costimulation in EAE and MS 
 The role of T cell costimulation in EAE and MS has been another area of active 
investigation. For instance, polymorphisms of CTLA4 have been associated with 
susceptibility to MS.314 Indeed, blockade of CTLA-4 in EAE results in exacerbation of 
EAE and lack of clinical remission in a relapsing-remitting model of EAE.315,316 In 
contrast, treatment with CTLA-4-Ig reduced EAE severity.317 However, CD80 and CD86 
have been shown to have differential roles in EAE. Treatment with an anti-CD80 F(ab) 
fragment blocked relapses in a SJL model of EAE.318 In contrast, treatment with an anti-
CD80 antibody resulted in exacerbation of EAE, which conflicts with data showing that a 
small molecular inhibitor of CD28 decreased disease.319-321 Anti-CD86 treatment has 
been shown to exacerbate disease or have no effect on disease outcome.322,323 
Additioanlly, treating with anti-CD86 antibody during the remission phase of a relapsing-
remitting proteolipid protein-induced EAE model did not affect disease progression, 
whereas treatment with anti-CD86 at disease induction exacerbated EAE severity.318,323  
 PDCD1 polymorphisms have also been associated with MS disease 
progression.324 Exemplifying this, blockade of PD-1 or PD-L2/B7-DC resulted in 
exacerbated disease in WT and CD28-/- animals.325 In contrast, PD-L1/B7-H1 blockade 
did not alter disease outcome.325 The presence of PD-L1/B7-H1 and the absence of PD-1 
on CD8+ T cells in MS lesions has been suggested to be one pathogenic mechanism in 
MS.326,327 Similar to PD-1 blockade, ICOS deficiency exacerbates EAE 328,329.   
 Very few TNF superfamily molecules have been tested in EAE and whether those 
observed effects are T cell-intrinsic is unclear. However, those that have been tested have 
shown a therapeutic benefit. For instance, OX40-/- and OX40L-/- mice are significantly 
protected from EAE.330,331 These results are supported by therapeutic use of an OX40-Ig 
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fusion protein and an anti-OX40L neutralizing antibody, which also protected from 
EAE.332,333 Also, an agonist antibody against 4-1BB inhibited EAE.334 In contrast, 
immunization of BTLA-/- and HVEM-/- mice exacerbated and prolonged EAE.335,336 
Lastly, MBP TCR transgenic CD40L-/- mice and CD40-/- mice were resistant to EAE 
compare to MBP TCR transgenic and WT mice, respectively.337,338 CD40 deficiency was 
required in both the hematopoietic and non-hematopoietic compartments to achieve full 
protection from EAE.338 Similar to CD40L-/- mice, mice treated with an anti-CD40L 
blocking antibody had significantly reduced EAE even if administration occurred after 
disease induction.339 Collectively, these data suggest that costimulatory molecules could 
be interesting therapeutic targets in EAE and in MS. Data shown in Chapters 2, 3, and 4 
suggest that Notch may act as a T cell costimulation receptor during GVHD.223,250,340 
Similarly, data described in this chapter suggest that Notch may behave similarly in EAE 
and thus may also be an attractive therapeutic target in MS, as suggested in GVHD. 
 
5.2.4 Notch in Experimental Autoimmune Encephalomyelitis 
 Prior studies showed that systemic Notch blockade can attenuate EAE, but 
provided conflicting information about the intensity and mechanisms of this effect (Table 
5.1). Using GSIs, Notch1 activation and a Notch1 antisense strategy, Osborne and 
collaborators reported that Notch directly regulates expression of Tbx21 (encoding T-bet) 
in T cells during EAE.117 GSIs were also described to enhance remyelination and axonal 
survival in EAE.341,342 Another study using GSIs and neutralizing antibodies described 
Notch3 as a dominant receptor influencing EAE via PKCθ expression in Th1 and Th17 
CD4+ T cells.343 Systemic anti-Dll4 treatment was shown to bolster peripheral Treg 
function during EAE, while others using a similar approach reported altered T cell 
differentiation or chemotaxis.118,119 Another group that used Dll4 blockade reported a 
mild delay in disease when administered before EAE induction and no protection when 
administered on day 8 after induction.344 They attributed their mild protection to reduced 
cytokine responses in the spleen.344 Moreover, Jagged1-Fc treatment slightly reduced 
EAE while Dll1-Fc exacerbated EAE, attributable to altered cytokine responses in 
secondary lymphoid organs without an effect on Tregs.345 Jagged2 activation was 
reported to reduce IL-17A in secondary lymphoid organs and increase Treg responses.124 
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Finally, Notch signaling was recently linked to Th9 differentiation in EAE.124 At least in 
part, these discrepant results might reflect the use of heterogeneous experimental systems 
based on systemic Notch modulation or gain-of-function approaches, which can trigger 
unintended off- and on-target effects and hinder accurate conclusions about Notch 
function specifically in T cells. This is particularly important in EAE since Notch affects 
many immune and non-immune cells that contribute to disease pathogenesis (Chapter 
1).60,346 
 
Table 5.1 Role of Notch signaling in experimental autoimmune encephalomyelitis. 
Notch manipulation Notch effect(s) Reference 
GSI, Notch1 AS, ICN 
overexpression 
Notch1 directly regulates T-
bet expression and 
decreased IFN-γ 
117 
Jag1-Fc and Dll1-Fc fusion 
proteins, Jag1 and Dll1 
blocking Abs 
Jag1-Fc decreased IFN-γ 
and EAE, increased IL-10 
345 
GSI, Notch1 and 3 blocking 
antibodies 
Decreased IFN-γ and PKCθ 
activation 
343 
Anti-Dll4 blocking Ab Decreased IL-17, increased Foxp3/Tregs 
118 
Anti-Dll4 blocking Ab Decreased T cell chemotaxis to CNS (Ccr1, 2, 5, 6) 
119 
Anti-Dll4 blocking Ab 
Slightly reduced EAE, 
reduced IL-17, IL-2, GM-
CSF, IL-6 
344 
Jagged2-Fc, Dll1-Fc, ICN1 
overexpression, 
Notch1f/fNotch2f/f x Cd4-cre 
Notch1 directly regulates 
IL-9 leading to decreased 
IL-17 
124 
GSI in vitro 
Decreased active Notch1 in 
murine oligodendrocytes, 
decreased demyelination 
and increased myelination 
341,342 
 
 To resolve these conflicting results, we investigated Notch function specifically in 
mature T cells during EAE using several complementary genetic loss-of-function 
approaches, including expression of the pan-Notch inhibitor DNMAML and inactivation 
of Notch receptor genes. T cell-specific Notch inhibition resulted in nearly complete 
protection from EAE, independent of effects on T cell activation and effector 
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differentiation in secondary lymphoid organs. Notch-deprived CD4+ T cells failed to 
accumulate in the CNS post-immunization despite preserved in vitro migration. Parking 
WT and DNMAML CD4+ T cells together in bone marrow chimeras increased 
accumulation of Notch-deprived CD4+ T cells in the CNS but did not suppress disease. In 
the CNS, Notch-deprived myelin-reactive CD4+ T cells failed to produce IL-17A and 
IFN-γ, despite preserved expression of the master transcription factor, T-bet. Our data 
demonstrate that Notch specifically regulates the secondary response of myelin-reactive 
CD4+ T cells in the CNS independently of effects on T-bet and Tregs during the primary 
immune response in lymphoid organs. 
 
5.3 Results 
5.3.1 Notch inhibition in myelin-reactive CD4+ T cells prevents EAE.  
 To overcome limitations of past studies, we used in vivo genetic loss-of-function 
models to investigate Notch signaling specifically in T cells during EAE (Fig. 5.1A). We 
inhibited the Notch transcriptional activation complex downstream of all Notch receptors 
in mature T cells by expressing a dominant negative Mastermind-like (DNMAML) 
mutant or by inactivating Rbpj, encoding the DNA-binding factor CSL/RBP-Jκ.86,115 In 
selected experiments, DNMAML was introduced into 2D2 transgenic T cells, 
recognizing MOG35-55.347 Notch inhibition efficiently prevented EAE, with fewer than 
8% of mice developing symptoms upon DNMAML expression or CSL/RBP-Jκ loss in T 
cells, as compared to ~95% of controls (Fig. 5.1B, C). When DNMAML was expressed 
in transgenic myelin-reactive 2D2 T cells, disease incidence was also markedly reduced 
(Fig. 5.1D, E). Decreased EAE correlated with reduced demyelination (Fig. 5.1F) and 
cellular infiltrates (Fig. 5.1G, H) in the CNS. Previous approaches yielded significantly 
less protection, likely because of incomplete Notch blockade or redundancy with other 
family members when only Notch1, Notch3 or Dll4 was inhibited.117-119,124,343,344 Thus, 
Notch inhibition specifically in T cells markedly reduced EAE, even with a high 
frequency of myelin-reactive T cells in TCR transgenic mice. 
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5.3.2 Preserved effector differentiation of myelin-reactive Notch-deprived CD4+ T 
cells in lymphoid tissues.  
 Previous studies in EAE suggested that Notch modulates effector T cell 
differentiation in secondary lymphoid tissues.117,118,124 We assessed T cell responses at 
peak disease using primarily 2D2 transgenic mice in which myelin-reactive T cells can be 
identified based on Vα3.2+Vβ11+ TCR expression.347 DNMAML expression in CD4+ T 
cells preserved T cell activation in draining lymph nodes (DLN) as measured by 
increased CD44 expression (Fig. 5.2A). Analysis of DLN IFN-γ and IL-17A-producing 
cells, two important EAE drivers, revealed no significant difference between WT and 
Notch-inhibited CD4+ T cells as assessed by ELISpot (Fig. 5.2B).348 By flow cytometry, 
intracellular IL-17A and IFN-γ expression by activated myelin-reactive 2D2/DNMAML 
T cells was also largely preserved (Fig. 5.2C). These data suggest that Notch inhibition in 
peripheral myelin-reactive CD4+ T cells did not significantly impact IFN-γ and IL-17A 
production. These results are similar to data showing that anti-Dll4 treatment did not alter 
IFNγ and IL-17A production by proteolipid protein-specific T cells in another EAE 
model.119 
 Prior studies suggested that Notch1 regulates expression of Tbx21 (encoding T-
bet) in Th1 cells, while Dll4-mediated signaling can increase Rorc mRNA (encoding 
Rorγt) in Th17 cells.117 However, we found no significant change in Tbx21 transcripts 
and a trend for increased Rorc expression in activated myelin-reactive 2D2/DNMAML 
CD4+ T cells post-immunization (Fig. 5.2D). We next studied T-bet expression after 
verifying antibody specificity in Tbx21–/– mice during EAE (Fig. 5.2E).226 We observed a 
preserved frequency of T-bet+ cells and normal staining intensity among Notch-deprived 
myelin-reactive 2D2/DNMAML CD4+ T cells, consistent with normal T-bet expression 
in DLN (Fig. 5.2F). Past work suggested that Notch receptors, in particular Notch1, can 
enhance NF-κB activation in T cells by CSL/RBP-Jκ and MAML-independent 
pathways.349 To address this, we studied IFNγ production and T-bet expression in T cells 
lacking Notch1 or both Notch1/Notch2 during EAE. Disease incidence and severity were 
drastically reduced in the absence of Notch1 or Notch1/2 (not shown), consistent with the 
dominance of these receptors in T cells. We observed a normal frequency of IFNγ+ cells 
(Fig. 5.2G) and preserved or even slightly increased T-bet levels (Fig. 5.2H) in Notch1-
 86 
deficient and Notch1/2-deficient T cells, respectively. Thus, blockade of the Notch 
transcriptional complex or Notch1/2 inactivation does not impact T-bet and IFNγ 
production by DLN T cells during EAE.  
 
Figure 5.1 Inhibition of Notch signaling in myelin-reactive CD4+ T cells markedly 
attenuates EAE. 
(A) Experimental design; (B) Mean clinical EAE score (>2 experiments); (C) Percent disease 
incidence (score>2) of immunized WT, DNMAML, or RBKO mice (>2 experiments); (D) Mean 
clinical score in TCR transgenic 2D2 or 2D2/DNMAML mice (expressing DNMAML in T cells) 
(>3 experiments); (E) Percent disease incidence (score>2) of immunized 2D2 and 
2D2/DNMAML mice (>2 experiments); (F) Luxol fast blue and (G) H&E staining of spinal cord 
lumbar sections from 2D2 and 2D2/DNMAML mice (representative of n=3 mice/group; 2 




Figure 5.2 Notch inhibition in myelin-reactive CD4+ T cells does not alter initial 
activation or effector T cell differentiation. 
(A) Percent and number of Vβ11+CD4+CD44+ T cells (n=3-4 mice/group; >2 experiments). (B) 
Number of IFNγ and IL-17A-secreting cells by ELISpot in DLN from immunized WT, 
DNMAML, 2D2, and 2D2/DNMAML (n=3-4 mice/group; >2 experiments); (C) Frequency of 
IFNγ and IL-17A-producing DLN Vβ11+CD4+CD44+ T cells restimulated with anti-CD3/CD28 
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and stained for intracellular cytokines (n=3-4 mice/group; 2 experiments); (D) Tbx21 and Rorc 
mRNA in 2D2/DNMAML and 2D2 CD4+ T cells (n=3-4 mice/group; 2 experiments); (E) 
Specificity of T-bet detection. Representative flow cytometry plot; (F) Intracellular T-bet in 
Vβ11+CD4+CD44+ T cells by intracellular flow cytometry (2 experiments; n=3-4 mice/group); 
(G) Number of IFNγ and IL-17A-secreting cells by ELISpot in DLN from immunized WT, 
N1KO and N1/2KO (n=2-3 mice/group; >2 experiments); (H) Frequency of T-bet+CD44+CD4+ 
N1KO and N1/2KO T cells measured by intracellular flow cytometry (2 experiments; n=3-4 
mice/group).  
 
5.3.3 Notch-inhibited CD4+ T cells fail to accumulate in the CNS despite preserved 
in vitro migration.  
 Since T cell responses were preserved in lymphoid tissues, we investigated the 
role of Notch signaling in central nervous system (CNS)-infiltrating CD4+ T cells at peak 
disease. 2D2/DNMAML CD4+ T cells showed markedly reduced accumulation in the 
CNS post-immunization (Fig. 5.3A). Similar findings were observed with polyclonal T 
cells expressing DNMAML or lacking CSL/RBP-Jκ (Fig. 5.3B), as well as in the absence 
of Notch1/2 and to a slightly lesser extent Notch1 (Fig. 5.3C). To investigate if Notch-
deprived CD4+ T cells failed to traffic to the CNS, α4β1 expression and in vitro 
migration were assessed. The integrin α4β1 drives T cell trafficking into the CNS.350 We 
found no difference in α4β1 expression between 2D2 and 2D2/DNMAML CD4+ T cells 
post-immunization (Fig. 5.3D). Prior work reported that anti-Dll4 inhibits chemotaxis to 
the CNS due to decreased expression of Ccr2, 5 and 6.119 In addition, Notch can regulate 
Ccr7 expression in CNS-infiltrating leukemic T cells.351 Other chemokine receptors have 
been linked to CD4+ T cell infiltration into the inflamed CNS, such as Cxcr3.352 
However, we found no significant change in expression of these chemokine receptors by 
2D2/DNMAML T cells during EAE (data not shown). Next, we assessed responses of 
Notch-deprived myelin-reactive CD4+ T cell to all candidate chemokine receptors in vitro 
(Fig. 5.3E). Purified, primed 2D2/DNMAML CD4+ T cells migrated at least as well as 
control 2D2 T cells post-immunization. These data indicate that Notch-deprived myelin-
reactive CD4+ T cells can migrate towards chemotactic signals at least in vitro, in 




Figure 5.3 Notch-deprived myelin-reactive CD4+ T cells fail to accumulate in the 
CNS in vivo but have preserved trafficking in vitro. 
Spinal cord and brain infiltrates from immunized (A) 2D2, 2D2/DNMAML; (B) WT, DNMAML, 
RBKO; (C) WT, N1KO, N1/2KO mice. Numbers of CD4+ T cells were measured by flow 
cytometry (n=2-4 mice/group; >2 experiments); (D) Expression of α4β1 in 2D2/DNMAML 
Vα3.2+Vβ11+CD4+CD44+ T cells measured by flow cytometry (n=3-4 mice/group; 3 
experiments); (E) Transwell migration of 2D2/DNMAML Vβ11+CD4+CD44+ T cells towards 
indicated chemokines. Dotted line shows background number of primed 2D2 
Vα3.2+Vβ11+CD4+CD44+ T cells migrating without chemokine (n=3-4 mice/group; 3 
experiments). 
5.3.4 Myelin-reactive Notch-deprived CD4+ T cells do not suppress EAE induced by 
WT CD4+ T cells.  
 Past studies using systemic Notch ligand fusion proteins and antibodies suggested 
that Notch modulation increased Treg frequency, resulting in decreased EAE severity.118 
To assess if increased Treg frequency or function contributed to protection from EAE, we 
assessed Foxp3 expression, focusing on non-transgenic T cells that have the most Treg 
activity.353 No change in Treg frequency was observed in 2D2/DNMAML mice post-
immunization (Fig. 5.4A). We observed a slight but significant increase in Treg 
frequency in DNMAML compared to WT CD4+ T cells post-immunization (Fig. 5.4B). 
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To assess suppressive capacity of DNMAML T cells post-immunization, we generated 
mixed bone marrow chimeras to park WT and DNMAML T cells in the same recipients 
(Fig. 5.4C). WT/DNMAML chimeras succumbed to EAE at the same frequency as mice 
containing only WT T cells, suggesting the absence of dominant suppressor function in 
DNMAML T cells (Fig. 5.4D-E).  
 The very low abundance of DNMAML T cells in the CNS prevented accurate 
assessment of their effector function. It was previously shown that Ccr6-deficient T cells 
failed to efficiently traffick to the CNS during EAE.354 However, bystander WT T cells 
induced Ccr6-independent effector T cell migration into the CNS. To determine if WT T 
cells could overcome the inability of Notch-deprived CD4+ T cells to accumulate in the 
CNS, we measured T cell numbers in the CNS of bone marrow chimeras at peak disease. 
DNMAML CD4+ T cells partially regained their ability to accumulate in the CNS in the 
presence of WT CD4+ T cells (Fig. 5.4F). This strategy suggests that bystander WT T 
cell inflammation can induce Notch-deprived T cells to accumulate in the CNS, allowing 
us to study their effector function in the CNS. 
 
5.3.5 Inhibition of Notch signaling in myelin-reactive CD4+ T cells in the CNS blocks 
IL-17A and IFN-γ  expression independently of T-bet.  
 Decreased T cell reactivation in the CNS can result in reduced EAE severity.292 
Since DNMAML CD4+ T cells accumulate in the CNS in the presence of WT T cells 
(Fig. 5.4F), we studied the impact of Notch inhibition on T cell effector differentiation in 
the CNS. In immunized mixed bone marrow chimeras, wild-type CD45.1+ competitor T 
cells were an internal positive control. While DNMAML CD4+ T cells produced IFNγ 
and IL-17A in DLN (Fig. 5.2B, C, F, 5.5B), they had markedly reduced production of 
IFNγ or IL-17A in the CNS (Fig. 5.5A). The blunted cytokine response occurred without 
defect in T-bet expression, as evidenced by the presence of many T-bet+IFNγ– cells (Fig. 
5.5B). Our results suggest that Notch-mediated regulation of IFNγ production is an 
important feature of its effects in EAE, but through mechanisms that are independent of 
T-bet and CNS-restricted. Moreover, decreased T cell migration into the CNS could 
account for some of the effects of Notch inhibition. However, it cannot fully explain 
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protection from EAE as Notch-inhibited CD4+ T cells that enter the CNS in the presence 
of bystander wild-type T cells have markedly reduced effector function.  
 
 
Figure 5.4 CNS accumulation of DNMAML CD4+ T cells is enhanced in the 
presence of WT CD4+ T cells, but Notch-deprived CD4+ T cells fail to suppress 
disease. 
Foxp3 expression in (A) Vβ11–CD4+ 2D2/DNMAML and (B) CD4+ DNMAML T cells measured 
by intracellular flow cytometry (n=3-4 mice/group; >2 experiments); (C) Experimental design; 
(D) Mean clinical score (representative) (score>2; 5 experiments); (E) Percent disease incidence 
(score>2) of immunized BM chimeras (3 experiments); (F) Representative flow cytometry plots 
from BM chimeras. T cells were tracked by CD45.1 and CD45.2 expression at peak disease (n=4-




Figure 5.5 Notch-deprived CD4+ T cells have markedly reduced IL-17A and IFNγ  
production in the CNS despite preserved T-bet expression. 
Spinal cord infiltrates from immunized BM chimeras restimulated for 6 hours with anti-
CD3/CD28. (A) Frequency and number of IFNγ and IL-17A-producing DNMAML CD4+ T cells 
in the DLN or CNS by intracellular flow cytometry (n=4-5 mice/group; 2 experiments); (B) 
Intracellular T-bet and IFNγ expression by DN CD4+ T cells in the CNS by flow cytometry (n=4-
5 mice/group; 2 experiments). 
 
5.4 Discussion 
 Our findings highlight an essential role for Notch signaling in CD4+ T cells 
mediating experimental autoimmune encephalomyelitis (EAE). We used pan-Notch 
genetic inhibition as well as inactivation of individual Notch receptor genes to fully 
determine the impact of Notch signaling loss-of-function on CD4+ T cells during EAE. 
We found that pan-Notch inhibition in MOG-transgenic T cells and polyclonal T cells 
nearly completely protected from EAE. This protection was not due to an effect on 
myelin-reactive T cell activation or differentiation in secondary lymphoid tissues or a 
dominant suppressor function of DNMAML T cells. In contrast, Notch-deprived T cells 
failed to accumulate in the CNS, despite preserved in vitro chemotaxis. Parking WT and 
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DNMAML T cells together in bone marrow chimeras resulted in enhanced accumulation 
of DNMAML T cells in the CNS. Analysis of accumulated DNMAML T cells in the 
CNS of bone marrow chimeras revealed a significant defect in IL-17A and IFNγ 
production, despite preserved T-bet expression. Collectively, Notch signaling regulates 
myelin-reactive T cells during EAE through mechanisms that have not previously been 
reported. 
 Past work suggested that Notch regulates myelin-reactive T cells in secondary 
lymphoid organs through regulation of T-bet, IFNγ, IL-17A, or Treg function117,118,124,345 
In contrast, our work highlights a function for Notch signaling in myelin-reactive T cells 
in the CNS and not in secondary lymphoid tissues. Indeed, inhibition of Notch signaling 
in T cells in secondary lymphoid tissues did not substantially affect T-bet expression, 
IFNγ and IL-17A production, or Treg function. The reasons for these differences are 
unclear but may reflect the various methods of Notch signaling modulation used. For 
instance, many past reports have relied on overexpression of Notch receptors or systemic 
modulation of Notch signaling with GSIs, blocking antibodies, or agonistic fusion 
proteins. As discussed in Chapter 1, many cell populations in the immune system require 
Notch signaling and presence of Notch ligands and receptors does not necessarily lead to 
active Notch signaling. Thus, using approaches that exceed physiological levels of Notch 
signaling or systemically modulate Notch signaling may result in bystander effects on 
other cell types that impact T cells, independently of Notch signaling in T cells. 
Preserved T cell differentiation in secondary lymphoid tissues was reported with Dll4 
blockade during EAE.119 However, they reported defects in T cell chemotaxis which we 
did not replicate using genetic loss-of-function approaches in T cells. 
 Notch signaling has previously been suggested to regulate T-bet expression.117 
Despite drastically decreased IFNγ production in the CNS by Notch-inhibited T cells, 
myelin-reactive Notch-deprived T cells had preserved expression of T-bet. This is similar 
to previous work published by our laboratory in which allogeneic Notch-deprived T cells 
had preserved expression of T-bet but failed to produce IFNγ (Chapter 3).223,250 Other 
signaling cascades such as IL-12 and IL-27 have been shown to elicit T-bet expression 
and could account for preserved T-bet expression in Notch-deprived T cells.243,355 
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 Chemotaxis to the CNS is regulated by many redundant signaling cascades.356 Of 
these, Notch has been suggested to regulate CCR1, CCR2, CCR5, and CCR6 in EAE, 
and CCR7 in CNS-homing leukemia cells.119,351 In contrast, we found that pan-Notch 
inhibition in myelin-reactive T cells did not affect migration in response to these 
chemotactic signals, at least in vitro. These differences may reflect differences in 
systemic blockade with Dll4 versus genetic inhibition of Notch in T cells. Inhibition of 
Dll4 in other populations in secondary lymphoid organs may elicit chemotaxis changes in 
T cells that are not intrinsic to Notch-inhibited T cells. Additionally, Notch signaling may 
modulate integrin expression and/or function. For example, the integrin, α4β1, is 
required for T cell chemotaxis to the CNS during EAE and MS.350,357 Although Notch-
deprived T cells expressed similar levels of surface α4β1, the functionality of this 
integrin was not determined and could account for their decreased accumulation in the 
CNS. Prior work has shown that IFNγ induces expression of the α4β1 ligand, VCAM-1, 
on endothelial cells to facilitate cell adhesion followed by transendothelial 
migration.358,359 It is possible that Notch-inhibited T cells acquire a defect in IFNγ 
production in route to the CNS and fail to trigger VCAM-1 upregulation on endothelial 
cells. This would be consistent with partial rescue of CNS accumulation in the presence 
of bystander wild-type T cells. Alternatively, Notch-deprived T cells may have preserved 
migration to the CNS, which is suggested by our in vitro studies, but may fail to survive 
or proliferate in the CNS. Failure of myelin-reactive T cells to be locally reactivated in 
the CNS could account for decreased accumulation of Notch-deprived T cells in the 
CNS.292,293  
 Notch-inhibited myelin-reactive T cells failed to suppress disease induced by WT 
T cells in mixed bone marrow chimeras. This is in contrast to prior work suggesting that 
Dll4 blockade expanded Tregs, which resulted in slightly reduced EAE severity.118 These 
discrepancies could reflect differences in experimental strategy. Notch-inhibited T cells 
were mixed with WT T cells in bone marrow chimeras. A mild increase in suppressive 
capacity intrinsic to Notch-deprived T cells may have been overcome by the large 
population of WT T cells in the same animal, preventing a complete analysis of Treg-
mediated suppression. Also, TCR transgenic mice in which Tregs are present in the non-
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transgenic T cell fraction still succumb to EAE, indicating that Tregs may contribute to 
suppressing disease but are not the only explanation.353 
 Collectively, our results suggest a function for Notch in T cells during EAE that is 
compartment-specific and CNS-restricted. Inhibition of Notch signaling in mature T cells 
preserved T cell differentiation in secondary lymphoid organs but not in the CNS. The 
reason for this difference is unclear but could be explained by local exposure to Notch 
ligands during T cell restimulation in the CNS. In contrast, Notch may signal in T cells in 
secondary lymphoid organs or vasculature with the importance of the Notch signals only 
becoming apparent in the CNS (Figure 5.6). Future experiments will work to localize the 
source of Notch ligand(s) responsible for T cell function during EAE. 
 
 
Figure 5.6 Potential sources of Notch signaling during experimental autoimmune 
encephalomyelitis. 
Notch signaling may act on T cells in secondary lymphoid tissues with effects only appearing 
once they are in the CNS. Alternatively, T cells may receive Notch signals in the blood stream, at 
the blood-brain-barrier (BBB), or in the CNS that results in potent cytokine production in the 
central nervous system independently of T-bet. 
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 In summary, we provide clear definitive evidence for a role for Notch signaling in 
myelin-reactive CD4+ T cells mediating EAE that differs from all prior reports of Notch 
function in T cells during EAE. Since we inhibited the Notch transcriptional activation 
complex in T cells, future work will focus on identifying target genes downstream of 
Notch signaling that elicit these effects. With new humanized Notch ligand and receptor 
specific antibodies being made recently available, it will be interesting to determine the 
critical Notch receptors and ligands mediating EAE.221 This knowledge will contribute 
towards therapeutic strategies for targeting Notch signaling in MS to decrease MS 






















Chapter 6  
Conclusions and Perspectives 
6.1 Summary 
 Collectively, the data presented in this thesis demonstrate that Notch signaling 
modulates T cell responses in two medically relevant T cell-mediated immune disorders: 
GVHD and EAE. In Chapters 2, 3, and 4 we demonstrated that inhibition of Notch 
signaling in alloreactive CD4+ and CD8+ T cells significantly reduced GVHD severity 
and lethality in CD4- and CD8-dependent MHC and miHA models of GVHD 
(Summarized in Figure 4.12).223,250,340 Notch-deprived T cells had preserved activation 
but significantly reduced production of several proinflammatory cytokines. Despite 
blunted IFNγ production by Notch-deprived CD4+ and CD8+ T cells, Notch-deficient T 
cells had preserved or even enhanced expression of T-bet and Eomesodermin, two drivers 
of IFNγ production in CD4+ and CD8+ T cells, respectively. These data demonstrate that 
Notch-deficiency did not result in a classical Th1 or CD8+ T cell effector differentiation 
defect. However, defective IFNγ production could be partially to fully rescued by 
bypassing more proximal steps of TCR signaling pharmacologically. Downstream of 
TCR signaling, we found a significant defect in Ras/MAPK and NF-κB pathway 
activation in Notch-deprived CD4+ and CD8+ T cells. Additionally, Notch-deprived 
CD4+ and CD8+ T cells had several features that were reminiscent of anergic T cells (Fig. 
3.12).233,234,240 Concomitant with reduced proinflammatory cytokine secretion and an 
anergy-like phenotype, Notch-deprived CD4+ T cells contained a higher frequency of 
natural Tregs after allo-BMT. Lastly, Notch-deprived CD4+ and CD8+ T cells maintained 
cytotoxic potential in in vitro and in vivo cytotoxicity assays, suggesting a “split-anergy” 
phenotype. Together, these data illustrate that inhibition of Notch signaling dissociates 
cytokine production from cytotoxic function and may be an attractive therapeutic target 
after allo-BMT.  
 Analysis of the receptors and ligands mediating Notch effects in T cells revealed a 
dominant role for Notch1 and Dll4 with minor roles for Notch2 and Dll1 in mediating 
GVHD.340 Therapeutic targeting of Dll1 and Dll4 using neutralizing humanized 
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monoclonal antibodies demonstrated that even a short two-week burst of treatment was 
able to protect mice long-term from acute, lethal GVHD. Remarkably, treatment with 
anti-Dll1 and Dll4 did not inhibit hematopoietic recovery post allo-BMT. Moreover, anti-
Dll1/Dll4 treatment preserved the cytotoxic potential of the T cells after BMT. Thus, 
therapeutic inhibition of Notch signaling after allo-BMT achieves beneficial 
immunomodulation without global immunosuppression.  
 In Chapter 5, we investigated the role of Notch signaling in EAE. We observed 
that inhibition of Notch signaling in myelin-reactive T cells significantly protected from 
EAE, more so than previously reported approaches to inhibit Notch signaling. In contrast 
to prior results with systemic Notch inhibition or Notch gain-of-function, the protection 
from EAE was not explained by an effect on T cell activation or differentiation in 
secondary lymphoid tissues. We observed preserved IL-17A and IFNγ production and 
expression of T-bet (for Th1 cells) and Rorγt (for Th17 cells) in myelin-reactive CD4+ T 
cells in secondary lymphoid organs. However, Notch-deprived T cells failed to 
accumulate in the CNS post-immunization, despite preserved in vitro chemotaxis. 
Parking WT and Notch-deprived T cells together in bone marrow chimeras enhanced the 
accumulation of Notch-deprived T cells in the CNS. Additionally, Notch-deficient T cells 
were unable to prevent disease induced by WT T cells, suggesting the absence of a 
dominant suppressor function of Notch-inhibited T cells. Analysis of Notch-deprived T 
cells that did accumulate in the CNS of bone marrow chimeras revealed a significant 
defect in their production of IL-17A and IFNγ, despite preserved expression of T-bet. 
These data are the first to clearly define a role for Notch signaling in myelin-reactive T 
cells during EAE and promote Notch as a potential therapeutic target in MS.  
 Our results in GVHD and EAE differ from all prior reports of Notch function in 
mature T cells, demonstrating the benefit of using T cell-specific loss-of-function 
approaches to study Notch signaling in mature T cells. Moreover, our data reveal that 
Notch signaling regulates T cell responses in a context-dependent manner. 
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6.2 Mechanistic insights into Notch regulation of T cell function 
 Prior studies in the hematopoietic system have sought to determine a role for 
Notch signaling in T cell differentiation and function. For instance, Notch has been 
suggested to directly regulate a large array of cytokines and effector molecules. These 
results were achieved through a variety of approaches, many of them being gain-of-
function or systemic modulation of Notch signaling. These findings highlight several 
questions about the mechanism(s) of Notch action in mature T cells. First, does Notch 
signaling play the same role in T cells regardless of the immune context? Second, do 
varied results between different experimental systems and immune responses appear to 
be similar when in fact some effects may have been attributed to the incorrect 
mechanisms of Notch action? Third, does Notch truly regulate immune responses in a 
context-dependent manner?  
 Early work on Notch in mature T cells attempted to frame Notch into its historical 
context as a lineage determinant. For instance, studies in Drosophila demonstrated that 
Notch was pivotal for specifying one cellular fate at the expense of another. Similarly, 
investigations of Notch in T cells showed that Notch signaling specified the T cell fate at 
the expense of B cells. Fitting into this paradigm, initial work on Notch in T cell 
differentiation suggested that Delta ligands promoted Th1 development while Jagged 
ligands elicited Th2 development.111 However, our laboratory’s work and data presented 
in this thesis suggest that Notch does not simply drive lineage decisions based on its 
regulation of one transcription factor or cytokine over another. In fact, Notch signaling 
may integrate with larger signaling networks, such as TCR signaling and costimulation, 
to impact T cell differentiation and function in a context-dependent fashion.  
 Detecting ICN or CSL/RBP-Jκ bound to transcription factor or cytokine target 
gene loci has often been sufficient to suggest that Notch signaling regulates these loci. 
However, there is new insight from Aster and colleagues who performed ChIP-Seq on the 
genomes of three T-ALL cell lines.360 They showed that only 36% of CSL/RBP-Jκ 
binding sites overlapped with Notch1 binding sites. Moreover, 97% of genes with Notch1 
binding in the promoter did not respond significantly to Notch signaling. This result is 
similar to data in yeast showing that only 3% of occupied promoters responded to 
disruptions of transcription factors.361 Since these data were performed in T cell lines that 
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were grown in vitro, they may not accurately reflect the function of Notch signaling in 
vivo in mature T cells. However, it does raise the question of whether simply finding 
Notch or CSL/RBP-Jκ bound to a gene translates to functional and meaningful regulation 
of that gene. The data from Aster and colleagues would suggest that indeed it does not, 
although these data do not rule out the possibility that many new targets downstream of 
Notch signaling may still exist. Despite this possibility, it is unlikely that Notch signaling 
independently regulates specific T cell differentiation transcription factors and cytokines. 
Instead, Notch signaling may intercept larger signaling pathways to elicit context-
dependent effects. For example, Notch crosstalks with pre-TCR and PI3K/Akt signaling 
to elicit changes in DN3 thymocytes, perhaps through direct regulation of HES1.362 In 
GVHD, Notch signaling context-dependently modulates TCR signals to dampen cytokine 
responses. In EAE, Notch signaling does not alter T cell function in secondary lymphoid 
organs, but in the specific context of the CNS, dampens cytokine responses potentially 
through crosstalk with TCR signaling and costimulatory molecules.  
  Several possibilities emerge that could explain the ability of Notch signaling to 
regulate immune responses in a context-dependent manner. First, exposure to specific 
Notch ligands could differ in various immune responses. For instance, in the highly 
inflammatory environment of GVHD, Notch ligands could be differentially expressed 
and regulated in comparison to other immune responses where inflammation is more 
spatially restricted. Second, Notch signaling could be actively maintained in an off state 
in certain tissues despite the presence of Notch ligand. For example, in B cell 
development in the bone marrow, Notch signaling is actively maintained off through the 
inhibitory actions of LRF on Dll4 expression in erythroblasts.65 During EAE, Notch 
signaling could be prevented in T cells in secondary lymphoid organs through an LRF-
like mechanism in a T cell-interacting cell but the absence of this factor in CNS-resident 
cells could promote Notch signaling in T cells in the CNS. Third, expression of specific 
Notch receptors or post-translational modification of these receptors by fringe 
glycosyltransferases could modify the response of T cells to Notch ligands. In developing 
thymocytes, Notch1, 2, and 3 are all expressed, but Notch1 preferentially interacts with 
Dll4 due to actions of Lunatic Fringe.34,363 In GVHD, Notch1 and Dll4 are the dominant 
receptor and ligand, respectively, despite other Notch receptors and ligands being present. 
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340 Fringe modification of Notch1 or spatial and temporal availability of Notch ligands 
could explain the context-dependent regulation of GVHD by Notch signaling. Fourth, 
certain inflammatory contexts or factors produced during different immune responses 
could bypass the requirement for Notch signaling. For instance, clearance of Leishmania 
major in mice does not require Notch signaling in T cells.115  
 Collectively, Notch signaling may regulate immune responses in a context-
dependent manner. Evidence from studies in different hematopoietic cells suggests that 
the context-dependence of Notch regulation is determined by availability of Notch 
ligands, presence of active negative regulators of Notch signaling, post-translational 
modification of Notch receptors, and the inflammatory context of the immune response.  
 
6.3 Notch signaling as a modulator of costimulation pathways? 
 Our data revealing a role for Notch in T cells during GVHD and EAE paint Notch 
signaling as a costimulatory pathway or a modulator of signaling pathways that alters T 
cell function in a context-dependent fashion. In the absence of Notch signaling, T cell 
cytokine responses are significantly dampened despite preserved expression of master 
transcription factors for T cell differentiation. In contrast, presence of Notch signaling 
results in robust pro-inflammatory T cell responses, eliciting severe, lethal GVHD and 
EAE. Similar roles for other costimulatory molecules have been observed in GVHD and 
EAE. For example, mice treated with an agonistic 4-1BB antibody had increased GVHD 
severity and production of IFNγ and TNFα by thoracic duct lymphocytes.193 In contrast, 
deficiency in OX40 during EAE induction resulted in significantly reduced IFNγ, IL-2, 
and IL-6 production and protection from EAE.330 Thus, similar to these data, Notch may 
be functioning as a costimulatory molecule or modulating costimulatory pathways in 
GVHD and EAE to stimulate context-dependent effects in these T cell-mediated immune 
disorders. For instance, work presented in Chapter 3 suggest that absence of Notch 
signaling in T cells during GVHD elicits a hyporesponsive phenotype reminiscent of T 
cells that failed to receive a costimulation signal. Also, data in Chapter 4 demonstrated 
that short-term inhibition of Notch signaling during the first two weeks of GVHD 
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resulted in long-lasting protection, suggesting induction of tolerance similar to failed 
costimulation. 
 The question remains open as to how Notch signaling crosstalks with other 
pathways or functions as a costimulatory molecule in T cell-mediated immune disorders. 
Several possibilities can be considered. First, Notch signaling could directly regulate 
costimulatory molecule gene expression, which has been suggested in T-ALL.364 Second, 
Notch could directly regulate genes required to amplify TCR or costimulatory signals. 
Third, Notch could directly regulate Hes or Hey proteins, which could turn off negative 
regulators of TCR signaling or costimulatory pathways, which has been suggested to 
occur in T cell development with HES1 regulation of PTEN.362 The idea of Notch 
modulating another signaling cascade is not a novel idea. For instance, the data we 
provided in Chapter 3 demonstrates that Notch signaling positively regulates TCR 
signaling, and in the absence of Notch signaling, TCR signaling is blunted. Another 
example of Notch signaling modulating another signaling pathway is in T cell 
development in the thymus. At the pre-TCR checkpoint at the DN3 stage of T cell 
development, Notch signaling, pre-TCR signals, and PI3K/Akt signaling synergize to 
promote cellular metabolism and survival.98,99  
 If Notch influences signaling by costimulatory receptors in T cells mediating 
GVHD and EAE, then it is essential to understand how the expression of Notch ligands is 
regulated and if this regulation shares similarities with that of costimulatory ligands. 
Previous studies have shown that TRIF-dependent and –independent TLR signaling can 
regulate costimulatory molecule expression.365 Likewise, TLR signaling was reported to 
enhance Dll4 and Jagged1 expression in antigen presenting cells.366,367 Thus, conditioning 
regimens prior to transplantation may promote cellular damage as well as release of gut 
constituents, leading to enhanced TLR signaling and increased Notch ligand expression 
in allo-BMT recipients. However, TLR-independent mechanisms of Notch ligand 
upregulation have also been reported.368,369 If Notch cooperates with classically defined 
costimulation pathways, then it is tempting to speculate that Notch ligands would be 
expressed by the same cells presenting allo- or auto-antigens. For instance, prior work 
demonstrated that optimal T cell responses occur when the peptide antigen and 
costimulation machinery are expressed on the same antigen presenting cell.370 In GVHD 
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and EAE, it remains unclear exactly which cell(s) is/are presenting the peptide antigen 
and the Notch ligand(s) and in which compartment these cells reside. It remains possible 
that distinct cells can present MHC/antigen complexes and Notch ligands to T cells, 
either simultaneously or sequentially. 
 In view of our experimental approach using DNMAML, it is clear that the effects 
of Notch signaling in T cells during EAE and GVHD involve the canonical Notch 
transcriptional activation complex. We interfered with the Notch transcriptional 
activation complex, which indicates that Notch is directly regulating a target gene(s) that 
is (are) then used to alter T cell differentiation and function, perhaps through intercepting 
another signaling pathway. The direct targets of Notch signaling in alloreactive and 
autoreactive T cells that would elicit these effects are unknown but it is a focus of future 
research. Additionally, interfering with the Notch transcriptional activation complex rules 
out a non-canonical function of Notch signaling. Non-canonical functions of Notch 
signaling have been proposed to occur in mammals, but the mechanisms underlying these 
effects are ill defined.49,50 Our GVHD and EAE work utilized loss-of-function of Notch 
receptors and Notch transcriptional complex factors, which resulted in the same 
phenotype. The functional and phenotypic changes we observed in Notch-deprived T 
cells were the result of decreased expression of a Notch target gene(s). 
 Thus, there is precedence for Notch modulating other pathways to alter T cell 
function, and data provided in this thesis suggest that in mature T cells, Notch may 
synergize with T cell signaling pathways or act as a costimulatory molecule to support T 
cell function in its context-dependent regulation of T cell-mediated immune disorders. 
 
6.4 Notch as a therapeutic target in T cell-mediated immune disorders? 
 Data provided in Chapter 4 suggest that targeting individual Notch receptors 
and/or ligands may be an effective strategy for treating T cell mediated immune 
disorders. In Chapter 4, we demonstrated that targeting Dll1/4 in GVHD even during a 
short course provided long-lasting protection from GVHD, while preserving T cell 
cytotoxicity and hematopoietic reconstitution after allo-BMT. Targeting individual 
ligands was key to the therapeutic success of this strategy since pan-Notch inhibition with 
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GSIs resulted in on-target side effects in the gut, leading to lethality due to a severe lack 
of gastrointestinal tissue regeneration rather than GVHD. These GSI toxicity results are 
corroborated by clinical trials with GSIs that reported several side effects, including 
diarrhea and severe fatigue.371 Although treatment with GSIs after allo-BMT did not lead 
to goblet cell hyperplasia, which is the usual on-target side effect of Notch inhibition in 
the gut.372 Rather, the GI tract was much more acutely sensitive to inhibition of Notch 
signaling in the post-irradiation environment, likely due to an effect on the intestinal stem 
cells rather than on cellular differentiation in the gut.266,373 Likely, in the case of MS, 
using GSIs as a therapeutic would result in similar gastrointestinal side effects, like 
diarrhea, as those observed in clinical trials, since the intestine would not be sensitized by 
irradiation.371 Thus, targeting individual Notch receptors and ligands appears to be a more 
advantageous therapeutic approach. 
 Targeting the individual Notch ligand Dll4 has been explored in angiogenesis 
based on data showing that Dll4 haploinsufficiency leads to angiogenesis defects and 
embryonic lethality.374-376 Blocking Dll4 as an anti-angiogenic therapy revealed that anti-
Dll4 promoted non-productive vasculogenesis in the tumor, inhibiting tumor growth. 
Normally, Notch1-Dll4 signaling restricts the number of tip cells and promotes stalk cell 
development whereas Dll4 inhibition induces tip cells at the expense of stalk cells, 
leading to nonproductive vasculature.35 Chronic administration of anti-Dll4 antibodies 
has been associated with adverse events, including vascular hyperproliferation in the liver 
and vascular neoplasms.377,378 Thus, chronic inhibition of Dll4 may not be therapeutically 
advantageous for patients given these side effects. Fortunately, long-term protection form 
GVHD is achieved with only a short course of treatment, suggesting that these negative 
side effects could be avoided. In contrast, if Dll4 turns out to be the dominant ligand 
mediating Notch effects in EAE, these side effects would be more concerning. For 
instance, chronic inhibition of Notch signaling may be required for therapeutic use of 
Notch inhibitors in MS. However, short-term treatment could result in long-lasting 
effects in T cells negating chronic use of Notch inhibitors in EAE as shown in GVHD.  
 Blocking other Notch ligands and receptors therapeutically besides Dll4 has not 
been well studied. The most commonly described role for other Notch receptors and 
ligands is in organ development rather than tissue homeostasis. For instance, Notch2 
 105 
function is associated with heart, kidney, and eye development.379 Jagged1 dysfunction is 
found in Alagille syndrome, which is characterized by liver, heart, eye, skeletal, 
craniofacial and kidney abnormalities.380 Presumably, a developmental role for certain 
Notch ligands and receptors would negate a role for Notch in tissue homeostasis of these 
organs. In contrast, Notch1 and Jagged2 are important for terminal differentiation of 
keratinocytes, whereby loss of Notch signaling promotes tumorigenesis.15,381 These data 
indicate that chronic inhibition of Notch1 or Jagged2 may not be therapeutically 
advantageous. As indicated in Chapter 4, we found that the post-irradiation intestine is 
acutely sensitive to Notch1/2 blockade, making this therapeutic modality unreasonable 
for treating GVHD.340 Chronic blockade of Notch signaling could also have implications 
for immunity to pathogens because of the role of Notch signaling in the innate and 
adaptive immune system, although there is a lack of studies in support of this hypothesis.  
 Altogether, the time is ripe for studying inhibition of Notch signaling in T cell-
mediated immune disorders and other diseases characterized by dysregulated Notch 
signaling. Humanized anti-mouse/human antibodies targeting all Notch receptors and 
ligands have been developed and provide the tools necessary to inhibit Notch signaling 
selectively while bypassing side effects associated with global Notch inhibition.221 The 
immunoglobulin backbone of these Notch receptor and ligand neutralizing antibodies is 
IgG1.221 Despite the fact that IgG1 fixes complement, which could lead to target cell 
lysis, our results in Chapter 5 demonstrate that blocking Notch1, Notch2, Dll1, or Dll4 
with these neutralizing antibodies does not elicit target cell depletion.340,382 In contrast, 
we observed preserved or even enhanced T cell expansion.340 Moreover, identification of 
Notch target genes in T cells during T cell-mediated immune disorders will also aid in 
therapeutic targeting of Notch signaling. It is possible that with the identification of genes 
that mediate the effects of Notch signaling, therapies could be developed that more 
specifically target the effectors of Notch signaling in a particular context rather than the 
overall effects of the pathway. 
 Collectively, this thesis demonstrates the utility of studying Notch signaling using 
strict genetic loss-of-function approaches and then moving towards therapeutic options 
supported by fundamental biological questions. Our work reveals positive consequences 
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of Notch blockade in T cell-mediated immune disorders that could lead to new 

























Chapter 7  
Materials and Methods 
7.1 Mice 
 BALB/c (H-2d) and C57BL/6 (B6, H-2b, CD45.2+) mice were from Harlan 
(Indianapolis, IN); B6xDBA/2 F1 (BDF1, H-2b/d), BALB/b (H-2b), and Foxp3-IRES-
RFP (FIR) from The Jackson Laboratory (Bar Harbor, ME) 242; C57BL/6.Ptprca (B6-SJL, 
H-2b, CD45.1+) from National Cancer Institute (Frederick, MD). NF-kB reporter mice 
(NGL) were described previously 230. B6.129S6-Tbx21tm1Glm/J mice were provided by 
Dr. Segal (University of Michigan) 226; Eomesf/f x Cd4-Cre mice by Dr. Reiner 
(Columbia University) 383. C57BL/6-Tg (Tcra2D2, Tcrb2D2)1Kuch/J (2D2) T cell 
receptor transgenic were provided by Dr. Segal (University of Michigan) 347. 
ROSA26DNMAMLf/+ mice generated as described were crossed to Cd4-Cre transgenic mice 
before backcrossing to the B6 background (> 8 generations) 82,115. In some experiments, 
ROSA26DNMAMLf x Cd4-cre mice were crossed to 2D2 mice. Rbpjf/f mice were kindly 
provided by Tasuku Honjo (Kyoto, Japan) 86. Notch1f/f mice by Dr. Kopan (St. Louis, 
MO) and Notch2f/f by Dr. Gridley (Scarborough, ME) 380 384. Because no effect of Cre 
expression was observed in alloreactive and myelin-reactive T cells (data not shown), 
Cd4-Cre+ or Cd4-Cre– controls were used. Protocols were approved by the University of 
Pennsylvania's Office of Regulatory Affairs and the University of Michigan's Committee 
on Use and Care of Animals.  
7.2 Antibodies, flow cytometry, and cell lines 
The following antibodies were from BioLegend (San Diego, CA): anti-CD3, CD4, 
CD8α, CD25, CD69, CD44, CD45.1, CD45.2, CD62L, TCRβ, CD3, H-2Kb, H-2Kd, 
IFNγ, IL-2, TNFα, Vβ11, Vα3.2, CD28 (37.51), CD152/Ctla-4 (UC10-4B9), and 
CD279/Pd-1 (RMP1-30). Anti-Foxp3, T-bet (4B10), Eomesodermin (Dan11mag), and 
CD272/Btla (6F7) antibodies were from eBioscience (San Diego, CA). CD49d (α1) and 
CD29 (β4) were from BD Biosciences. For restimulation, we used anti-CD3 (145-2C11) 
and anti-CD28 (37.51; 2.5 µg/mL each; Biolegend) or phorbol myristate acetate (PMA; 
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50 ng/mL) and ionomycin (50 ng/mL; Sigma-Aldrich). Intracellular flow cytometry was 
performed per manufacturer’s instructions after addition of Monensin or Brefeldin A (4 
hours) (BD). Analysis/sorting were on FACSCanto or FACSAria II/III (BD). Dead cells 
were excluded with DAPI (Sigma-Aldrich, St. Louis, MO). Files were analyzed in 
FlowJo (Tree Star, San Carlos, CA). A20 (BALB/c, H-2d) lymphoma/leukemia cells 
expressing luciferase were kindly provided by Marcel van den Brink (Memorial Sloan 
Kettering Cancer Center, New York, NY) 385. A20 lymphoma/leukemia cells not 
expressing luciferase were from ATCC (Manassas, VA). 
7.3 In vitro and in vivo proliferation assays 
Splenocytes or CD4+ and CD8+ T cells were MACS-purified according to manufacturer’s 
instructions (Miltenyi) and labeled with 2.5µM CFSE (Sigma-Aldrich). T cells were 
incubated for 3 days on anti-CD3/CD28+/-hrIL-2 (Peprotech). Splenocytes were 
transplanted into irradiated BALB/c mice. For BrdU incorporation, mice were pulsed 
with 1 mg BrdU intraperitoneally 6 hours before euthanasia. For BrdU pulse-chase, 
starting at day 4 post-transplantation, mice received 3 doses of BrdU (1 mg) 
intraperitoneally, 12 hours apart. Four hours (day 5) or 3 days (day 8) after the last BrdU, 
spleens were harvested for BrdU staining (BD), followed by DNA counterstaining (DAPI 
[4′,6-diamidino-2-phenylindole]). 
7.4 Cell preparations 
T cell–depleted bone marrow (TCD BM) was prepared with microbead-conjugated anti-
CD4/CD8 antibodies 386. CD4+ and CD8+ lymphocytes were isolated from spleens and 
lymph nodes using microbead-conjugated antibodies (Miltenyi Biotech, Auburn, CA). 
Purity was consistently >92%. In some experiments, T cell-depleted bone marrow (TCD 
BM) was prepared with anti-Thy1.2 antibodies and complement (Cedarlane Labs, 
Burlington, NC; >95% depletion).  
7.5 Induction of GVHD  
For the B6 anti-BALB/c model, we irradiated BALB/c recipients using 900 rads from a 
137Cs source, 4 hours apart. We transplanted donor B6 TCD BM (5.0 × 106) alone or with 
whole splenocytes or purified CD4+ or CD8+ T cells into irradiated BALB/c recipients (4-
 109 
10 mice/group per experiment). In experiments studying GVHD target organs, 850 rads 
were used. The GVHD score was assessed as described 387. GVHD severity was also 
assessed by histopathological analysis 388,389. Images were obtained with an Olympus 
BX41 microscope (10×/0.3 NA lens, 100× magnification, digital DP70 camera).  
7.6 Isolation of intestinal lymphocytes 
Intraepithelial and lamina propria lymphocytes (IELs, LPLs) were isolated from small 
intestines as described, with slight modifications 390. Briefly, intestines were washed, and 
Peyer patches removed. Fragments (0.5-1 cm) of intestine were incubated in phosphate-
buffered saline with 1mM EDTA and 1mM DTT for 45′ while shaking at 37°C. 
Supernatant was passed through nylon wool columns and IELs were isolated after 
centrifugation on a Percoll (Sigma-Aldrich) gradient. For LPL isolation, the remaining 
tissue was incubated in RPMI/fetal bovine serum 5% with 200 U/mL collagenase 
(Invitrogen) for 100′ while shaking at 37°C. Supernatant was filtered, and LPLs were 
isolated after centrifugation on a Percoll gradient. 
7.7 Cytokine measurements 
Protein levels of cytokines were quantified using a Bio-Plex bead-based (Luminex) 
cytokine assay purchased from Bio-Rad Laboratories. For serum cytokine analysis, serum 
was collected on day 5 post-transplantation. Serum IFNγ levels were measured by mouse 
IFNγ duoset (R&D Systems, Minneapolis, MN) per the manufacturer’s instructions 
(Immunology Core, University of Michigan Cancer Center). 
7. 9 Quantitative reverse-transcription PCR 
RNA was isolated using the RNEasy Micro kit (QIAGEN) or TRIzol (Invitrogen, 
Carlsbad, CA). cDNA was prepared with Superscript II (Invitrogen). Real-time 
polymerase chain reaction (PCR) was performed with TaqMan Master Mix or SybrGreen 
(Fisher, Rockford, IL) on Mastercycler realplex (Eppendorf, Westbury, NY). Transcript 
abundance was calculated using the ΔΔCt method (normalization with Hprt1). Primer 
sequences were from Applied Biosystems (Grand Island, NY) or PrimerBank 
(http://pga.mgh.harvard.edu.proxy.lib.umich.edu/primerbank): Eomes (5738950a2). 
Additional primers were: Ifng (5′-GGATGCATTCATGAGTATTGC-3′; 5′-
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CCTTTTCCGCTTCCTGAGG-3′), Tbx21 (5′-CAACAACCCCTTTGCCAAAG-3′; 5′-
TCCCCCAAGCAGTTGACAGT-3′), Hprt1 (5′-CTCCTCAGACCGCTTTTTGC-3′; 5′-
TAACCTGGTTCATCATC-GCTAATC-3′). 
7.10 SDS-PAGE and Western blotting 
Naïve (CD62LHighCD44Low) and alloreactive CD4+/CD8+ T cells were negatively selected 
using an anti-NK1.1/CD19/Gr-1/CD11b/CD11c cocktail. T cells were incubated on ice 
with anti-CD3/CD28 antibodies (0.2 µg/106 cells) followed by cross-linking with anti-
Armenian hamster IgG (0.5 µg/106 cells, Jackson ImmunoResearch, West Grove, PA) in 
RPMI-1640 at 37oC. Alternatively, T cells were activated with PMA (Sigma-Aldrich, 50 
ng/ml) at 37oC or DMSO. Cells were lysed in Laemmli buffer and 2-ME. Samples were 
run on 4-20% MiniTGX gels (Bio-Rad) and transferred to Immobilon-P membranes 
(GenHunter, Nashville, TN) (semi-dry transfer, Bio-Rad). Membranes were blocked in 
10% FBS+TBS-T (25 mM TrisBase-pH8, 125 mM NaCl, 0.05% Tween). Antibodies 
were from Cell Signaling (Danvers, MA): anti-MEK1/2 rabbit (47E6), p44/42 MAPK-
Erk1/2 mouse (3A7), phospho-MEK1/2 (Ser217/221) rabbit (41G9), phospho-p44/42 
MAPK-Erk1/2 (Thr202/Tyr204) (E10). Secondary antibodies were peroxidase-
conjugated goat anti-rabbit IgG(H+L) or donkey anti-mouse IgG(H+L) (Jackson 
ImmunoResearch). Blots were developed with ECL Substrate (Thermo) and HyBlotCL 
(Denville Scientific, South Plainfield, NJ). 
7.11 Intracellular cAMP assay 
cAMP was measured using ELISA, per manufacturer’s instructions (Enzo LifeSciences, 
Farmingdale, NY). 
7.12 Luciferase assay for NFκB activity 
Sort-purified alloreactive T cells were restimulated with plate-bound anti-CD3/CD28 
(Biolegend, 2.5 µg/mL) for 16 hours. Luciferase activity was measured using the 
Luciferase Assay System (Promega, Madison, WI) and read on PerkinElmer Enspire2300 
(Waltham, MA). 
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7.13 Ex vivo cytotoxicity assays 
CFSE-based cytotoxicity assays were as described 391. CD4+ T cells were isolated from 
WT B6 mice (unstimulated) or recovered from spleens and livers of BALB/c recipients 
of WT or DNMAML CD4+ T cells 14 days after transplantation. On day 14, alloreactive 
WT and DNMAML CD4+ T cells were sort-purified and co-incubated with CFSE-labeled 
BALB/c-derived (H2Kd) A20 tumor cells (ATCC, Manassas, VA) for 8 hours. Naïve 
CD4+ T cells were sorted in a similar manner and used as a control. Specific lysis was 
calculated as 100-((unlysed A20/bacgkround A20)*100) and normalized with counting 
beads (Bangs Laboratories, Inc., IN). For 51chromium release assays, spleen and lymph 
nodes were harvested on day 8 post-transplantation. WT and DNMAML CD8+ T cells 
were purified by MACS according to the manufacturer’s instructions (Miltenyi). A20 (H-
2d) and P815 (H-2d) cells were used as allogeneic targets, with EL4 (H-2b) as syngeneic 
control targets. Tumor targets were labeled with 2MBq of Na251CrO4 (PerkinElmer Life, 
Boston, MA, USA) for 2 hours. After washing 3 times, labeled targets were plated at 5 × 
103 cells per well in U-bottom 96-well plates (Corning-Costar Corp., Cambridge, MA). 
Splenocytes were added in triplicate wells at varying E:T ratios, and incubated for 5 
hours. 51Cr activity in supernatants was read in a LumaPlate (PerkinElmer, Waltham, 
MA) in an auto-gamma counter (Packard Instrument Company, Meriden, CT). Maximal 
and background release were determined by the addition of 2% Triton X-100 (Sigma) or 
media alone to targets, respectively. The percentage of specific lysis was calculated as 
100 × (sample count – background count)/(maximal count – background count). 
7.14 In vivo cytotoxicity assay 
BALB/c allogeneic target splenocytes were labeled with 2.5µM CFSE. Control targets 
were B6/SJL splenocytes labeled at a low CFSE concentration (0.25µM). On day 13, we 
infused a 1:1 mixture of CFSE-labeled BALB/c and B6/SJL splenocytes (107) into 
BALB/c recipients. Spleens were harvested 18 hours later to assess killing of BALB/c-
derived CFSEHigh target B cells. In some experiments, elimination of CFSEHigh BALB/c 
allogeneic targets was measured by flow cytometry in the spleen. 
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7.15 EAE induction 
 On day 0, age-matched (6-14 weeks) and sex-matched mice were immunized with 
Complete Freund’s Adjuvant containing heat-killed Mycobacterium tuberculosis (Fisher, 
Pittsburg, PA) and myelin oligodendrocyte glycoprotein (MOG35–55) peptide 
(MEVGWYRSPFSRVVHLYRNGK; 0.25 µg/site; Biosynthesis, Lewisville, TN). On 
day 0 and 2, mice received pertussis toxin (Fisher) (300 ng i.p.). Mice were scored for 
disease severity according to the following scale: 1= limp tail; 2=inability to right 
oneself; 3=hind limb weakness; 4=hind limb paralysis; 5=moribund. All analyses of T 
cell function were done at peak disease (score 3-5). 
7.16 Isolation of CNS-infiltrating cells.  
 Mice were perfused with PBS. Brains and spinal cords were digested with 
Collagenase (2.125 mg/mL; Invitrogen, Grand Island , NY) and DNase I (1mg/mL; 
Roche. Indianapolis, IN) followed by purification on a 30/70% Percoll (Sigma, St. Louis, 
MO) gradient. 
7.17 ELISpot 
 Draining lymph node cells (axial, brachial, inguinal) from immunized mice at 
peak disease were restimulated in MultiScreen HTS Filter plates (Millipore, Billerica, 
MA) +/- 50 mg/mL MOG35-55 for 18 hours. Antibodies used for cytokine detection were 
from eBioscience (anti-IFN-γ and IL-17A). Streptavidin-Horseradish peroxidase (HRP) 
was from Southern Biotech (Birmingham, AL). HRP substrate was from Vector 
Laboratories (Burlingame, CA). 
7.18 Transwell migration assays 
 The following chemokine ligands were from R&D Systems (Minneapolis, MN): 
Ccl20/Mip-3a, Ccl2/Mcp-1, Cxcl10/Crg-2, Ccl3/Mip-1a, and Ccl21/6Ckine. CD4+ T 
cells from 2D2 and 2D2/DN immunized mice at peak disease were purified by Miltenyi 
Magnetic Bead technology (Auburn, CA). Purified CD4+ T cells were resensitized at 
37oC, plated in a NeuroProbe ChemoTx System (Gaithersburg, MD) and allowed to 
migrate for 4 hours before analysis of migrated CD4+Vα3.2+Vβ11+CD44+ T cells in 
bottom wells by flow cytometry. Number of cells migrated was normalized using a 
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standard curve of known numbers of T cells and a fixed number of counting beads 
(Bangs Laboratories, Fishers, IN) by flow cytometry. Specificity of migration was 
determined by enumerating the number of activated 2D2 CD4+Vα3.2+Vβ11+CD44+ T 
cells that migrated to the bottom well in the absence of chemokines. 
7.19 Generation of mixed bone marrow chimeras for EAE 
immunization 
 Lethally irradiated (900 rads) B6-CD45.1 mice received CD45.2-WT B6 or 
CD45.2-DN and CD45.1-B6 bone marrow (mixed at 1:1 or 7:3 ratio). Mice were allowed 
to reconstitute for 8-12 weeks before EAE induction. 
7.20 Statistical analysis 
 All statistical analyses were performed using GraphPad-Prism (La Jolla, CA). 
Survival in different groups was compared using the log-rank test. Comparison of 2 
means was analyzed using the 2-tailed unpaired Student t test. When less than five data 
points were available per group, we used the unpaired Mann-Whitney U test. EAE 
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